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Abstract

The ability to flexibly react to our dynamic environment is a cardinal
component of cognition and our human identity. Millions across the globe are
affected by disorders of cognition, affecting their ability to live independently. The
prefrontal cortex is required for optimal cognitive functioning, but its circuitry is
often disrupted in conditions of impaired cognition. In addition, the cholinergic
system is vital to optimal executive function, but this is disrupted in a number of
conditions, including Alzheimer’s disease and schizophrenia. The actions of
cholinergic receptors were explored in this project with local application of
cholinergic compounds onto prefrontal neurons as rhesus monkeys performed a
rule-based saccadic task that requires working memory maintenance. The
antisaccade task is a useful probe of prefrontal cortex function that elicits errors
in neuropsychiatric conditions. Some prefrontal neurons respond to different task
aspects of the antisaccade task, e.g., discharging preferentially for one task rule
over the other (pro- or antisaccades), and are thought to be involved in the
circuitry for correct behavioural responses. Chapter 2 explored the effect of
general stimulation of cholinergic receptors on rhesus PFC neuronal activity
during antisaccade performance. In Chapter 3, newly developed cholinergic
receptor subtype-specific compounds were utilized to examine the actions of
muscarinic M1 receptor stimulation on prefrontal activity. Cortical oscillations are
emerging as an important aspect of cognitive circuitry, such as during working
memory maintenance. Chapter 4 examined the influence of local cholinergic
receptor stimulation and blockade on the power of local field potential in different
	
  

ii

	
  
frequency bands. This project characterized the role of cholinergic receptors in
prefrontal cortical neurons that were actively involved in cognitive circuitry. This
and future work on the cholinergic influence on prefrontal cortex will provide
insights into the altered cognitive functioning in Alzheimer’s disease and
schizophrenia, which are also affected by disrupted cholinergic systems.

Keywords
Cholinergic, muscarinic, acetylcholine, prefrontal cortex, dorsolateral prefrontal
cortex, working memory, antisaccade, iontophoresis, local field potential, single
neuron electrophysiology, macaque, rule
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CHAPTER 1 – INTRODUCTION

1.1

Disorders of Cognition

1.1.1 Alzheimer’s disease
Dementia is a neurodegenerative condition that affects over 500,000
Canadians as of 2019 (~1.3% of population; approx. 2/3 women and 1/3 men).
This number is expected to rise to over 1.1 million by 2038 (Alzheimer Society of
Canada, 2010). Alzheimer’s disease (AD) is the most common type of dementia
and is progressive, degenerative, and often leads to death within seven to 10
years of diagnosis. It often has an insidious onset characterized by behavioural
and mood changes, loss of memory, decreased ability to communicate, and
cognitive decline.
The Alzheimer Society of Canada quantifies the total economic burden of
dementia by summing direct costs (medication, staff, administration, physicians),
unpaid caregiver opportunity cost (i.e., unpaid time spent by family members
caring for their loved ones), and indirect costs (loss of wages and reduced
productivity). In the landmark report, Rising Tide: The Impact of Dementia on
Canadian Society (Alzheimer Society of Canada, 2010), the total annual
economic burden of dementia was estimated to be over $36 billion in 2018 and
expected to rise to over $152 billion by 2038. Thus for many reasons, there is
rising urgency to reduce the incidence of this disease and improve care as the
years progress.
Physiologically, AD is characterized by degeneration of neurons and
synapses in many areas of the brain, causing widespread atrophy. Acetylcholine	
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producing neurons in the brain are among the affected targets. Acetylcholine
(ACh) is one of the primary neurotransmitters in the brain, as well as in the
periphery. The cholinergic hypothesis of AD (Bartus et al., 1982), posits the
disease is caused by a deficient cholinergic system (Whitehouse et al., 1982).
This includes decreased choline acetyltransferase (Bowen et al., 1976; Davies
and Maloney, 1976), reduced choline uptake (Rylett et al., 1983), ACh release
(Nilsson et al., 1986), and loss of cholinergic neurons in the nucleus basalis of
Meynert (Whitehouse et al., 1982). Although a deficient cholinergic system does
not fully explain the disease (Francis et al., 1999), cholinergic receptors are
surely involved. Aptly, one of the primary treatments for AD is the use of
acetylcholinesterase inhibitors, which slow the metabolism of ACh in synapses
(the other mainstay treatment is memantine, an NMDA receptor antagonist).
However, the magnitude of effect of these drugs is small and has been criticized
as a temporary, symptomatic approach (Fisher, 2012; Birks and Harvey, 2018).
Over the past couple decades the amyloid hypothesis of AD has likely
been the most popular. This theory suggests the neurodegeneration observed in
AD is caused by aggregation of amyloid beta proteins (Glenner and Wong, 1984;
Selkoe and Hardy, 2016). Indeed early-onset familial AD (3.5% of cases, Harvey
et al., 2003) is a devastating variant of AD that is caused by dominant genetic
mutations that alter the processing of amyloid precursor protein, resulting in a
greater proportion of toxic amyloid beta. In general, amyloid beta is found
extracellularly in both soluble and insoluble forms and is thought to aggregate in
plaques or oligomers to degenerate cells via contested mechanisms (Masters et
al., 1985; Lue et al., 1999; Zhao et al., 2012). Many investigators have attempted
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to treat AD by reducing amyloid beta load by inhibiting production, increasing
clearance, and preventing deposition (Panza et al., 2019) and although many of
these trials are still underway, clinical trials to treat AD have been anything but
fruitful in recent years. In fact, no new drugs for AD have emerged from clinical
trials in the past 15 years (Panza et al., 2019). This paucity of clinical progress
ultimately led the pharmaceutical giant Pfizer to announce its exit from AD
research in January of 2018 (Hawkes, 2018). In March of 2019 Biogen
announced the halt of phase 3 clinical trials for aducanumab, a promising amyloid
beta antibody and potential AD treatment, due to lack of efficacy.
There are many other proposed contributors to AD pathophysiology that
are regrettably outside the scope of this thesis, including toxic accumulation of
tau protein (Ballatore et al., 2007), dysfunction of the blood-brain barrier (Hawkins
and Davis, 2005), oxidative stress (Lin and Beal, 2006), air pollution (Moulton and
Yang, 2012), gum disease (Dominy et al., 2019), low sleep quality (Minakawa et
al., 2019) and of course a lack of proper diet (Liu, 2003; Morris et al., 2003; Sofi
et al., 2008) and exercise (Laurin et al., 2001; Lautenschlager et al., 2008).
Iaccarino et al. (2016) recently suggested an unusual treatment strategy: flashing
light and pulsing audio stimuli at 40 Hz, which reduced amyloid plaque deposition
in a mouse model of AD.
Despite decades of research, an optimal treatment strategy for AD
remains elusive. This project will attempt to contribute to this work by observing
neuronal activity during cognitive behaviour and characterizing the involvement of
cholinergic receptors, which appear to be associated with some AD
symptomology.
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1.1.2 Schizophrenia
Schizophrenia (SZ) is a mental condition that affects approximately 1%
Canadians. Although there are sex differences in age of incidence (e.g., men are
often diagnosed earlier than women), no difference in prevalence between sexes
has been reported (McGrath et al., 2008). People with SZ display a wide range of
behavioural symptoms, broadly categorized into three groups: positive, negative,
and cognitive (Kay et al., 1987). Positive symptoms include hallucinations,
delusions, disorganized thoughts, difficulty concentrating, and catatonic
movements. Negative symptoms include anhedonia, difficulty communicating,
blunted emotions, avolition, and social withdrawal. Cognitive symptoms include
deficits in decision making, response inhibition, and working memory (WM).
According to Bowen et al. (1994) it is the cognitive deficits of SZ, such as WM
impairment, that lead to poor social and occupational functioning. For example, if
an effective treatment for these cognitive symptoms could be addressed, people
with SZ may be able to lead happier, more fulfilling lives. SZ is often comorbid
with other conditions such as substance abuse. Treatment of SZ has limited
efficacy and involves the use of antipsychotics, in addition to behavioural therapy
and social support networks. Antipsychotics are typically suitable for suppressing
the positive symptoms of SZ, but are less effective at addressing negative and
cognitive symptoms (Carbon and Correll, 2014).
Although the causes of SZ remain unclear, it is thought to involve both
genetics and the environment. There are some notable differences in the SZ
physiology that may provide clues towards more effective future treatments.
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Revealed by postmortem studies, such brain changes include: enlarged
ventricles, smaller grey matter and whole brain volume, smaller medial temporal
lobe and thalamic volume, and smaller cortical pyramidal neurons (Harrison,
2000). Importantly, there are no signs of gliosis or AD neurodegeneration (such
as amyloid plaques, neurofibrillary tangles) in postmortem SZ brain histology
(Arnold et al., 1998), suggesting these conditions arise from very different
mechanisms. For example, many have postulated SZ is a type of developmental
disorder, with changes occurring during neural development in the fetus. Indeed,
researchers have found several aberrations in SZ cytoarchitecture including
abnormal neuronal organization in entorhinal cortex, hippocampus, and white
matter (Kovelman and Scheibel, 1984; Jakob and Beckmann, 1986; Akbarian et
al., 1993).
The dopamine hypothesis is another popular theory of SZ. SZ postmortem
studies have found increased dopamine D2 receptors and decreased cortical
dopamine innervation (Seeman and Niznik, 1990; Akil et al., 1999). In addition,
although psychosis and SZ are not synonymous, dopaminergic compounds
produce psychosis. And of course antipsychotics, the mainstay of SZ treatment,
are all dopamine D2 receptor antagonists.
Although the aforementioned are important clues towards etiology and
future treatment strategies, there are many other neurotransmitter systems that
are disrupted in SZ, including the glutamatergic system (i.e., the glutamate
hypothesis of schizophrenia and NMDA blockade model of schizophrenia; Javitt,
1987; Coyle, 1996; Gil-da-Costa et al., 2013; Ma et al., 2018), the serotoninergic
system, and the GABAergic system (Harrison, 1999). The cholinergic system,
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despite not receiving as much attention in SZ as other neurotransmitters, is also
disrupted in SZ. For example, expression of muscarinic M1 receptors is
decreased in SZ (Dean et al., 2002). People with SZ are 5x more likely to be
smokers (de Leon and Diaz, 2005; McClave et al., 2010). Although it is difficult to
pin causality on SZ, especially considering the number of comorbid and lifestyle
situations of people with SZ, some have posited smoking may be a form of selftreatment (the self-medication hypothesis; Kumari and Postma, 2005). For
example, stimulation of nicotinic receptors (nicotine is the main psychoactive
compound in cigarettes) is known to improve performance in a number of
cognitive tasks (Levin et al., 2006). However, a recent meta-analysis found that
smokers with SZ did not have a distinct cognitive advantage over nonsmokers
with SZ, and the effect of smoking likely differs based on the cognitive domain
tested (Wang et al., 2019).
SZ, similar to AD, is associated with both impaired cognition and altered
cholinergic system. Although many models of schizophrenia have been
proposed, there is a gap in knowledge to be addressed regarding how
acetylcholine modulates both normal and abnormal cognitive circuitry. The
prefrontal cortex, which receives dense cholinergic innervation, has been a
prominent focus of cognitive neuroscience. This investigation will explore the role
of cholinergic receptors in prefrontal activity, attempting to provide insights into
the cholinergic pathology in conditions of impaired cognition such as AD and SZ.

1.2
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The primate lateral prefrontal cortex (PFC) contributes to a range of higher

order cognitive functions (Miller and Cohen, 2001), including attention, response
inhibition, WM maintenance and manipulation, and context-dependent or goaldirected behaviour. PFC is particularly sensitive to atrophy in AD
(Giannakopoulos et al., 1997). Total PFC grey matter is reduced in AD compared
to age-matched controls (Salat et al., 2001) and both presynaptic terminals and
synapses are also reduced (Brion et al., 1991; Masliah et al., 1991). Young et al.
(2014) reported that in AD, pyramidal dendritic spines in PFC degrade faster than
V1 spines. This degeneration likely contributes to cognitive symptoms. Serra et
al. (2010) found cingulate and right middle frontal gyri grey matter volume
inversely correlated with disinhibition scores of AD patients. PFC is also
abnormal in SZ: pyramidal spine density is decreased (Glantz and Lewis, 2000),
parvalbumin expression in interneurons is decreased (Hashimoto et al., 2003),
inflammatory markers are increased (Fillman et al., 2013), and regulation of
presynaptic gene expression is reduced (Mirnics et al., 2000). Individuals with SZ
show abnormal activation of PFC during performance of executive tasks (Barch
et al., 2001), and task performance is correlated with degree of altered prefrontal
activation (Weinberger et al., 1986; Perlstein et al., 2001). Thus, there is
evidence for a role of PFC in the cognitive deficits observed in AD and SZ. The
necessity of PFC in executive function can be experimentally determined by
observing the effects of prefrontal lesions. The next section will overview previous
reports examining PFC lesions and resultant effects on cognition.

1.2.1 Lesions of PFC
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Studies examining the effects of brain lesions have been used for decades

and have provided many insights into the functions of different brain regions. For
example, topographical mapping of the visual field onto area V1 was aided by
observing how V1 scotomas affected vision in different portions of the visual field
(Lister and Holmes, 1916). There are numerous investigations reporting the
effects of frontal lobe lesions in humans. For example, Milner, 1963 had epileptic
patients perform the Wisconsin Card Sorting Test (WCST) before and after
unilateral cortical excisions to relieve seizures. Dorsolateral frontal lesions
resulted in marked reductions in WCST performance: number of errors was
increased and number of categories achieved was decreased. The increase in
errors was largely perseverative errors, e.g., patients would be told their choice of
card was wrong but they would not correct this behaviour in future actions. Milner
suspected there was a disconnect between observation of an error and change to
the appropriate action. Deficits in planning and WM were also found by Owen et
al. (1990), which tested patients with frontal lobe lesions.
Of course, the extent of frontal lesions in humans is highly variable,
depending on the reason for excision (e.g., epilepsy, aneurysm, cancer). This can
make interpretations on the functions of individual brain regions difficult, since
surgical excisions do not adhere to cytoarchitecturally-defined brain areas. The
use of nonhuman primates (NHPs) is extremely useful for this reason, since
experimental ablations can be confined to a particular region (e.g., principal
sulcus) and consistent across subjects. The use of NHPs is invaluable in
research towards treating conditions of disrupted cognition such as AD and SZ, in
which PFC function is altered. Although the use of rodent models is pivotal for
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many areas of neuroscience research, rats do not have a granular PFC
analogous to that of humans (Preuss, 1995).
Several investigators have explored the effects of ablation to principal
sulcus and surrounding area on WM (Gross and Weiskrantz, 1962; Butters and
Pandya, 1969; Mishkin and Manning, 1978; Passingham, 1985; Funahashi et al.,
1993a). These findings support a vital role of dorsolateral PFC (DLPFC), and
especially principal sulcus, in successful performance in spatial WM tasks.
Funahashi et al. (1993a) found unilateral principal sulcus lesions disrupted
performance of memory-guided saccades in the contralateral visual field. These
deficits were exaggerated with increased delay length, suggesting optimal
DLPFC function is required even more during greater WM load. Deactivation of
DLPFC can also be examined using local injections of muscimol, a GABAA
receptor agonist. Similar to ablation, muscimol injections caused increased errors
and saccadic dispersion to the contralateral targets during memory-guided
saccades (Sawaguchi and Iba, 2001).
Gregoriou et al. (2014) lesioned right PFC (including FEF), corpus
callosum, and anterior commissure and recorded from both right (no prefrontal
input) and left (control) visual area V4 in two rhesus macaques. Compared to the
control hemisphere, right V4 then experienced diminished effects of attention and
reduced spiking coherence with cortical oscillations.
Experiments using lesions have thus illuminated the role of PFC in
executive function, including WM and attention. As discussed in the following
section, due to the interregional connections of PFC, it is well suited to
accumulate sensory inputs and coordinate goal-directed behaviour, such as
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during WM tasks.

1.2.2 Anatomical connections of PFC
The PFC is interconnected with many of cortical and subcortical regions,
making it well positioned to receive sensory information, communicate between
regions, and execute appropriate actions (Fig. 1.1; Miller and Cohen, 2001).
Taking context into account and flexibly choosing the appropriate action is
believed to be a cardinal function of PFC. The expansion of association cortices
such as PFC has accelerated over the course of evolution at a faster rate than in
our relative species (Rilling and Insel, 1999). The cognitive specializations of PFC
are likely involved in development of human intelligence and our identity as a
species (Roth and Dicke, 2005). Human PFC has a disproportionately high
degree of connectivity, measured by white matter volume (Schoenemann et al.,
2005).
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Figure 1.1
Intrinsic and extrinsic connections of the prefrontal cortex.
Regions of prefrontal cortex is heavily connected with other prefrontal regions,
and distant brain areas such as sensory cortices, motor regions, basal ganglia,
temporal cortex, and thalamus. Through these extensive connections, prefrontal
cortex is well suited to flexibly coordinate cognitive control. Solid lines represent
bidirectional connections; arrows indicate unidirectional connections. Reprinted
with permission from: Miller and Cohen. (2001) An integrative theory of prefrontal
cortex function. Annual Review of Neurosciscience. 24:167–202.
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Lateral PFC receives input from a wide range of regions, including

occipital, temporal, and parietal cortices. In particular, DLPFC is thought to
converge multisensory information, with inputs from visual, auditory, and
somatosensory cortices, and also regions that are themselves multimodal (Bruce
et al., 1981; Goldman-Rakic and Schwartz, 1982; Barbas and Pandya, 1989;
Pandya and Yeterian, 1990).
DLPFC is proposed to maintain goals during delayed responses and
influence output motor regions via direct connections. Although DLPFC does not
terminate on M1 directly, it has afferents in supplementary motor area, presupplementary motor area, and premotor cortex, where it is thought to promote
actions related to premeditated goals (Bates and Goldman-Rakic, 1993; Lu et al.,
1994). DLPFC also influences saccadic behaviour directly with connections to
superior colliculus (Goldman and Nauta, 1976; Johnston and Everling, 2009), and
indirectly via the frontal eye fields (FEF) and basal ganglia (Stanton et al., 1993).
Prefrontal influence on SC was historically thought to be inhibitory, thereby
suppressing inappropriate saccades during tasks such as the antisaccade task
(Guitton et al., 1985; Pierrot-Deseilligny et al., 1991). However, recent work
involving cortical cooling of rhesus DLPFC and concurrent SC recordings suggest
that PFC instead has an excitatory influence on SC, promoting saccades towards
goal-directed targets (Koval et al., 2011; Everling and Johnston, 2013; Johnston
et al., 2014).
There are also dense connections from PFC to basal ganglia (BG), and
back from BG to PFC (via the thalamus). The BG is involved in several corticalsubcortical-thalamic loops (Alexander et al., 1986), and is known for its role in
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facilitating or inhibiting movement. Degeneration of these cortical-BG loops may
elicit the cognitive deficits in Parkinson’s disease and Huntington disease
(Stocchi and Brusa, 2000).
PFC is also interconnected with hippocampus (Goldman-Rakic et al.,
1984) and the two areas oscillate synchronously during WM tasks (O'Neill et al.,
2013; Tamura et al., 2017), suggesting flow of information. These connections
may mediate reflection of past experiences to gauge current context
(Eichenbaum, 2017). Finally, PFC is also connected with the amygdala (Porrino
et al., 1981; Amaral and Price, 1984; Barbas and De Olmos, 1990) and the
hypothalamus (Rempel-Clower and Barbas, 1998). Through these
communication channels, PFC is thought to process emotional and internal
states (Miller and Cohen, 2001).
Thus, the PFC is densely interconnected with many brain regions and is
well suited to intake and process sensory information, maintain this
representation in WM, and output and appropriate response. This begets the next
question: how is maintenance of a short-term memory represented in the brain?
Many investigators have explored this question using NHP electrophysiology.

1.2.3 Delay Activity
For decades, in vivo NHP electrophysiology has been a powerful tool for
exploring cortical representations of WM. This technique allows observation of
neuronal activity from a primate with a granular PFC similar to that of humans
(Petrides and Pandya, 1999; Croxson et al., 2005), concurrent with performance
of executive tasks. One fascination of electrophysiologists was the ability of some
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neurons in lateral PFC to discharge persistently during a delay period of WM
tasks, i.e., after a cue directing a later action and in the absence of sensory
stimuli. For example, Kubota and Niki (1971) found neurons around the macaque
principal sulcus that would preferentially discharge during the 5 s delay period of
a delayed alternation task. These delay cells have been found by many other
investigators (Fuster and Alexander, 1971; Fuster, 1973; Niki, 1974a; Niki,
1974b; Niki, 1974c; Niki and Watanabe, 1976; Fuster et al., 1982; Kojima and
Goldman-Rakic, 1982; Kojima and Goldman-Rakic, 1984; Batuev et al., 1985).
A very common task in NHP electrophysiology is the oculomotor delayedresponse task, also known as memory-guided saccades (Fig. 1.2A). In this
experimental task, monkeys are head-fixed in front of a monitor and trained to
fixate on a central dot. Next, a cue is flashed in the periphery at one of eight
locations and the monkey must maintain central fixation over a delay period
(typically 1–3 s). Finally, the central fixation dot disappears and the monkey must
saccade to the previously cued location. When prefrontal neurons are recorded
during performance of this task, especially around the principal sulcus,
approximately approx. 25–33% of neurons discharge preferentially during this
delay period (Fig. 1.2B; Funahashi et al., 1989). This persistent firing after the
removal of visual stimulation, and despite the presence of distractors (Jacob and
Nieder, 2014), led many to suspect this activity could be the neurophysiological
basis of WM maintenance (Funahashi et al., 1989; Goldman-Rakic, 1995). Other
cortical regions are much more susceptible to respond to distractors (Suzuki and
Gottlieb, 2013). Prefrontal delay cells also show directional selectivity, with many
firing only for cues in certain receptive fields (or “memory fields”).
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Figure 1.2
The memory-guided saccade task and delay cells.
A, This task begins with central fixation (FP) and a flashed cue in one of eight
peripheral locations. The subject must maintain fixation through this briefly
flashed cue (C) and the following delay epoch (D), which can vary from 1–3 s.
After the delay epoch comes the response epoch (R), when the central fixation
dot is extinguished and the subject must saccade to the location of the previous
peripheral cue. Rasters and spike histograms are shown for a single dorsolateral
prefrontal cortex neuron during eight different trial types, each with a different
peripheral cue location. This example neuron selectively discharges during the
delay epoch for the 270° visual angle. Modified with permission from Funahashi
et al. (1989) Mnemonic coding of visual space in the monkey's dorsolateral
prefrontal cortex. J Neurophysiol. 61(2):331–49. B, Shown are three of the cell
types observed in prefrontal cortex during performance of memory-guided
saccades: cue-, delay-, and response-selective cells. Delay cells discharge in the
absence of visual stimuli, often only for certain visual locations in memory.
Modified with permission from Goldman-Rakic. (1995) Cellular basis of working
memory. Neuron. 14(3):477–85.
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Based on these results, Goldman-Rakic (1995) popularized a theory of

WM maintenance, in which layer III of lateral PFC held information in WM by
recurrent excitation between reciprocally connected pyramidal neurons. As
discussed in the next subsection, the DLPFC indeed has suitable
cytoarchitecture for recurrent activation, with most layer III pyramidal neurons
synapsing onto other layer III pyramidal neurons (Melchitzky et al., 1998).
However, this model of WM involving delay cells and persistent activity
within PFC has recently come under criticism. Firstly, delay cells are found in a
wide variety of brain regions other than PFC, which appears to weaken the
necessity of prefrontal delay activity in WM (we know from lesion studies that WM
is reliant on PFC). Other regions with delay activity include parietal cortex (Qi et
al., 2010; Katsuki and Constantinidis, 2013), inferotemporal cortex (Fuster, 1990;
Freedman et al., 2003), visual cortices (Hayden and Gallant, 2013; van Kerkoerle
et al., 2017), somatosensory cortices (Zhou and Fuster, 1996), and thalamus
(Watanabe and Funahashi, 2004), albeit to varying degrees (Levitt et al., 1993).
The Miller lab has suggested that this persistent activity observed during
delay periods is not very prevalent in most prefrontal neurons, and their
appearance in single-unit and population spike density functions is the result of
averaging across trials and neurons. Several reports have shown spiking is in
fact sparse during individual trials (Lundqvist et al., 2016) and true delay cells are
overrepresented in publications due to the use of idealistic (instead of
representative) example neurons in figures. Delay activity could be related to
motor preparation instead of memory retention (Shafi et al., 2007). Indeed many
neurons show “ramp-up” activity that peaks upon motor or oculomotor response.
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The Miller lab believes transient discharges are sufficient for WM maintenance, in
which asynchronously active neurons take turns firing to maintain WM
information (Lundqvist et al., 2010). Transient gamma bursts are also observed
during memory-guided saccade WM maintenance (Lundqvist et al., 2016), can
show task-related tuning during WM tasks (Pesaran et al., 2002), and can predict
upcoming errors with higher accuracy than spiking alone (Lundqvist et al., 2018).
The Miller lab further proposes that instead of persistent spiking, short-term
information can be maintained via synaptic facilitation, augmentation, and
potentiation (Wang et al., 2006). Such non-spiking maintenance is less
metabolically expensive and possibly less prone to interruption from distractor
sensory input.

1.2.4 Dorsolateral PFC cytoarchitecture and microcircuits
Brodmann (1905) labelled the dorsolateral region of PFC as area 9. This
region of cortex was later split into two, adding area 46 (Walker, 1940) because
of area 46’s characteristic thick granular layer IV. Walker’s area 46 was ultimately
split again, adding new area 9/46 (Fig. 1.3) due to the large pyramidal neurons in
deep layer III of area 9/46 (Petrides and Pandya, 1999).
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Figure 1.3
Human and rhesus macaque prefrontal cortices.
Lateral views of human (A) and rhesus macaque (B) left prefrontal cortices.
Homologous prefrontal regions are shown. Recordings during this project were
performed in dorsal area 9/46. This area, medial to the posterior principal sulcus
corresponds to the human middle frontal gyrus. Modified with permission from
Petrides and Pandya. (1999) Dorsolateral prefrontal cortex: comparative
cytoarchitectonic analysis in the human and the macaque brain and
corticocortical connection patterns. Eur J Neurosci. 11(3):1011–36.
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One of the reasons DLPFC has been the subject of WM conversations is

because of its extensive local interconnections, which may support recurrent
activity during WM maintenance. Histological studies have indeed shown that
layer III pyramidal neurons of DLPFC have bidirectional connections with layer III
of nearby cortical columns (Levitt et al., 1993; Kritzer and Goldman-Rakic, 1995;
Pucak et al., 1996). DLPFC also has bidirectional connections with distant brain
regions such as parietal cortex (Leichnetz, 1980; Goldman-Rakic and Schwartz,
1982; Schwartz and Goldman-Rakic, 1984). As discussed previously, if delay
activity (or persistent activity) is indeed a component of WM maintenance, these
dense recurrent connections may support such activity. Melchitzky et al. (1998)
provided a convincing example of these recurrent connections in macaque PFC:
over 95% of layer III pyramidal neuron terminations were onto other layer III
pyramidal neurons in PFC. These pyramidal-to-spine terminals appear to be
especially prevalent when synapsing onto a different prefrontal column or
terminating in another PFC area (Melchitzky et al., 2001).
Dendrites of pyramidal neurons have a unique profile in human PFC, with
a high number of spines and branches. Human PFC has many more spines than
neurons in other areas such as V1 (Jacobs et al., 2001; Elston, 2003) and has
23x more layer III dendritic spines than rhesus macaque PFC (Elston, 2001). This
dendritic labyrinth is interpreted as allowing for greater information processing
capacity in human PFC and may contribute to the advanced cognitive flexibility of
humans (Roth and Dicke, 2005). Prefrontal spines express a variety of
neuromodulatory receptors and are actively being investigated as
pharmacological targets (Arnsten et al., 2012). Intriguingly, all three of the
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following conditions with deficient cognition—AD, SZ, and normal aging—involve
reduction of PFC layer III spines (Peters et al., 2008; Boros et al., 2017; Hoftman
et al., 2017). Prefrontal spine density correlates with indicators of cognitive
function during aging (Dumitriu et al., 2010), and in AD prefrontal spines degrade
faster than spines in V1 (Young et al., 2014).
Interneurons (approx. 20–30% of cortical neurons) also play a prominent
role in prefrontal circuits. Compared to pyramidal neurons, cortical interneurons
are diverse in morphology, physiological properties, and function. There are
different methods of classifying interneurons, including based on molecular
markers, morphology (including synapse morphology), and electrical properties.
For example, calcium-binding proteins parvalbumin (PV), calretinin (CR), and
calbindin (CB) are commonly used to aid in interneuron identification
(Demeulemeester et al., Neurosci LEtt, 1989; Rogers and Resibois,
Neuroscience, 1992; Kubota et al., 1994). Neuropeptides such as somatostatin
(SOM), vasoactive intestinal polypeptide (VIP), cholecystokinin (CCK), and
neuropeptide Y (NPY) can also aid in identification (Hendry et al., 1984).
However, distinction using molecular markers are cannot accurately identify
interneuron type unless multiple markers are used in conjunction (Markram et al.,
2004). Rudy et al., (2011) have proposed that distinction using PV, SOM, and
serotonin receptor 3a can account for nearly all GABAergic neurons. Conde et al.
(1994) used immunohistochemistry to find the laminar distribution of interneurons
in rhesus macaque area 46. They found the highest density of interneurons in
superficial layers, although PV neurons were also present in granular and
infragranular layers (see Fig. 1.4).
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Figure 1.4
Laminar distribution of GABAergic interneurons in macaque area 46.
Laminar distributions of calretinin (CR), calbindin (CB), and parvalbumin (PV)
immunoreactive structures are shown in macaque area 46. CR and CB neurons
were most prominent in supragranular layers, and PV neurons were mostly in
layer IV, followed by layer III. Modified with permission from Condé et al. (1994)
Local circuit neurons immunoreactive for calretinin, calbindin D-28k or
parvalbumin in monkey prefrontal cortex: distribution and morphology. J Comp
Neurol. 341(1):95–116.
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During extracellular electrophysiological recordings in vivo, neurons can

only be putatively classified based on waveform shape (other properties such as
discharge rate can also be useful in classification; Connors and Gutnick, 1990;
Kawaguchi, 1993; Gonzalez-Burgos et al., 2005). Neurons with broad waveforms
(longer trough-to-peak duration) are putatively labelled as pyramidal and neurons
with narrow waveforms (shorter trough-to-peak duration) can be labelled as
nonpyramidal. Specifically, narrow-spiking neurons are thought to often be PV
interneurons. Other types of interneurons do not exhibit this narrow waveform,
e.g., VIP interneurons often have broad spike waveforms similar to that of
pyramidal neurons (Mesik et al., 2015). SOM interneurons can have either
narrow or broad waveforms, depending on the subtype (Kim et al., 2016). Indeed,
this classification scheme is not perfect, pyramidal tract neurons with narrow
waveforms have been identified in macaque motor areas (Vigneswaran et al.,
2011).
Rao et al. (1999) simultaneously recorded putative pyramidal and
nonpyramidal neurons during macaque performance of memory-guided
saccades. They found similar directional tuning between adjacent pairs, whereas
pairs that were further away from each other displayed opposite directional
preference (Wilson et al., 1994). These findings, combined with anatomy showing
recurrent connectivity within PFC, led to a proposed role of interneurons in
directional tuning during memory-guided saccades. As pyramidal neurons
propagate activity to similarly-tuned cortical columns, they also activate
GABAergic interneurons within their own cortical column, which go on to
suppress activity in other, dissimilarly-tuned cortical columns (e.g., containing
	
  

	
  
pyramidal neurons that preferentially fire for a different stimulus direction or
“memory field”; see Fig. 1.5). This GABAergic control of neuron directional
preference was supported by local application of GABAA receptor antagonist
bicuculine, which abolished memory-guided saccade directional tuning by
increasing activity (likely disinhibition) for nonpreferred directions (Rao et al.,
2000).
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Figure 1.5
Goldman-Rakic model of the prefrontal working memory circuit.
In this model of working memory maintenance during memory-guided saccades,
the location of the peripheral cue is maintained throughout the delay period by
recurrent connections between layer III pyramidal neurons (triangles) in prefrontal
cortex. Different cortical columns represent different peripheral angles or
“memory fields”. For example, after a 270° cue, there is recurrent discharging
between pyramidal neurons (some in different columns) that are selective for
270° cues. Further, inhibitory interneurons (circles) suppress activity in pyramidal
neurons that represent different cue locations (e.g., 90° cue). Modified with
permission from Goldman-Rakic. (1995) Cellular basis of working memory.
Neuron. 14(3):477–85.
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A circuit model of interneuron function during WM maintenance was

proposed by Wang et al. (2004). PV neurons have wide horizontal arborizations
(e.g., basket cells) and are proposed to cause widespread inhibition to pyramidal
neurons across multiple cortical columns, and also to CR neurons within the
same column (Fig. 1.6). CB neurons provide local suppression of pyramidal
dendrites.	
  Finally, CR neurons inhibit nearby CB neurons (thus disinhibiting the
local pyramidal neurons). This model was able to successfully show persistent
activity of pyramidal neurons during a delay period and was resilient to distractor
cues. This ability to avoid distractors was related to the ratio of dendritic vs.
somatic inhibition onto pyramidal neurons. CB interneurons are decreased in SZ
and AD (Ferrer et al., 1993; Beasley and Reynolds, 1997), but CR neurons (and
PV neurons in AD) are spared (Woo et al., 1998).
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CB

CR

PV

Figure 1.6
Diagram of pyramidal neurons and interneurons in proposed microcircuit of
working memory.
Similar to the model previously proposed by Goldman-Rakic (Neuron, 1995),
activation of a pyramidal neuron (P) results in inhibition of nearby pyramidal
neurons that are responsive to different memory-guided saccade cue locations.
This lateral inhibition is carried via parvalbumin (PV) GABAergic interneurons.
Calbindin (CB) interneurons provide local inhibition to pyramidal neurons.
Calretinin (CR) interneurons inhibit CB interneurons, thus disinhibiting local
pyramidal cells. Modified with permission from Wang et al. (2004) Division of
labor among distinct subtypes of inhibitory neurons in a cortical microcircuit of
working memory. PNAS. 101(5):1368–73.

	
  

	
  

27
Future work showing how different neuromodulators are expressed on

different interneurons in PFC would be very helpful in determining how this circuit
could be affected in different neuromodulatory states. For example, dopamine D1
receptor stimulation may increase the dendritic/somatic inhibition ratio and help
filter out distracting stimuli during WM tasks (Gao et al., 2003; Wang et al., 2004).
Interestingly, Disney and Aoki (2008) found different interneurons in macaque V1
showed differential expression of muscarinic M1 receptors, with PV neurons
being the most likely to express muscarinic M1 receptors.
Together, pyramidal and interneurons form microcircuits across the six
layers of PFC that are important for WM. Superficial layers are most commonly
associated with task-related activity during WM tasks, especially during the delay
period (Sawaguchi et al., 1989), which then direct deeper layers that are
considered the output layer (Song et al., 2012). In the example of oculomotor
tasks, deep layer pyramidal neurons send projections to SC to influence saccadic
responses (Goldman and Nauta, 1976; Johnston and Everling, 2009).
Until recently, electrophysiological recordings were performed using single
electrodes and therefore the exact cortical layer of recordings could not be
reported with high confidence. With the use of laminar electrodes, the roles of
different cortical layers have now been explored across neocortex (Lakatos et al.,
2007; Takeuchi et al., 2011; Godlove et al., 2014; Chandrasekaran et al., 2017;
Nandy et al., 2017; Bastos et al., 2018). For example, Opris et al. (2012) found
similar spatial tuning between prefrontal layer III neurons and layer V neurons
within the same cortical column.
Cortical columns in different cortical regions appear to share patterns of
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connectivity. Bastos et al. (2012) have proposed a canonical cortical microcircuit
that details the temporal flow of information between layers and between areas in
both bottom-up and top-down directions (Fig. 1.7). Briefly, supragranular layer III
receives feedforward connections from granular layer IV as well as feedback
information from higher cortical areas. Layer III neurons then project to
infragranular neurons in the same column, make lateral connections with other
layer III neurons in the same area, and send projections to higher cortical areas
as feedforward information (van Kerkoerle et al., 2017). Infragranular output
layers V and VI send long range projections to subcortical areas, thalamus, and
also feedback projections to lower cortical areas (typically terminating on supraand infragranular layers, but not layer IV). These deep layers also send intrinsic
projections to superficial layers of the same column. Recently, alpha oscillations
from deep layer PFC of macaques (Bastos et al., 2018) and marmosets
(Johnston et al., 2019) have been reported to inhibit gamma power and spiking
activity in superficial layers of the same column.
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Figure 1.7
Proposed canonical microcircuit of feedforward and feedback cortical
connections.
This laminar organization of connections is proposed to be consistent across
different cortical areas. Feedforward connections such as sensory input enters a
cortical column in layer IV and next from layer IV to layers II/III. These layers
project to both higher cortical areas and deep layers V/VI of the same column.
These deep layers send feedback signals to lower cortical areas, thalamus, and
output information to brainstem. Feedback information from higher cortical areas
often enters via layers II/III and V/VI. Reprinted with permission from Bastos et al.
(2012) Canonical microcircuits for predictive coding. Neuron. 76(4):695–711.
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Cholinergic System
ACh is a neurotransmitter that was already identified in 1914 (Dale, 1914)

and acts upon two classes of cholinergic receptors – muscarinic receptors and
nicotinic receptors – that are found throughout the central and peripheral nervous
system. Although there are some neurons in rat neocortex that produce ACh
(Levey et al., 1984; Houser et al., 1985), cholinergic afferents from deep brain
structures, such as the nucleus basalis of Meynert and medial septal nucleus, are
the main source of cortical ACh (Fig. 1.8; Kievit and Kuypers, 1975; Mesulam and
Van Hoesen, 1976; Mesulam et al., 1983). Cholinergic nuclei are referred to as
Ch1–Ch4. Uncovering the inputs to cholinergic nuclei can reveal what type of
activity can drive ACh release. For example, top-down attention is a form of
attention that is driven by higher order processes such as short-term memory
goals, and may be elicited by connections from PFC to basal forebrain.
Projections to basal forebrain from rat medial PFC may mediate such top-down
attention (Gaykema et al., 1991; Zaborszky et al., 1997). In macaques, cortical
projections to nucleus basalis were not identified from DLPFC, but from
orbitofrontal cortex and other cortical regions including prepyriform cortex,
entorhinal cortex, inferotemporal cortex (Mesulam and Mufson, 1984). The basal
forebrain also receives input from subcortical regions (medial hypothalamus,
septal nuclei, nucleus accumbens-ventral pallidum, amygdala; Price and Amaral,
1981; Mesulam and Mufson, 1984) and catecholaminergic nuclei (Smiley and
Mesulam, 1999; Smiley et al., 1999).
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Figure 1.8
Cholinergic nuclei of the human brain.
Different cholinergic nuclei innervate different brain regions with cholinergic
afferents. The basal forebrain, including the nucleus basalis of Meynert (nBM), is
the main contributor of acetylcholine to neocortex. MS, medial septal nucleus;
DB, diagonal band of Broca; LDT, laterodorsal pontine tegmentum; PPT,
pedunculopontine tegmental nucleus. Reprinted with permission from Newman et
al. (2012) Cholinergic modulation of cognitive processing: insights drawn from
computational models. Front Behav Neurosci. 13:6–24.
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The cholinergic system has been associated with a variety of different

functions, including learning and memory (Saar et al., 2001), perception (Evans,
1975; Bartus and Johnson, 1976), attention (Kozak et al., 2006), and cognitive
functions such as WM maintenance (Green et al., 2005). ACh release varies
greatly during the sleep/wake cycle (Marrosu et al., 1995). High ACh levels
during rapid eye movement (REM) sleep are a proposed mechanism behind the
REM deactivation of DLPFC (Braun et al., 1997). ACC activity is increased during
REM sleep (Buchsbaum et al., 2001) and ACC to PFC terminals (Muzur et al.,
2002) gated by muscarinic M2 receptors have been proposed as a specific locus
of this REM DLPFC inhibition (Medalla and Barbas, 2012).
Lesions of the basal forebrain have been used extensively in rats to
examine the behavioural effects of removing endogenous ACh. One of the first
basal forebrain lesions was performed by Dubois et al. (1985), who tested the
effect on acquisition and reversal of spatial memory. They and others (Hepler et
al., 1985) observed a variety of behavioural changes including increased
locomotion and decreased memory capabilities in multiple tasks. The
methodology was improved with the development of immunotoxins that could
selectively destroy cholinergic neurons, but not the non-cholinergic neurons of
basal forebrain (Wiley et al., 1991). These injections indeed produced less
extensive deficits on learning and memory (Wenk et al., 1994). McGaughy et al.
(2002) explored the effects of these cholinergic-specific lesions to rat basal
forebrain in the five-choice serial reaction time task that probes attention. In this
task, rats must attend 5 possible locations and perform a nose poke after a light
is flashed in one of those locations (Robbins, 2002). It was found that these
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lesions decreased performance in several ways, such as increased omissions
and response latencies, indicating decreased attention. The authors further
postulated this effect was not motivational, as increasing the length of the flashed
cue ameliorated the deficit. Upon histological examination they found choline
acetyltransferase-reactive neuron count significantly correlated with choice
accuracy, implicating a role in cholinergic innervation in successful task
performance. Intriguingly, basal forebrain lesions in rats have also been reported
to slow recorded frequencies in EEG (Stewart et al., 1984; Buzsaki et al., 1988),
similar to what is observed in EEG of AD patients with neurodegeneration of the
cholinergic system (Jeong, 2004).
Cholinergic-neuron-specific immunotoxins were eventually tested in
marmoset and rhesus macaque cortex (Fine et al., 1997), which elicited
behavioural deficits in learning/memory, visual discrimination, and visual WM
(Ridley et al., 1999; Turchi et al., 2005). In a landmark study by Croxson et al.
(2011), cholinergic immunotoxin ME20.4-saporin was injected over several areas
of PFC to probe the effect of ablating cholinergic input to PFC. These monkeys
were trained in a variety of tasks including object-in-place learning, strategy
implementation, reward devaluation, and spatial WM. These monkeys were
unaffected in all tasks except the spatial WM task, implicating an important role of
prefrontal cholinergic stimulation in performance of spatial WM. Later chapters of
this thesis will continue this exploration of the role of cholinergic receptors in PFC
during WM performance.
Deep brain stimulation (DBS) of the basal forebrain has been examined in
different animal models and is being explored as a potential treatment option for
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AD (Bittlinger and Muller, 2018). Basal forebrain stimulation in rats can increase
ACh release in cortex (Kurosawa et al., 1989), increase cerebral blood flow
(Biesold et al., 1989; Adachi et al., 1990), and may increase nerve growth factor
via nicotinic stimulation (Hotta et al., 2009). This increased release of ACh may
be able to improve cognitive performance. Kang et al. (2014) found basal
forebrain stimulation increased performance of rats in a visual water maze task.
The potential cognitive benefit of electrically stimulating cholinergic nuclei was
bolstered by Liu et al. (2017), who reported intermittent stimulation of the nucleus
basalis of Meynert in rhesus macaques improved performance in the delayed
match-to-sample task, an effect that was blocked by nicotinic or muscarinic
blockade. These effects persisted in the following months, even on test days
without stimulation. In humans, multiple research groups have attempted DBS in
patient populations, with mixed results (Lozano et al., 2019). A Canadian group
conducted phase I and II clinical trials performing DBS on the fornix of AD
patients (Laxton et al., 2010; Lozano et al., 2016). They reported increased
glucose metabolism and small cognitive improvements, but only on an older
subgroup of participants. A different group performed DBS to the nucleus basalis
of Meynert (Kuhn et al., 2015; Hardenacke et al., 2016). Their results suggest
stimulation may slow disease progression, particularly in cases of milder AD. The
future of human DBS research for AD is in its infancy, with many technical and
ethical considerations (Bittlinger and Muller, 2018).
Apart from cholinergic lesions, another source of information for the
functional roles of cholinergic receptors was the systemic administration of
antagonists. For example, atropine and scopolamine are general muscarinic
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antagonists and mecamylamine is a general nicotinic antagonist. Scopolamine
has been used extensively for decades to test the role of muscarinic receptors in
a variety of cognitive tasks (reviewed by Klinkenberg and Blokland, 2010).
Scopolamine-induced impairments include signal discrimination (Drinkenburg et
al., 1995; Harder et al., 1998; Wilson, 2001), attention (Callahan et al., 1993;
Spinelli et al., 2006), and both learning/long-term memory (Spencer, 1983) and
short-term WM (Rupniak et al., 1991; Green et al., 2005). Nicotinic blockade also
elicits cognitive deficits such as attention, alertness, word recall, and spatial
associative memory (Newhouse et al., 1992; Moran, 1993; Katner et al., 2004;
Baakman et al., 2017). The cognitive effects of nicotinic blockade are dosedependent and typically less extreme than muscarinic blockade, possibly due to
lesser sedative effects (Baakman et al., 2017). Combined nicotinic and
muscarinic receptor challenge can synergistically reduce cognitive performance
(Green et al., 2005; Greenwood et al., 2009).
We can also gain insights on the function of the cholinergic system with
systemic stimulation of receptors. One of the most prevalent examples is the use
of acetylcholinesterase inhibitors in AD. Repantis et al. (2010) reviewed several
studies that explored the effects of acetylcholinesterase inhibitors (mostly
donepezil) on healthy participants. Results were mixed, with some studies
reporting no effect and two studies reporting disrupted performance after drug
administration. However, small improvements compared to placebo were
observed in verbal memory recall, procedural memory, and spatial WM.
Donepezil was able to improve visual attention and short-term memory in sleep-
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deprived participants (Chuah and Chee, 2008), suggesting acetylcholinesterase
inhibitors may only be effective in states of impaired cognition.
The most commonly occurring exogenous stimulation of cholinergic
receptors is an activity involving approximately one billion participants worldwide:
smoking tobacco cigarettes (Ng et al., 2014). Nicotine is naturally occurring in
tobacco and the main psychoactive ingredient in tobacco smoke. Nicotine is an
agonist for most nicotinic receptor subtypes, and thus inspired the name of this
cholinergic receptor class. Systemic nicotine exposure (e.g., smoking a cigarette)
results in a variety of both central and peripheral effects. Peripheral effects to
naïve users include increased heart rate and blood pressure, tremor, headache,
and nausea (Srivastava et al., 1991). A number of studies have reported that the
central effects of nicotine can include increased cognitive performance in
attention and WM (e.g., word recall and n-back tasks; Heishman et al., 2010).
This is one reason some investigators have speculated the higher prevalence of
smoking in people with SZ (a condition with cognitive deficits) is a form of selftreatment (Kumari and Postma, 2005).

1.3.1 Cholinergic innervation
A large proportion of neuroscience progress is based on work using rodent
models. Although work with rodents has been invaluable to progress in the
cholinergic system, many differences have been revealed between the rodent
and primate (and between NHP and human). Coppola and Disney (2018a)
provide a detailed review on the differences between rodent and primate
cholinergic systems.
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Cholinergic afferents originate in subcortical cholinergic nuclei Ch1–Ch4

and are generally thought to be analogous across species (Mesulam et al., 1983;
Butcher and Semba, 1989). Relevant to work on PFC is Ch4, which refers to the
nucleus basalis/substantia innominata in primates that has cholinergic afferents
projecting to various cortical regions, including PFC (principal sulcus), medial
frontal pole, cingulate, medial parietal cortex, peristriate cortex, and many others
(Mesulam et al., 1983; Luiten et al., 1987). One striking difference between
rhesus and rodent cholinergic nuclei is the proportion of cholinergic neurons.
Gritti et al. (2006) reported only 5% of neurons were cholinergic in the rat basal
forebrain, whereas the proportion was up to 90% in rhesus macaque Ch4
(Mesulam et al., 1983). The remaining basal forebrain neurons are either
glutamatergic or GABAergic.
Cortical cholinergic innervation is measured histochemically using
quantification of acetylcholinesterase or choline acetyltransferase in cholinergic
axons (Mesulam and Mufson, 1984). Innervation has many differences between
species, yet an overall pattern appears consistent between primates, cats, and
rats: the highest density of innervation is present in sensorimotor areas (primary
motor area and primary somatosensory area), followed by frontal areas, and the lowest density of cholinergic innervation is found in primary sensory regions
(primary visual area and primary auditory area; Coppola and Disney, 2018a).
Different cortical layers receive varying degrees of cholinergic innervation.
The general agreement across studies is that cholinergic fibers are present in all
layers, but superficial layers I, II, and III receive the strongest cholinergic
innervation, followed by deeper layers V and VI, and finally layer IV receives the
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least amount of cholinergic input (Mesulam and Mufson, 1984; DeKosky et al.,
1985; Lewis, 1991; Mrzljak et al., 1995). However, within this general trend there
are marked differences between species and brain regions. Figure 1.9 shows a
schematic summary of primary visual cortex cholinergic axon densities across six
different species (Gu, 2003).

	
  

	
  

39

Figure 1.9
Density of cholinergic axons in primary visual cortex of six different species.
The density of cholinergic innervation in primary visual cortex, measured with
choline acetyltransferase immunoreactivity, is shown for six different species:
human, macaque, cat, ferret, rat, and mouse. Reprinted with permission from Gu.
(2003) Contribution of acetylcholine to visual cortex plasticity. Neurobiol Learn
Mem. 80(3):291–301.
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Raghanti et al., 2008a provides a detailed comparison of cholinergic

innervation of PFC in human, chimpanzee, and moor macaques. Specifically,
Brodmann areas 9 (DLPFC), 32 (dorsal ACC), and 4 (primary motor cortex) were
measured for choline acetyltransferase immunoreactivity. Overall, cholinergic
innervation appeared similar between species. Innervation was the highest in
motor cortex for all three species. Humans had less layer I innervation than in
layer III or layer V/VI. This is seemingly opposite to what was found in rats:
Mechawar et al. (2000) found layer I medial PFC had the highest density of
cholinergic axons. Humans and chimps had greater cholinergic axon density in
layer III and layer V/VI compared to macaques, possibly suggesting a shift over
the course of evolution. These authors and others (Mesulam et al., 1992) also
noted clusters of cholinergic axons, similar to dopaminergic and serotonergic
clusters in human cortex (Raghanti et al., 2008b; Raghanti et al., 2008c). The
function of these clusters remains unknown, but it is curious that they were
identified in humans and chimpanzees, but not in macaques.

1.3.2 Wired vs. Volume transmission
There is an ongoing debate as to whether ACh is selectively released with
high spatial and temporal accuracy (wired transmission) or en masse into large
volumes of tissue during situations of increased attentional requirements (volume
transmission; Sarter et al., 2009). For example, does the basal forebrain release
ACh throughout the cortical mantle as a slow arousal system (Coull, 1998)? Or is
ACh released more precisely to specific areas? My impression from the literature
is that precise ACh release (wired transmission) is indeed present, although both
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transmission types may coexist. Firstly, the organization of cholinergic neurons in
the basal forebrain is not homogenous – cholinergic neurons are clustered
(Zaborszky, 2002) and certain basal forebrain neurons project to certain cortical
areas (Price and Stern, 1983; Koliatsos et al., 1988). For example, Zmarowski et
al. (2007) have shown nucleus accumbens stimulation can cause ACh release in
PFC but not parietal cortex. More recent work suggests rat basal forebrain may
have some topographical organization (Zaborszky et al., 2015). Secondly, the
idea of nonspecific release and slow spread of ACh via volume transmission
seems impeded by the fact that acetylcholinesterase is one of the fastest known
enzymes (Lawler, 1961; Soreq and Seidman, 2001). ACh could only spread over
a large volume if it avoided synapses, wherein acetylcholinesterase is found
(Quinn, 1987; Coppola et al., 2016). Thirdly, the use of modern enzyme-coated
arrays has allowed the detection of ACh on a second-to-second scale, a much
higher temporal resolution than older methods such as microdialysis (Burmeister,
2001; albeit still slower than synaptic transmission). Parikh et al. (2007) reported
variable choline levels (precursor and metabolite of ACh, and proxy for its
extracellular concentration) during a cue detection task, with briefly elevated
choline on trials after a cue is correctly detected and a lack of transient choline
surge after missed cues (Fig. 1.10). This work shows that ACh can be released
transiently on the order of seconds and quickly broken down in the synapse. In a
corroborating report, neurons in the rhesus nucleus basalis of Meynert were
found to preferentially discharge at specific times during a delayed response task:
especially during the cue, stimulus, and reward epochs (Richardson and DeLong,

	
  

	
  
1986). Local ACh may also be finely regulated by presynaptic glutamatergic
receptors on cholinergic afferents (Parikh et al., 2008).
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Figure 1.10
Transient release of choline in rat medial prefrontal cortex.
Choline signal levels in rat medial prefrontal cortex are shown. Choline is the
precursor and metabolite of acetylcholine and is used as a proxy for extracellular
acetylcholine concentration. As a rat performs a task requiring attention, choline
levels differ depending on whether or not a cue was noticed. Choline levels are
measured with choline oxidase-coated probes. Modified with permission from
Parikh et al. (2007) Prefrontal acetylcholine release controls cue detection on
multiple timescales. Neuron. 56(1):141–54.
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Yet, compelling evidence for volume transmission has been reported and

both wired and volume transmission may be present in cortex. Cholinergic
receptors have been histologically located at non-cholinergic synapses. Umbriaco
et al. (1994) found that the predominant expression of choline acetyltransferase
(enzyme for ACh synthesis) in rat parietal cortex was in nonsynaptic varicosities,
opposed to synaptic varicosities. There are species differences: in human
temporal cortex, two thirds of cholinergic varicosities formed synaptic
specializations (Smiley et al., 1997). However, more recent electron microscopy
evidence suggests there may be more cholinergic synapses in mouse neocortex
than previously thought (Takacs et al., 2013). Thus, it’s possible that cholinergic
innervation of rat cortex is relatively more skewed towards volume transmission
than human cortex. Many investigators have found that there may be basal levels
of ACh in the extracellular space, which also supports a volume transmission role
of ACh (i.e., ACh does not solely exist within the synapse; reviewed by
Descarries et al., 1997). It should be noted that there are other, nonsynaptic
reasons for the volume release of ACh, such as effects on microglial
inflammatory response (Carnevale et al., 2007), myelinating glia (Fields et al.,
2017), and microvasculature (Chedotal et al., 1994). The differences between
wired and volume transmission holds clinical relevance, as the dynamics of
systemic administration of cholinergic compounds (such as cholinergic agonists)
are much more similar to volume transmission than precise, synaptic ACh
release in wired transmission (e.g., stimulation of extrasynaptic cholinergic
receptors).
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1.3.3 Muscarinic receptors
ACh acts on two classes of receptors: metabotropic muscarinic receptors
and ionotropic nicotinic receptors. Nicotinic receptors (discussed below) are
ligand-gated cation channels, and thus excite membrane potential almost
immediately after stimulation. Muscarinic receptors are GPCRs linked to Gα
proteins, and therefore exert their effects on a longer timescale via second
messenger signaling cascades. These signaling pathways further depend on the
subtype of muscarinic receptor that is stimulated. Muscarinic receptor subtypes
are broadly classified into two families: the muscarinic M1 receptor (M1R) family
(including M1Rs, muscarinic M3 receptors, and muscarinic M5 receptors) and the
muscarinic M2 receptor (M2R) family (M2Rs and muscarinic M4 receptors). This
distinction is based on the different Gα proteins targeted. M1R family receptor
subtypes target Gαq/11 and M2R family subtypes target Gαi.
M1R family stimulation, via Gαq/11, leads to a variety of effects, including
PLC-mediated increase in IP3 and DAG, Ca2+ release from internal endoplasmic
reticulum stores, PKC activation. Historically, the ultimate result of M1R
stimulation is thought to be depolarization of the cellular membrane via opening
of cation channels (allowing entry of Na+ and Ca2+) and closure of potassium
channels (blocking exit of K+; see Thiele, 2013). However, the effect of M1R
stimulation may depend on the type of neuron and brain region of interest (Digby
et al., 2012). M2R family stimulation is typically considered to hyperpolarize
membrane potential, through activation of potassium channels, inhibition of
adenyl cyclase, and closure of cation channels.
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Until recently, there was a lack of compounds that could selectively bind

individual muscarinic receptor subtypes. For example, pirenzepine, an M1Rpreferring antagonist, has been a very popular and useful drug to explore the
actions of the M1R family in general, but since it also has weak activity on M3Rs
(Pediani et al., 2016), the interpretations from its experiments relating to M1R
function must come with the disclaimer that M3Rs were also blocked.
Compounds selective for muscarinic receptor subtypes have been difficult to
design because of the subtypes’ homologous structure and highly conserved
ACh-binding pocket (Bubser et al., 2012). Nevertheless, pirenzepine provided
many insights into the action of M1Rs in the central nervous system. M1R
stimulation is typically excitatory to in vitro cortical slice preparations (Carr and
Surmeier, 2007). McCormick and Prince (1985) found transient application of
ACh onto guinea pig cortical slices produced brief hyperpolarization, followed by
prolonged depolarization. They found pirenzepine was able to block the slow
excitatory effect of ACh, but no the inhibition. Egorov et al. (2002) showed
carbachol could produce persistent activity in rat entorhinal cortex. This excitation
was determined to be reliant on muscarinic receptor activation, as it could be
blocked by either muscarinic antagonist atropine or M1R-preferring antagonist
pirenzepine.
Due to the wide variety of second messengers of muscarinic receptors,
one potential clinical research avenue is the targeting of specific signaling
pathways using compounds with functional selectivity (Urban et al., 2007).
Sometimes the desired effect of a drug is attributable to one signaling pathway,
but another coactivated pathway results in unwelcome side effects. For example,
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some M1R allosteric agonists have been shown to activate some second
messengers preferentially over others (Thomas et al., 2008). More recently,
Digby et al. (2012) reported M1R allosteric agonists VU0357017 and VU0364572
differentially activated M1R-coupling to calcium, beta-arrestin, and MAPK
pathways. Future drug discovery investigations must continue to probe which
downstream effectors are being targeted to ensure they are achieving the desired
therapeutic effect.
Of the muscarinic receptor subtypes, M1Rs and M2Rs are the most
commonly expressed in primate neocortex (Mash et al., 1988; Thiele, 2013).
Expression of muscarinic receptors varies through different layers of cortex. Most
investigations have agreed that muscarinic receptors are present in all layers,
with enhanced expression in superficial layers, and to a lesser extent deeper
layers (Lidow et al., 1989; Zilles et al., 1989; Vannucchi and Goldman-Rakic,
1991; Mrzljak et al., 1993; Rodriguez-Puertas et al., 1997). M2Rs are not as
widely expressed, but appear to show the same laminar pattern (Mrzljak et al.,
1998; Erisir et al., 2001; Medalla and Barbas, 2012).
Although the aforementioned studies report both receptor subtypes are
present in both pyramidal and nonpyramidal neurons, Disney et al., 2006 found
GABAergic neurons are much more likely to express muscarinic receptors than
pyramidal neurons in rhesus V1. Further, they found muscarinic receptors were
densely expressed in GABAergic neurons of both rhesus V1 and MT (Disney and
Aoki, 2008; Disney and Reynolds, 2014; Disney et al., 2014). Finally, they found
different GABAergic neurons have different likelihoods of expressing M1Rs
(Coppola and Disney, 2018b), with parvalbumin neurons being the most likely to
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express M1Rs (~75%), followed by calbindin neurons (~55%), and calretinin
neurons (10–40%). These anatomical investigations are important for
understanding how cholinergic innervation affects local circuitry. More detailed
histological examinations, as performed for M2Rs by Medalla and Barbas, 2012,
are required for other muscarinic receptor subtypes in PFC and other brain
regions.
A noteworthy model of GABAergic inhibitory control is widespread
inhibition via the ascending layer I axons of SOM interneurons (Wang et al.,
2004). Disinhibition can then excite and “open holes in this blanket of inhibition”
via VIP interneuron GABAergic connections onto SOM interneurons (Pfeffer et
al., 2013, Karnani et al., 2016). Notably, VIP interneurons in mouse V1 have
been shown to receive cholinergic innervation from basal forebrain via VIP
postsynaptic nicotinic receptors (Alitto and Dan, 2013; Fu et al., 2014). Thus,
specific cholinergic innervation of VIP interneurons may control excitation of local
cortical circuits.
Although it appears the amyloid hypothesis of AD is losing credence and
amyloid now appears to be more of a symptom than a root cause, it remains
important to study the mechanisms of its accumulation. Interestingly, there
appear to be several connections between M1R stimulation and amyloid beta
accumulation, linking the amyloid and cholinergic hypotheses of AD (Potter et al.,
2011; Fisher, 2012). In vitro, M1R stimulation has been found to divert the
amyloid precursor protein pathway away from amyloid beta production (Pittel et
al., 1996). Many of the downstream effectors of M1Rs influence the processing of
amyloid precursor protein, such as PKC (Cisse et al., 2011), MAPK (Haring et al.,
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1998), and BACE1 (Zuchner et al., 2004). M1R stimulation has been shown to be
inversely correlated with amyloid beta expression in several in vitro studies
(Buxbaum et al., 1992; Nitsch et al., 1992; Slack et al., 1995; Haring et al., 1998;
Jones et al., 2008), and one rat study (Caccamo et al., 2006). M1R stimulation
may also prevent hyperphosphorylation of tau protein (Sadot et al., 1996;
Caccamo et al., 2006), increase prefrontal blood flow (Uslaner et al., 2013) and
provide long-term neurotrophic effects (Fisher, 1997). Conversely, amyloid
accumulation may disrupt cholinergic signalling, creating a positive feedback
loop. Amyloid beta decreases ACh synthesis and release (Kar et al., 1996; Hoshi
et al., 1997) and has been reported to uncouple M1Rs from G proteins in postmortem AD brains (Kelly et al., 1996; Ladner and Lee, 1999; Shiozaki and Iseki,
2004). In a M1R knock-out mouse model, Davis et al. (2010) observed large
increases in amyloid beta accumulation. M1Rs continue to be an intriguing
pharmacological target for the treatment of AD.

1.3.4 Nicotinic receptors
Although the focus of this thesis is primarily muscarinic receptors, a brief
description of cortical nicotinic receptors is provided. Indeed, the experiment
described in Chapter 2 uses a general cholinergic agonist carbachol, which
stimulates nicotinic in addition to muscarinic receptors (although carbachol may
predominantly exert its effects via muscarinic receptors and nicotinic receptors
have more sparse cortical expression compared to muscarinic receptors; Akk and
Auerbach, 1999).
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Nicotinic receptor subtypes can be broadly classified into two families:

homomeric and heteromeric receptors. Homomeric α7 nicotinic receptors are
composed of five identical α7 protein subunits. α7 receptors have a lower binding
affinity to ACh and lesser net inward change than heteromeric receptors (Wallace
and Bertrand, 2013). Although seventeen nicotinic receptor subunits have been
identified (Millar and Gotti, 2009), the most commonly explored heteromeric
nicotinic receptor is the α4β2 subtype. The α4β2 subtype is the most widely
expressed in cortex (Gotti et al., 2009) and experiences less desensitization than
the α7 subtype (Fenster et al., 1997).
The α7 nicotinic receptor has received burgeoning interest as a potential
clinical target in alleviating cognitive deficits (Williams et al., 2011). This is
partially because it is thought that other nicotinic subtypes such as the highaffinity α4β2 receptors may be the subtype responsible for addiction (Picciotto
and Kenny, 2013). For example, knockout of α7 subunits in mice did not affect
nicotine place preference in mice (Walters et al., 2006) or nicotine selfadministration (Pons et al., 2008) and α7 blockade in rat ventral tegmental area
reduced food seeking in rats (Schilstrom et al., 1998). For cognitive
enhancement, positive allosteric modulators of α7 receptors are an intriguing
option because they do not produce the fast desensitization of orthosteric α7
agonists. Stimulation of α7 receptors have yielded improved performance in
multiple cognitive tasks in rats, such as the radial arm maze and Morris water
maze (Levin et al., 1999; Ng et al., 2007; Timmermann et al., 2007). α7 receptor
stimulation may also have clinical relevance. Expression of nicotinic α7 receptor
genes is altered in people with schizophrenia (Grigorenko et al., 2001; Leonard et
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al., 2002; Lewis et al., 2017; Kalmady et al., 2018). Additionally, amyloid beta
appears to interact with α7 receptors, which in AD ultimately leads to pathological
amyloid beta aggregation and receptor inactivation (Parri et al., 2011). α7
receptor positive allosteric modulators have been tested as a treatment option for
AD and SZ. Although some studies have shown mild cognitive benefits, a metaanalysis conducted by Lewis et al. (2017) compiled 18 studies testing systemic
α7 receptor stimulation and found no significant effects in eight cognitive
domains.
The Arnsten lab has extensively explored the local effects of nicotinic
receptor stimulation in primate PFC. Briefly, PFC neurons were recorded in
rhesus monkeys during the performance of memory-guided saccades and
specific nicotinic agonists were locally ejected via iontophoresis. Using
compounds selective for different nicotinic receptor subtypes (α7 and α4β2
receptors), they found stimulation of either subtype was excitatory to neuronal
discharge rates and could enhance delay period activity for the preferred
memory-guided saccade location (Yang et al., 2013; Sun et al., 2017).
Conversely, specific antagonism of either receptor subtype decreased delay
period firing for the preferred direction. Systemic administration of α7 receptor
agonist was also examined and revealed a Yerkes-Dodson curve or “inverted-U”
effect of dose, wherein moderate doses improved task performance and
excessive doses were not beneficial.

1.4

	
  

Antisaccade Task
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The study of cognition employs cognitive tasks in both human and animal

models such that we might discern the mechanisms of cognitive disruption in
conditions such as AD and SZ. Memory-guided saccades have been used
extensively to investigate visuospatial WM. The antisaccade task is another
common oculomotor task (Fig. 2.1A) used to probe executive function, such as
the use of abstract rules, WM maintenance and manipulation, and inhibition. This
task was first introduced by Peter Hallett (1978) of the Department of Physiology
at University of Toronto. There are two trial types: prosaccades and
antisaccades. A typical trial begins with central fixation, followed by one of two
cues that specifies the current trial type (“rule”). These cues can be different
colours or different shapes, etc. Cues can be flashed briefly then removed, or left
visible for the entire delay period, depending on desired task difficulty. After the
cue, the delay period begins, which is typically 1–3 s, often with the central
fixation dot returned. A brief gap period (removal of central fixation) can be
introduced after the delay period to increase task difficulty (Fischer and Weber,
1996; Everling and Fischer, 1998). Next, a peripheral stimulus is shown on the on
the left or right side. During prosaccade trials, the subject must simply make a
saccade to the peripheral stimulus. During antisaccade trials, the subject must
inhibit the prepotent response to look towards the stimulus, and instead look at
the mirror location in order for the trial to be correct. Antisaccade trials result in
more directional errors (i.e., looking at the stimulus instead of empty space) and
hypometric saccades, and longer reaction times.
A circuit for the antisaccade task has been proposed (Fig. 1.11; Munoz
and Everling, 2004). Briefly, visual information enters the retina, lateral geniculate
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nucleus, and visual cortices. This information travels through parietal cortex to
frontal areas such as the FEF, supplementary eye fields, and DLPFC. For
example, FEF is thought to be involved in generating and informing SC on
potential eye movement destinations during voluntary saccades (Gaymard et al.,
1998). Cortical regions influence saccade generators directly, but also indirectly
through basal ganglia structures. DLPFC was initially thought to play an inhibitory
role during antisaccade trials, by suppressing SC from initiating a saccade
towards the prepotent saccade location (i.e., the peripheral stimulus; Guitton et
al., 1985; Pierrot-Deseilligny et al., 2003).
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Figure 1.11
The antisaccade circuit.
This proposed circuit details how visual information is distributed to different brain
regions during performance of antisaccades. For example, visual information can
travel through visual and parietal areas to reach prefrontal cortical regions such
as dorsolateral prefrontal cortex (DLPFC), frontal eye field (FEF), and
supplementary eye field (SEF). These frontal areas can influence saccadic
behaviour through direct and indirect connections to superior colliculus (SC).
Modified with permission from Munoz and Everling. (2004) Look away: the antisaccade task and the voluntary control of eye movement. Nat Rev Neurosci.
5(3):218–28.
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The role of DLPFC in this circuit has been bolstered by findings from

frontal lesions. Lesions to frontal cortex in humans has been reported to increase
errors in the antisaccade task, especially during antisaccade trials (Guitton et al.,
1985; Pierrot-Deseilligny et al., 2003; Ploner et al., 2005). DLPFC can be
deactivated with greater precision using NHP models. Both local muscimol
activation (Condy et al., 2007) and cryogenic deactivation (Koval et al., 2011)
increased antisaccade errors in macaques.
DLPFC neurons can be selective for various aspects of the antisaccade
task. For example, some neurons discharge at a higher frequency for one rule
than the other (pro- or antisaccade-preferring neurons). These “rule neurons” can
show this task preference in varying task epochs, including during and
immediately after cue presentation (early delay period), the late delay period
(preparatory period), during stimulus presentation, or during reward period.
These neurons are thought to be involved in the cognitive circuitry during
antisaccade performance.
Although the role of DLPFC during antisaccades was initially thought to be
an inhibitory influence on SC, more recent evidence has challenged this theory.
Everling and Johnston (2013) note that by the time task-related (i.e.,
preferentially firing for pro- or anti-saccades) PFC activity is established,
downstream saccade-related neurons in SC have already established preference
for trial type (Johnston et al., 2009; Koval et al., 2011). Thus, it seems unlikely
PFC neurons directed this pre-established selectivity in SC. Perhaps the most
compelling evidence against the inhibition model came from cryogenic
deactivation of DLPFC and concurrent recording of macaque SC during
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antisaccade performance (Koval et al., 2011). Cryogenic deactivation produced
an effect opposite to the inhibition model predictions: ipsilateral SC decreased
activity when PFC was deactivated. This suggests PFC effect is excitatory
instead of inhibitory. Everling and Johnston (2013) go on to propose that PFC
aids in maintaining the current task set (pro- or antisaccade rule) through
excitatory drive to SC neurons.
The antisaccade task can be an important clinical tool to quickly assess
top-down control at the bedside or to probe executive function in neuropsychiatric
research (Everling and Fischer, 1998). A number of neuropsychiatric conditions
show antisaccade errors, including AD and SZ (Fukushima et al., 1990; Broerse
et al., 2001; Abel et al., 2002; Kaufman et al., 2010). A disrupted cholinergic
system may contribute further to this aberrant prefrontal function. However, few
studies have examined cholinergic receptor manipulation during antisaccade
performance (Depatie et al., 2002; Powell et al., 2002; Major et al., 2015).

1.5

Iontophoresis
Iontophoresis a pharmacological technique of drug delivery, which

employs the use of electrical current to eject small, electrically charged molecules
such as neurotransmitters. We use glass iontophoretic probes with one tungsten
recording electrode surrounded by six peripheral drug barrels (Fig. 1.12). In this
way, we can lower probes into cortex to perform extracellular recordings and
simultaneously eject one or multiple neuroactive compounds. Although such
probes are available for purchase, we custom fabricate these probes, as
described below.
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A
B
Glass barrels containing dissolved drug

C

Tungsten recording electrode
-50 nA Glutamate

1 sec

Figure 1.12
Iontophoretic electrode and drug ejection.
A, Photo of early stage of probe design. Tungsten wire in the central barrel of
seven-barreled glass capillaries is shown after being heated and pulled though
PMP107L-e Multipipette Puller, forming a fine tip with a small amount of tungsten
wire exposed. B, Idealized illustration of the magnified probe tip. Central tungsten
recording electrode is shown, surround by peripheral drug barrels, which are filled
to the tip with drug solution. C, Example iontophoretic ejection of glutamate. Each
vertical line represents an action potential of an extracellularly recorded neuron
from an iontophoretic electrode. Iontophoretic glutamate application with a
magnitude of 50 nA increased discharge rate of this neuron with a fast onset.
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Tungsten wire (50 µm diameter, Midwest Tungsten Service) was

electrochemically etched (model EE-ID, Bak Electronics) using a sodium nitrite
and potassium hydroxide solution (Thiele et al., 2006) and inserted into the
central barrel of a seven-barreled glass pipette (Friedrich and Dimmock). This
would ultimately serve as the recording electrode. The glass was then pulled over
the wire using a PMP107L-e Multipipette Puller (MicroData Instrument), resulting
in an ~11 cm electrode shaft with a fine tip (approx. 15–30 µm diameter) with a
small amount of tungsten exposed. Recording impedance ranged from 0.5 to 1
MΩ (measured at 1 kHz). Carbachol (carbamoylcholine chloride, 100 mM),
scopolamine (scopolamine hydrobromide 100 mM), and VU0357017
(VU0357017 hydrochloride, 10 mM; Tocris Biosciences) were dissolved in pH 3
deionized water and stored in 30 µL aliquots at −20°C. Before use, drug solution
was thawed and injected into the peripheral glass barrels, then pneumatically
pushed to the tip remove any air. More tungsten wires were inserted into
peripheral barrels and secured to ultimately eject current using an iontophoretic
constant current generator (Neurophore BH-2, Harvard Apparatus). DC
impedences of drug barrels varied between 50 to 300 MΩ. The electrode was
mounted on a hydraulic micromanipulator (MO-95, Narishige) and lowered into
cortex through a 23-gauge dura-penetrating stainless steel guide tube.
Placement of the probe was guided by a plastic recording grid (1 mm spacing,
Crist Instruments). During drug conditions, current was manually set by the
experimenter, ranging from 5 to 100 nA. A constant −8 nA retention current was
passed over unused drug barrels (e.g., during control conditions) to prevent
leakage of our positively charged drugs. Current ejection and pH of drug solution
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have been shown to not strongly effect neuronal discharge rates in macaque
cortex (Disney et al., 2007; Vijayraghavan et al., 2007). Further details of
recording system are discussed in later chapters.
The advantage of iontophoretic drug ejection over other local ejection
techniques is two-fold. Firstly, these probes are very thin (approx. 15–30 µm
diameter at the tip), meaning there is minimized damaged as it enters cortex. And
secondly, the ejection is localized to very small volume surrounding the electrode
tip (Purves, 1979). There are several factors that impact the flow of drug out of
the probe, including diameter of the tip, angle of taper, acidity of drug solution,
previous retention currents, and composition of extracellular matrix (Herr and
Wightman, 2013). Trubatch and Van Harreveld (1972) quantified the spread of
glutamate out of a micropipette into rat cortical tissue and found that the volumes
of ejection are on the order of a cortical microcolumn. For example, the authors
applied glutamate at 250 nA for 1hr and found the diameter of affected area was
approx. 250 µm. Therefore, the effects of iontophoretic drug ejection typically do
not affect behaviour. However, when behavioural effects of iontophoretic drug
ejection are found, they are typically miniscule (e.g., changes in saccadic reaction
of a few milliseconds; Herrero et al., 2008; Herrero et al., 2013; Ott et al., 2014).
For comparison, local pressure ejection spreads over a larger area, potentially
damaging tissue, and is more likely to elicit behavioural effects (Davidson and
Marrocco, 2000). Further, ejected drug has a tendency to spread vertically along
the shaft, creating an elliptical volume of affected areas (Hupe et al., 1999)
instead of spherical, as in iontophoresis. One drawback of iontophoretic ejection
is that only charged drugs can be used. However, some investigators have
	
  

	
  

60

reported that neutral drugs can be used as well via “bulk flow” out of the drug
barrel (i.e., neutral drug molecules follow ionic molecules out of the drug into
extracellular fluid; Herr et al., 2008).
Iontophoresis is a useful technique for focal drug delivery and can be
combined with extracellular recording to observe the direct effects of drug
receptor stimulation on neuronal physiology.

1.6

Objectives
The PFC sends top-down projections to other brain areas to influence

functions such as maintenance of task set. Cognitive deficits observed in people
with conditions such as AD and SZ may be partially attributable to degeneration
of PFC or altered prefrontal organization. In addition, these conditions are known
to have altered cholinergic systems. Cholinergic innervation of PFC is necessary
for optimal WM performance in rhesus macaques (Croxson et al., 2011).
Although there are between-species differences in cholinergic functioning
(Coppola and Disney, 2018a), systemic drug administration in humans
corroborates the idea that prefrontal cholinergic receptors are important for
optimal cognitive functioning. The objective of this research project was to
explore the effects of different cholinergic receptors on prefrontal neuronal activity
involved in an executive task, such that we may ultimately glean insights into
altered cognitive function in conditions with disrupted cholinergic activity.

1.6.1 Examine the effects of local cholinergic stimulation using general agonist
carbachol
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The cholinergic system has been studied extensively using systemic

administration of compounds, such as acetylcholinesterase inhibitors for the
treatment of AD. Similarly, nicotine from cigarettes may benefit alertness and
certain cognitive domains. However, it is difficult to conclusively derive
electrophysiological results during systemic drug administration because effects
on recorded neurons may be due to interregional interactions. For example, even
though scopolamine is strongly inhibitory to neurons, systemic scopolamine
administration paradoxically increased stimulus-responsive activity of macaque
inferotemporal neurons (Miller and Desimone, 1993). Local application of
cholinergic compounds can be used to determine the direct effects of cholinergic
receptors stimulation on neurons. Previously, we had shown that local application
of scopolamine dose-dependently decreased prefrontal neuron discharge rates
and task-related activity during rhesus performance of the antisaccade task
(Major et al., 2015). Carbachol is a general cholinergic agonist and mimetic of
ACh that has been used extensively in electrophysiology. The first objective was
to explore the effects of general cholinergic agonism on prefrontal neuron
discharge rate and task-related activity during macaque performance of the
antisaccade task.

1.6.2 Examine the effects of selective stimulation and blockade of muscarinic
M1 receptors using VU0357017 and pirenzepine
Next, we aspired to determine the effects of individual muscarinic
receptors subtypes. We had previously speculated that the suppressive effects of
scopolamine were mediated via blockade of M1Rs, as they had typically been
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considered excitatory in vitro and are the most widely expressed muscarinic
receptor subtype in cortex. Exploration of specific muscarinic receptor subtypes
was historically difficult because of the conserved ACh binding pocket. For
example, muscarinic agonist McN-A-343, a drug commonly used to probe M1R
function, also binds muscarinic M4 receptors, and other neuromodulatory
receptors to a lesser degree (Mitchelson, 2012). More recently, compounds have
been produced that can selectively target muscarinic subtypes, such as
VU0357017 that can bind M1Rs at allosteric sites. The second objective was to
explore the effect of selective stimulation and blockade of M1Rs on prefrontal
spiking and task-related activity using allosteric agonist VU0357017 and M1Rpreferring antagonist pirenzepine.

1.6.3 Examine the influence local cholinergic receptor perturbation on prefrontal
LFP power
Oscillations of local field potential (LFP) are informative of local neuronal
events and are important for communication between brain areas. Altered
oscillatory activity is observed in conditions with cognitive impairment, such as
AD and SZ (Jeong, 2004; Uhlhaas and Singer, 2010), and during systemic
administration of cholinergic compounds (Kikuchi et al., 1999; Fisher et al., 2012).
In addition to interregional communication, LFPs are important for local circuitry
(Bastos et al., 2018; Johnston et al., 2019) and are important indicators of optimal
WM circuitry (Miller et al., 2018). The third objective was to examine changes in
LFP power when prefrontal cholinergic receptors were locally manipulated using

	
  

	
  
general muscarinic antagonist scopolamine and general cholinergic agonist
carbachol.
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CHAPTER 2 – CHOLINERGIC OVERSTIMULATION ATTENUATES RULE
SELECTIVITY IN MACAQUE PREFRONTAL CORTEX

2.1

Introduction
Acetylcholine (ACh) is central to optimal cognitive performance in primates

(Ballinger et al., 2016). Lesions of the basal forebrain nuclei, which provide
corticopetal cholinergic innervation in primates (Mesulam et al., 1983), cause
deficits in a variety of contexts, including acquisition of visual discriminations
(Ridley et al., 1984), shifting of spatial attention (Voytko et al., 1994), and
mnemonic tasks such as delayed match-to-sample (Aigner et al., 1991). The
importance of prefrontal cholinergic tone was delineated by Croxson et al. (2011),
who tested macaques on a variety of tasks after cholinergic deafferentation of
prefrontal cortex (PFC). Ablation of cholinergic neurons revealed selective, delaydependent deficits in spatial working memory performance, but not in other PFCdependent behavioural tasks.
Extensive degeneration of cholinergic neurons is also a hallmark of
Alzheimer's disease (Whitehouse et al., 1982). Cholinesterase inhibitors are the
mainstay of pharmacological treatment, but their efficacy has been questioned
(Amenta et al., 2001). Alternative measures of enhancing cholinergic stimulation
are being investigated as treatment strategies (Caccamo et al., 2009; FoucaultFruchard and Antier, 2017). For example, recent evidence indicates that
intermittent electrical stimulation of the basal forebrain cholinergic nuclei is
beneficial to working memory performance (Liu et al., 2017). In addition,
advancements in the design of cholinergic agonists allow researchers to
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dissociate the actions of specific receptor subtypes (Bubser et al., 2012; FerreiraVieira et al., 2016). Although cholinergic stimulation has shown some promise in
improving cognitive performance in macaques (Buccafusco and Terry, 2004;
Tsukada et al., 2004) and Alzheimer's disease patients (Bodick et al., 1997), its
influence on local PFC neurophysiology has been less examined in primates
(Inoue et al., 1983; Sawaguchi and Matsumura, 1985).
Previously, we examined the role of muscarinic receptors in macaque
dorsolateral PFC (DLPFC) by iontophoretically applying the general muscarinic
receptor antagonist scopolamine during performance of a conditional saccade
task, in which subjects made a saccade toward a peripheral stimulus
(prosaccade) or made an antisaccade away from a stimulus, depending on a
previous instruction cue (Major et al., 2015). This cognitive control task, which
incorporates working memory for task rules, prepotent response inhibition, and
flexible stimulus–response associations, is sensitive to DLPFC integrity (PierrotDeseilligny et al., 2003; Condy et al., 2007; Hussein et al., 2014). Moreover,
deficits in antisaccade performance are a reliable indicator of prefrontal
dysfunction in neuropsychiatric disorders, including Alzheimer's disease and
schizophrenia (Fukushima et al., 1994; Kaufman et al., 2010). Iontophoretic
blockade of muscarinic receptors resulted in general inhibition of prefrontal
neuron activity and decreased selectivity related to rule, stimulus, and response
encoding (Major et al., 2015), exemplifying the cortical basis of cognitive deficits
following pharmacological insults to the cholinergic system (Klinkenberg and
Blokland, 2010). Here, we explored the neurophysiological consequences of
locally stimulating cholinergic receptors in macaque DLPFC using the general
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cholinergic agonist carbachol. Carbachol is a cholinomimetic, more resistant to
cholinesterase-mediated breakdown than ACh, and therefore hypothesized to
have longer-lasting effects than ACh (Rosenberry et al., 2008). Extensively
explored for its effects on neuronal physiology, carbachol results in the
generation of graded persistent activity in rodent entorhinal cortical neurons
(Egorov et al., 2002) and augments gamma oscillations in the mouse medial
PFC, which are associated with working memory performance (Pafundo et al.,
2013). Based on our previous results (Major et al., 2015), and other studies which
found that stimulation of DLPFC nicotinic receptor subtypes enhanced spatial
working memory representations (Yang et al., 2013; Sun et al., 2017), we
hypothesized that iontophoretic application of carbachol in macaque DLPFC
would increase neuronal discharge rates and augment neuronal representation of
task attributes during performance of prosaccades and antisaccades.
We found that carbachol had complex effects on DLPFC neuronal
excitability, increasing discharge rates in putative pyramidal neurons. Contrary to
our hypothesis, cholinergic stimulation of DLPFC disrupted neuronal
representation of task rules in working memory and diminished saccade direction
selectivity in putative pyramidal neurons. Our findings indicate that continuous
pharmacological stimulation of the DLPFC cholinergic system is detrimental to
cognitive performance.

2.2

Materials and Methods
Experimental procedures were performed on two adult male macaque

monkeys (Macaca mulatta; age 8–11 years, weight 9–12 kg) in accordance with
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the Canadian Council of Animal Care policy and a protocol approved by the
Animal Care Committee of the University of Western Ontario Council on Animal
Care. These two monkeys were previously the subjects of other published
studies, including iontophoretic investigations of muscarinic blockade (Major et
al., 2015), dopaminergic receptors (Vijayraghavan et al., 2016), and a
multielectrode investigation of the systemic effects of ketamine on prefrontal
cortex (Skoblenick and Everling, 2012, 2014; Ma et al., 2015; Skoblenick et al.,
2016). Both animals had a plastic head restraint and plastic recording chambers
implanted above their right lateral PFC as described previously (Skoblenick and
Everling, 2012).

2.2.1 Behavioural task
The behavioural task and physiological techniques are similar to those
described in previous reports (Major et al., 2015; Vijayraghavan et al., 2016).
Briefly, animals performed a variant of the prosaccade and antisaccade task
(Everling et al., 1998), in which the task rule had to be maintained in working
memory (Fig. 2.1A). After the monkey fixates on a central white spot (0.2°, 300
ms, fixation window 4° × 4°), this fixation spot briefly changed colour to red or
green (100 ms), indicating the task rule, before reverting to white. The rule cue
had to be maintained in working memory, while the subject maintained fixation
over the delay period (800–1300 ms). Subsequently, the fixation spot
disappeared and after a brief gap period (150–300 ms) a peripheral stimulus was
presented pseudorandomly to the left or right of the fixation spot (17°
eccentricity). Subjects had to make the appropriate saccade, specified by the
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current rule, either toward (prosaccade) or away from (antisaccade) the stimulus
within 500 ms to receive liquid reward. Task, behaviour monitoring, and reward
delivery were controlled using CORTEX (National Institutes of Mental Health).
The gap period was used to increase task difficulty (Everling et al., 1998). Rule
colours were counterbalanced between subjects and rule/stimulus combinations
were presented in pseudorandom order.
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Figure 2.1
Experimental paradigm and single neuron recording with concurrent
iontophoresis.
A, After central fixation, a green or red cue was flashed, signifying a prosaccade
or antisaccade trial, respectively. This task rule was maintained over an 800–
1300 ms delay and a short gap. Monkeys then performed a saccade toward
(prosaccade) or away from (antisaccade) the peripheral stimulus to receive liquid
reward. Dashed circles represent gaze of the animal and white arrows represent
saccade direction. ITI, Intertrial interval. B, Single neuron extracellular recordings
were performed in the right dorsolateral prefrontal cortices of two rhesus
macaques. Custom-made glass iontophoretic electrodes were used to eject
general cholinergic receptor agonist carbachol onto neurons. Beige area
represents recording locus. AC, Arcuate sulcus; PS, principal sulcus. C, Effect of
carbachol on discharge rate over experiment time course. Left, Discharge rate of
an example neuron is shown over the course of the recording. This neuron was
inhibited during application of carbachol (shaded gray). Right, Carbachol
application excited neuronal discharge rate of a different example neuron.
Discharge rates were derived from 1 s bins and smoothed with a 200 s width.
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2.2.2 Neuronal recordings and pharmacology
Carbachol was iontophoretically administered using custom-made sevenbarreled glass iontophoretic electrodes, which were modified from the design of
Millar and Williams (1989) and fabricated as described previously (Major et al.,
2015). Briefly, a 50 µm diameter tungsten wire (Midwest Tungsten Service),
which served as the recording electrode, was electrochemically etched and
inserted into the central capillary of a seven-barreled glass pipette (Friedrich and
Dimmock). The glass was then pulled over the wire resulting in a multi-barrelled
electrode with a fine tip (PMP107L-e Multipipette Puller, MicroData Instrument).
Typical recording electrode impedances ranged from 0.5 to 1 MΩ (measured at 1
kHz). Carbachol (carbamoylcholine chloride; Tocris Bioscience; 100 mm in pH 3
deionized water) was top-filled into the peripheral capillaries of the multi-barrelled
glass and pushed pneumatically to the tip of the iontophoretic electrode. Drugs
were ejected using a Neuro Phore BH-2 iontophoretic ejection system (Harvard
Apparatus). Constant ejection currents (5–100 nA, median: 30 nA) were manually
set and a retention current of −8 nA was used to prevent leakage of drug from the
barrel when ejection currents were not applied. Current balancing was not used
as drug ejection with such low current strengths typically does not stimulate
neurons or create electrophysiological noise with the electrode design used here
(Vijayraghavan et al., 2007). Previous iontophoretic studies have shown there is
no effect of pH of the drug solution on neuronal discharge rate (Disney et al.,
2007; Vijayraghavan et al., 2007). Carbachol was used as a proxy for ACh due to
its greater resistance to acetylcholinesterase-mediated breakdown (Rosenberry
et al., 2008), which we hypothesized would result in more reliable stimulation of
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cholinergic receptors. Carbachol has been shown to have slightly larger
magnitudes and duration of effect than ACh in cat (Crawford et al., 1966) and rat
cortex (Bassant et al., 1990). The electrode was mounted on a hydraulic
micromanipulator (MO-95, Narishige Group) and lowered into DLPFC (Fig. 2.1B)
through a 23-gauge dura-penetrating stainless steel guide tube.
Neuronal signals were amplified, digitized, and filtered (300 Hz–6 kHz,
four-pole Bessel) with an OmniPlex Neural Data Acquisition System (Plexon).
Neuron waveforms were sorted offline in principal component space (Offline
Sorter, Plexon) and analyzed offline (MATLAB, MathWorks). Spike density
functions were created by convolving spike trains with a 50 ms Gaussian
activation function (Richmond et al., 1987).
We collected data from blocks of trials with no drug application (control
condition), followed by drug delivery (drug condition). For some sessions, an
additional recovery condition was collected after cessation of drug application.
Conditions typically lasted longer than 10 min (Fig. 2.1C) and neurons with <8
correct trials for each rule (prosaccade/antisaccade) and saccade direction
(leftward/rightward) combination in any of the conditions were discarded from
further analysis (n = 5). Behavioural effects are not usually expected with
microiontophoretic drug application because the small amount of drug released
does not spread to a large enough volume of cortical neuropil to affect behaviour,
especially in areas of broad specialization like PFC (Vijayraghavan et al., 2007).

2.2.3 Data analysis
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Discharge rate analyses were performed in several epochs over the

course of the trial: “entire” trial epoch (1500 ms before to 1000 ms after stimulus
onset), fixation epoch (0–200 ms after fixation onset), cue epoch (0–200 ms after
coloured cue onset), and delay epoch (600 ms before to 70 ms after peripheral
stimulus onset). Based on prior studies, this delay epoch is when PFC neurons
are found to display maximal rule discriminability (Everling and DeSouza, 2005;
Bongard and Nieder, 2010). We also analyzed the stimulus epoch (0–400 ms
after peripheral stimulus onset), post-saccade epoch (0–400 ms after saccade
onset), and intertrial interval (0–1000 ms after reward onset). We excluded
neurons with very low discharge rates (<1 spike/s in both control and drug
conditions) from the analysis as the low firing rates precluded reliable analysis of
physiological effects of the drug. The task-selectivity profile of each included
neuron was determined by performing an ANOVA on the trial discharge rates in
the cue and delay epochs with two factors: drug condition and rule. Neurons with
a significant main effect of rule or an interaction of rule and drug (p < 0.05) were
classified as rule-selective neurons (“rule neurons”). Magnitude of rule selectivity
was further quantified using area under the receiver operating characteristic
curve (AUROC; 1000 steps; Green and Swets, 1966). AUROCs were computed
from the mean discharge rates during the delay epoch for prosaccades and
antisaccades. AUROC values range from 0 to 1. By convention, neurons showing
higher activity (preference) for the prosaccade rule were deemed to possess
AUROC values >0.5. The AUROC values for neurons with greater activity for the
antisaccade rule would thus be <0.5 and were subtracted from 1, therefore
reported AUROC values were for preferred versus nonpreferred rule. An AUROC
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of 1 signified a completely selective neuron with nonoverlapping distributions of
preferred and nonpreferred rule discharge rates. An AUROC of 0.5 signified a
lack of rule discriminability, wherein preferred and nonpreferred rule discharge
rate distributions completely overlapped. Analysis of task selectivity was also
performed on the stimulus epoch with three-way ANOVA (factors: drug condition,
rule, and peripheral stimulus direction), where neurons with a significant main
effect of stimulus direction or a significant interaction between stimulus direction
and condition were classified as “visual neurons”. These neurons significantly
discriminated between peripheral stimuli on the left versus right side of the
screen, regardless of trial rule. Similarly, discharge rates in the post-saccade
epoch were explored with three-way ANOVA (factors: drug condition, rule, and
saccade direction) to classify “saccade neurons”, with a significant main effect of
saccade direction or significant interaction between saccade direction and drug
condition. Activity of these neurons discriminated between leftward and rightward
saccade directions. Selectivities of visual and saccade neurons were also
quantified with AUROC between the contralateral and ipsilateral stimulus
directions or saccade directions, respectively. AUROC data are reported for the
preferred versus nonpreferred direction. Since a change in AUROC can be
explained by changes in either the mean discharge rates or trial-to-trial discharge
rate variances between trial types (e.g., prosaccade vs. antisaccade trials),
neuronal reliability was measured with Fano factor: trialwise discharge rate
variance divided by the mean. Fano factors for preferred and nonpreferred rule
trials were determined separately then averaged together, as these two trials
types intrinsically vary between each other in rule-selective neurons.
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To compare discharge rate changes across task-selective neurons, mean

discharge rates for preferred and nonpreferred trial types in the control and drug
conditions were normalized as follows:
𝑥!"#$ =

𝑥! −    𝑥!"#
𝑥!"# − 𝑥!"#

The preferred and nonpreferred trial type would be the preferred rule and
nonpreferred rule in the case of rule selectivity, and would be preferred and
nonpreferred saccade direction in the case of saccade direction selectivity. xt is
the mean discharge rate for a given trial type in control or drug (e.g., activity in
control preferred rule trials); xmin and xmax are the minimum and maximum
discharge rates among the four values: control preferred, control nonpreferred,
drug condition preferred, and drug condition nonpreferred mean discharge rate;
and xnorm is the normalized mean discharge rate for that given trial type (e.g.,
preferred rule trials in control condition). Relative contributions of changes in
mean and variability of discharge rate on changes in neuronal selectivity were
estimated for the population of rule-selective neurons with the following multiple
linear regression model:
Δ𝐴𝑈𝑅𝑂𝐶 =   𝛼 +    𝛽! Δ𝐹𝑅!"#$ + 𝛽! Δ𝐹𝑅!"!#$%& +    𝛽! Δ𝑉𝑎𝑟!"#$ +    𝛽! Δ𝑉𝑎𝑟!"!#$%& +   𝜀
Here, ΔFRpref represents the carbachol-induced change in normalized discharge
rate for the preferred rule between the control and carbachol conditions. β
coefficients represent the slope between the respective predictor and change in
AUROC when all other predictors are held constant.
We also performed an analysis of action potential waveforms to classify
neuronal types (“broad-spiking” putative pyramidal neurons and “narrow-spiking”
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putative nonpyramidal neurons), using methodology derived from previous
studies (Mountcastle et al., 1969; Mitchell et al., 2007; Johnston et al., 2009).
Action potential waveforms were extracted from the delay epoch during the
control condition at a temporal resolution of 25 µs (40 kHz sampling frequency)
and increased to 1 µs resolution with spline interpolation. After aligning to voltage
trough and averaging all waveforms, duration from waveform trough (negative
deflection) to peak (positive deflection) was measured. Neurons that did not show
the typical shape of a downward trough, followed by a positive peak in voltage,
were removed from further waveform analysis (n = 15; Jacob et al., 2013). A
neuron was defined as a broad-spiking neuron (putative pyramidal neuron) if
trough to peak duration was >270 µs (Johnston et al., 2009; Ma et al., 2015) and
defined as a narrow-spiking neuron (putative nonpyramidal neuron) if trough to
peak duration was <270 µs.
Wilcoxon rank sum test was used for determining significance of changes
in discharge rate among individual neurons. Significance of changes in
population discharge rate, Fano factor, and selectivity (AUROC) were determined
using the Wilcoxon signed rank test. Fisher's exact test was used to determine
whether excitability or suppression of discharge rate of task-selective neurons
was contingent on trial preference (e.g., preference for prosaccades or
antisaccades, or ipsilateral or contralateral saccade directions). To determine
unimodality of the distribution of trough to peak durations of narrow- and broadspiking neurons, we performed Hartigan's Dip Test (Hartigan and Hartigan,
1985).
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Results
Extracellular recordings and microiontophoretic carbachol application were

performed in 100 DLPFC neurons. After exclusion of neurons due to cutoff
criteria (see Materials and Methods) 83 neurons (50 from Monkey T, 33 from
Monkey O) over the course of 79 recording sessions remained for further
analysis (37 from Monkey T, 42 from Monkey O). Throughout control and drug
conditions, monkeys performed the prosaccade and antisaccade task (described
in Materials and Methods). Recovery from drug effects was tested in 28 recording
sessions. Although minute decreases in performance were observed for both
prosaccade (correct performance; mean ± SEM; control: 95.1 ± 0.01%,
carbachol: 93.4 ± 0.01%) and antisaccade trials (control: 90.7 ± 0.02%,
carbachol: 88.0 ± 0.02%), this declining trend continued into the recovery
condition (recovery prosaccade: 92.7 ± 0.01%, recovery antisaccade: 86.4 ±
0.02%), and therefore was more likely a consequence of non-drug-related
factors, such as waning motivation over the course of the experiment. Similarly,
reaction times were longer in the carbachol condition (control prosaccade: 138 ±
1 ms, carbachol prosaccade: 142 ± 1 ms; control antisaccade: 192 ± 3 ms,
carbachol antisaccade: 194 ± 3 ms), but continued to increase in recovery
conditions (recovery prosaccade: 144 ± 1 ms, recovery antisaccade: 196 ± 3 ms).

2.3.1 Effect of carbachol on discharge rates
We examined the effects of microiontophoretic application of carbachol at
various current doses on discharge rates of 83 prefrontal neurons. We found that
carbachol had heterogeneous effects on population activity. Figure 2.2A shows
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the mean discharge rate of each neuron in control (abscissa) and after drug
application (ordinate). Carbachol application did not have a significant overall
effect on population neuronal activity (p = 0.212, Wilcoxon signed rank test;
median change in discharge rate of +0.4 spikes/s), although individual neurons
were excited or suppressed. Of the 83 neurons, discharge rates of 41 neurons
(49%) were significantly increased (entire epoch, p < 0.05; Wilcoxon rank sum
test), 32 neurons (39%) were inhibited, and discharge rates of 10 neurons (12%)
were unaffected after carbachol application (Fig. 2.2A). Further, change in
population discharge rate was nonsignificant in every task epoch (fixation epoch:
p = 0.241, cue: p = 0.124, delay: p = 0.238, stimulus: p = 0.256, post-saccade: p
= 0.364, intertrial interval: p = 0.316; Wilcoxon signed rank test), indicating that
the drug did not differentially affect discharge rate during a specific component of
the task.
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Figure 2.2
Effects of carbachol on prefrontal neuron discharge rate.
A, Discharge rates during control (abscissa) and carbachol application (ordinate)
are plotted (filled circles: neurons significantly excited or inhibited by carbachol
application; open circles: no significant effect of carbachol application; entire
epoch, p < 0.05, Wilcoxon rank sum test). Dashed equality line is shown. Median
change in discharge rate was +0.4 spikes/s, although discharge rates were not
significantly affected by carbachol as a population (p = 0.212, Wilcoxon signed
rank test). Inset, Pie chart with proportions of neurons that were significantly
excited (red; n = 41, 49%), inhibited (blue; n = 32, 39%), or not affected (white; n
= 10, 12%) by carbachol application. Discharge rates are calculated from 1500
ms before stimulus onset to 1000 ms after stimulus onset. B, Bar charts depicting
the mean trial discharge rates for two example neurons. Top, Increasing dose of
carbachol progressively increased discharge rate of this neuron. Cessation of
drug ejection resulted in a significant, partial recovery of discharge rate. All
changes between sequential doses or recovery were significant. Bottom, In
another neuron, increasing doses of carbachol resulted in gradually stronger
inhibition of neuronal excitability. Partial recovery was observed. Statistical
significances were determined by Wilcoxon ranked sum test with HolmBonferroni correction for multiple comparisons. C, Population effects of carbachol
dose are shown. Mean discharge rates during control, low (≤30 nA), and high
(>30 nA) doses of carbachol (dose ranges based on median split of all applied
doses) are shown for neurons that were significantly excited (top) or inhibited
(bottom) by carbachol. In excited neurons, higher doses resulted in a further
significant increase to discharge rate. Among suppressed neurons, higher doses
of carbachol did not result in further suppression of discharge rate. Significance
determined by Wilcoxon signed rank test with Holm–Bonferroni correction for
multiple comparisons. D, Recovery of population discharge rates after cessation
of carbachol application. Top, Neurons significantly excited by carbachol (p <
0.05, Wilcoxon rank sum test) that were tested for recovery exhibited partial,
albeit nonsignificant (p = 0.169) recovery after cessation of carbachol application.
Bottom, Suppressed neurons did not recover discharge rates during our
observed recovery condition. Error bars indicate SEM. In all panels, asterisks
indicate significant (p < 0.05) comparisons with Holm–Bonferroni correction for
multiple comparisons, where applicable.
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To further explore the heterogeneous effects of carbachol application on

prefrontal neuronal activity, we examined 23 neurons on which successive doses
of carbachol were applied, and wherein drug application resulted in a significant
change (increase or decrease) in the discharge rate (entire epoch, p < 0.05;
Wilcoxon rank sum test). Figure 2.2B demonstrates the effects of progressively
increasing doses of carbachol on two of these DLPFC neurons that were excited
and suppressed by cholinergic stimulation (top and bottom, respectively).
Increasing doses of carbachol application on the neuron depicted in the top
progressively and significantly increased discharge rate (control: 5.3 ± 0.1
spikes/s; highest dose of carbachol: 14.2 ± 0.3 spikes/s). After cessation of drug
application, there was significant partial recovery from carbachol-induced
excitation, with neuronal discharge rate declining to 12.2 ± 0.2 spikes/s. However,
carbachol application did not have an excitatory effect on all recorded neurons.
This trend is illustrated by the neuron depicted in Figure 2.2B (bottom). This
neuron was gradually suppressed after successive doses of carbachol (control:
9.1 ± 0.2 spikes/s; highest dose of carbachol: 3.2 ± 0.1 spikes/s), followed by
partial recovery of discharge rate (control: 8.0 ± 0.2 spikes/s).
We further analyzed effects of dose on discharge rates in the 23
aforementioned neurons with multiple carbachol dose applications (13 excited, 10
inhibited) by grouping doses into “low” and “high”, based on a median split of the
applied dose range (median carbachol dose = 30 nA). Figure 2.2C shows the
effects of low and high doses of carbachol on neurons that were excited (top) and
inhibited (bottom) by drug application. Discharge rates of carbachol-excited
neurons increased monotonically with carbachol dose. Low-dose application
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caused significant increase in excitability compared with control, and high-dose
application resulted in further increases to neuronal discharge rate (Fig. 2.2C,
top; entire epoch). Carbachol-suppressed neurons, however, did not show
monotonicity of suppression with drug dose (Fig. 2.2C, bottom). High-dose
carbachol application (>30 nA) could not further suppress neuronal discharge
rates. It is noteworthy that this was not due to a floor effect, as neurons still had
substantial activity after high-dose application.
We tested 27 neurons (15 excited, 12 inhibited) for recovery from
physiological effects after cessation of drug application. Figure 2.2D shows these
data for neurons that were significantly excited (top) or inhibited (bottom) by
carbachol application. Neurons that were excited by carbachol had a reduction in
discharge rates after drug cessation, though not reaching significance, thus
indicating partial recovery from drug effects (entire epoch, p = 0.169; Wilcoxon
signed rank test). However, in neurons that were significantly suppressed,
recoveries did not occur during our recording sessions of ∼10 min (p = 1). Thus,
differential effects of carbachol on neuronal excitability were accompanied by
different post-drug physiological effects.

2.3.2 Effect of carbachol on task-selective neurons
Next, we examined the effects of cholinergic stimulation with carbachol on
task selectivity of neurons in the prosaccade and antisaccade task. Our task
involved retaining the specified rule in working memory, and we explored the
effects of carbachol on working memory representation of the rule in prefrontal
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neuronal activity (Everling and DeSouza, 2005). We identified task selectivity in
prefrontal neurons using a two-way ANOVA with factors: rule (prosaccade or
antisaccade trial) and drug condition (control or carbachol), using discharge rates
during the delay epoch of the task. Based on the ANOVA, we classified 24
neurons as possessing rule selectivity (rule neurons; significant main effect of
rule or interaction of rule and drug). We assessed the magnitude of rule
selectivity in this population with the AUROC metric (see Materials and Methods).
Figure 2.3A displays an example neuron that had a greater delay epoch
discharge rate in the control condition during antisaccade trials (17.4 ± 1.4
spikes/s) compared with prosaccade trials (9.0 ± 1.3 spikes/s). Upon carbachol
application, the baseline activity of this neuron was excited (fixation epoch control
vs. carbachol discharge rate: p < 0.0001; Wilcoxon rank sum test) and selectivity
for the task rule was decreased (carbachol antisaccade: 16.3 ± 0.8 spikes/s,
carbachol prosaccade: 11.5 ± 0.8 spikes/s; control AUROC: 0.74, carbachol
AUROC: 0.67). Another prefrontal neuron (Fig. 2.3B) displayed a preference for
antisaccades during the control condition delay epoch (antisaccade: 11.2 ± 0.4
spikes/s, prosaccade: 8.3 ± 0.3 spikes/s). Similar to the first example, this neuron
was excited in the fixation (p < 0.0001) and delay epochs (control: 9.8 ± 0.2
spikes/s, carbachol: 12.5 ± 0.1 spikes/s, p < 0.0001) after carbachol application
and rule selectivity was diminished (control AUROC: 0.76, carbachol AUROC:
0.59).
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Figure 2.3
Effect of carbachol application on two representative rule-selective prefrontal
neurons.
A, Rasters (top; each row of dots is from a single trial) and spike density
functions (bottom; mean ± SEM) are shown for a neuron with preferentially higher
discharge rate during antisaccade trials (red) compared with prosaccade trials
(blue) during the delay epoch, before (left) and after (right) iontophoretic
application of carbachol. Delay epoch is shaded in gray (see Materials and
Methods). Qualitative schematic of main trial events is shown above. After
carbachol application, this rule neuron increases delay epoch discharge rate and
preference for antisaccade trials is reduced. Rasters and spike density functions
are aligned to onset of peripheral stimulus. B, A neuron with selectivity for
antisaccades during the delay epoch is shown. All colours and conventions like
A. After carbachol application, discharge rate is increased, especially during
prosaccade trials, and rule preference is diminished.
	
  

	
  

109
For the 24 rule neurons, we examined changes in population rule

selectivity due to carbachol application (15 from Monkey T, 9 from Monkey O; 14
prosaccade-preferring, 10 antisaccade-preferring). Figure 2.4A shows the
population normalized spike density functions (mean ± SEM) of rule neurons
before (left; blue: preferred rule, green: nonpreferred rule) and after carbachol
application (right). Change in rule selectivity was quantified using AUROC. Figure
2.4B shows the AUROCs for each rule neuron during control (abscissa) and
carbachol conditions (ordinate). Although drug effects on selectivity of individual
neurons varied, carbachol significantly decreased population rule selectivity (p =
0.0397, Wilcoxon signed rank test; blue: prosaccade-rule-preferring, red:
antisaccade-rule-preferring). We also examined Fano factor as a measure of trialto-trial variability of neuronal spike count. Fano factor was not significantly
affected during application of carbachol (control: 2.7 ± 0.4, carbachol: 2.4 ± 0.3, p
= 0.0675). As reduced rule AUROC can be due to either reduced difference in
prosaccade versus antisaccade discharge rates or increased neuronal variability,
we explored the relative contributions of changes in neuronal discharge rate and
variability using multiple linear regression with four predictors: change in
normalized preferred rule discharge rate, change in normalized nonpreferred rule
discharge rate, change in preferred rule variance, and change in nonpreferred
rule variance (see Materials and Methods). This multiple regression model was
significant (F(4,19) = 25.56, p < 0.0001) with R2 = 0.843. As seen in Table 2.1,
carbachol-induced change in normalized preferred and nonpreferred rule
discharge rates and change in preferred rule variance were significant predictors
of change in AUROC. Of these three factors, change in preferred and
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nonpreferred rule discharge rate contributed the most to altered selectivity, as the
magnitude of their β coefficients were much larger than that of preferred rule
variance.
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Figure 2.4
Effects of carbachol on population rule selectivity.
A, Mean normalized spike density functions of preferred (blue) and nonpreferred
(green) rule trials for 24 DLPFC rule-selective neurons during control (left) and
carbachol conditions (right) are shown. Neurons were identified as rule-selective
by ANOVA (see Materials and Methods). Overall difference between discharge
rates for preferred and nonpreferred rules diminished. B, Rule selectivity
(measured by AUROC) is shown for each rule neuron during control (abscissa)
and carbachol application (ordinate). Drug application significantly decreased
selectivity of rule neurons, as quantified by AUROC (p = 0.0397, Wilcoxon signed
rank test). Prosaccade-preferring and antisaccade-preferring rule neurons are
represented in blue and red, respectively. Dashed equality line is shown. C,
Change in normalized discharge rate during preferred rule trials for 24 rule
neurons (abscissa) is compared with change in normalized discharge rate of
nonpreferred rule trials (ordinate). Based on k-means cluster analysis (k = 2), two
clusters of neurons were identified (labeled pink and orange; filled circles:
neurons with decreased AUROC; open circles: neurons with increased AUROC)
with centroids shown as black crosshairs. D, Dose-dependent effects on rule
selectivity by carbachol. Mean delay epoch rule AUROCs are shown for seven
rule neurons that were subject to both low (≤30 nA) and high doses (>30 nA) of
carbachol (split by median of applied dose range). High doses of carbachol
resulted in significant diminishment of delay epoch rule selectivity in this subset of
rule neurons whereas low-dose carbachol did not. Significance determined by
Wilcoxon signed rank test (p < 0.05; asterisk indicates significant comparison)
with Holm–Bonferroni correction for multiple comparisons.
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Predictor of ΔAUROC
ΔFRpref
ΔFRnonpref
ΔVar pref
ΔVar nonpref

β coefficient
0.231
-0.193
-0.0494
0.000602

p
1.04E-7
9.32E-6
0.0162
0.983

Table 2.1
Summary of multiple linear regression analysis for rule-selective neurons.
𝛽 coefficients and p values from the multiple regression analysis (see Materials
and Methods) are shown to asses the impact of four predictors on change in rule
AUROC: Δ𝐹𝑅!"#$ , change in mean normalized discharge rate during preferred
rule trials; Δ𝐹𝑅!"!#$%& , change in mean normalized discharge rate during
nonpreferred rule trials; Δ𝑉𝑎𝑟!"#$ , change in normalized variance during preferred
rule trials; Δ𝑉𝑎𝑟!"!"#$% , change in normalized variance during nonpreferred rule
trials.
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We further explored the relative changes in preferred and nonpreferred

discharge rate in Figure 2.4C. Change in normalized preferred discharge rate is
plotted (abscissa) against change in normalized nonpreferred discharge rate
(ordinate). Neurons in which carbachol application reduced or increased the
AUROC are labeled with filled and unfilled circles, respectively. Because change
in AUROC is largely determined by the change in preferred and nonpreferred
discharge rate, neurons above the equality line (dark gray dashed line) generally
experienced decreased AUROC and neurons below the line increased AUROC.
We observed two distinct clusters of neurons (k-means clustering, k = 2;
centroids shown as crosshairs), one of suppressed neurons (n = 10, 42%;
labeled in purple), and one of excited neurons (n = 14, 58%; orange). Carbachol
reduced selectivity of almost all suppressed neurons, although the change in
selectivity did not reach significance (n = 10, p = 0.0840). This decreased
selectivity was due to greater inhibition during preferred rule trials compared with
nonpreferred rule trials. Carbachol had more equivocal effects on the AUROC of
excited rule neurons (n = 14, p = 0.296). Some neurons decreased selectivity due
to relatively greater excitation of nonpreferred rule (above equality line), and
others increased selectivity due to greater excitation of preferred rule. Thus,
carbachol both excited and suppressed discharge rate of rule neurons, often
resulting in decreased selectivity, which can be attributed to either a relatively
greater suppression of activity for preferred rules or a relatively greater increase
in nonpreferred rule discharge rate.
Selectivity of prosaccade-preferring rule neurons (Fig. 2.4B, blue) were not
significantly affected by carbachol (n = 14, p = 0.463), but selectivity of
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antisaccade-preferring rule neurons (red) was significantly decreased (n = 10, p =
0.0371). The preference of rule neurons for prosaccade or antisaccade did not
have any bearing on whether rule neurons were excited or inhibited by carbachol
(p = 0.421, Fisher's exact test).
In some rule neurons (n = 7), multiple doses of carbachol were applied
(Fig. 2.4C). In these rule neurons, low doses (<30 nA) did not significantly change
AUROC values (p = 0.688), but high doses (>30 nA) resulted in significant
diminishment of rule selectivity (p = 0.0156). Thus, disruption of rule selectivity in
the delay period by cholinergic stimulation is dose-dependent.
Unlike the disruptive effects on rule representation in the delay epoch,
population rule selectivities were unaffected in the cue epoch (n = 11, p = 0.0830,
Wilcoxon signed rank test; 4 prosaccade-preferring, 7 antisaccade-preferring),
stimulus epoch (n = 25, p = 0.757; 11 prosaccade-preferring, 14 antisaccadepreferring), and post-saccade epoch (n = 24, p = 0.265; 6 prosaccade-preferring,
18 antisaccade-preferring).
We examined the effects of cholinergic stimulation on neurons with
selectivity for other attributes observed in the task. We identified 19 prefrontal
neurons that were selective for peripheral stimulus location during the stimulus
epoch (8 contralateral-stimulus-preferring, 11 ipsilateral-stimulus-preferring).
Additionally, 40 neurons were selective for the direction of saccade in the postsaccade epoch (32 contralateral-saccade-preferring, 8 ipsilateral-saccadepreferring). Carbachol application had equivocal effects on population selectivity
of both peripheral stimulus direction (control vs. carbachol stimulus direction
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AUROC: p = 0.968, Wilcoxon signed rank test) and for the saccade direction
(control vs. carbachol saccade direction AUROC: p = 0.122).

2.3.3 Effects of carbachol on putative pyramidal and nonpyramidal neurons
Past studies have reported that drug-induced modulation of discharge
characteristics, signal-to-noise ratio, and coding of task attributes can be different
between cortical neuronal classes (Mountcastle et al., 1969; Jacob et al., 2013;
Ma et al., 2015; Thiele et al., 2016). To ascertain whether cholinergic stimulation
had differential effects on putative pyramidal neurons and interneurons defined
by electrophysiological characteristics, we performed a similar analysis, whereby
we classified prefrontal neurons (n = 68; see Materials and Methods) as broadspiking (putative pyramidal neurons) or narrow-spiking (putative nonpyramidal
neurons; see Materials and Methods; Johnston et al., 2009). The distribution of
waveform trough to peak durations was not unimodal (Fig. 2.5A; p = 0.00910,
Hartigans' Dip Test; Hartigan and Hartigan, 1985). Based on a previous study in
our laboratory, neurons with a waveform trough to peak duration <270 µs were
classified as narrow-spiking and neurons with a trough to peak duration >270 µs
were classified as broad-spiking (Fig. 2.5B; green: mean narrow-spiking
waveforms, pink: broad-spiking waveforms), yielding 21 narrow waveform
neurons (31%) and 47 broad waveform neurons (69%).
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Figure 2.5
Effects of carbachol on putative pyramidal and nonpyramidal neurons.
Waveforms were extracted and trough to peak duration was measured in 68
neurons (see Materials and Methods). A, Histogram of trough to peak durations.
Trough to peak duration distribution was not unimodal as determined by
Hartigans' Dip Test (p = 0.00910). Similar to previous reports, a threshold of 270
µs (dashed line) was used to classify neuronal waveforms as narrow-spiking
(green, putative nonpyramidal neurons) or broad-spiking (pink, putative pyramidal
neurons). 30 µs bin width. B, Normalized waveforms aligned to initial trough
(negative inflection) are shown with narrow-spiking (green) or broad-spiking
(pink) label. C, Discharge rates among narrow-spiking neurons were not
significantly affected by carbachol (entire epoch, p = 0.876, Wilcoxon signed rank
test). Shown as filled circles, discharge rates of 8 neurons (38%) were
significantly excited (p < 0.05, Wilcoxon rank sum test) and 10 (48%) were
significantly suppressed. D, Broad-spiking neurons were significantly excited by
carbachol (p = 0.0444, Wilcoxon signed rank test). Discharge rates of 27 neurons
(57%) were significantly excited (p < 0.05, Wilcoxon rank sum test) and 16 (34%)
were significantly suppressed.
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Discharge rates of narrow-spiking neurons were not significantly affected

by carbachol application at the population level (Fig. 2.5C; entire epoch, p =
0.876, Wilcoxon signed rank test). Population discharge rate of narrow-spiking
neurons was not significantly excited or suppressed in any task epoch (fixation
epoch: p = 0.639, cue: p = 0.664, delay: p = 0.931, stimulus: p = 0.986, postsaccade: p = 0.848, intertrial interval: p = 0.903). In addition to the lack of
significant effect on discharge rates, carbachol also did not affect the selectivity of
task-selective narrow-spiking neurons for any task attributes, including rule
selectivity during the delay and cue epochs, stimulus direction selectivity in the
stimulus epoch, and saccade direction selectivity in the post-saccade epoch.
In contrast, we found that broad-spiking neurons were significantly excited
by carbachol application at the population level (Fig. 2.5D; p = 0.0444),
notwithstanding some individual neurons that were suppressed. Broad-spiking
neurons were also significantly excited in the fixation, cue, delay, and stimulus
epochs (p = 0.0235, p = 0.0163, p = 0.0490, p = 0.0455, respectively), but not in
the post-saccade (p = 0.0865) or intertrial interval epochs (p = 0.0904).
Carbachol did not significantly affect selectivity of broad-spiking ruleselective neurons in the cue or delay epochs, or broad-spiking visual neurons in
the stimulus epoch. However, although we found that saccade direction
selectivity in the population of 40 saccade neurons was not significantly changed
by carbachol, we found that the subset of this population comprised of broadspiking neurons did show changes in population saccade selectivity. Figure 2.6A
shows a prefrontal neuron with higher discharge rate for contralateral saccades
(2.9 ± 0.4 spikes/s) than for ipsilateral saccades (1.8 ± 0.3 spikes/s) during the
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post-saccade epoch, regardless of trial rule. Although the baseline activity of this
neuron was not significantly excited (fixation epoch control vs. carbachol, p =
0.06, Wilcoxon rank sum test) this neuron was excited in the post-saccade epoch
(control: 2.4 ± 0.3 spikes/s, carbachol: 3.8 ± 0.2 spikes/s, p = 0.000415) and
selectivity for saccade direction was reduced (control AUROC: 0.61, carbachol
AUROC: 0.53). Population normalized spike density functions of broad-spiking
saccade neurons show this augmentation of population discharge rates (Fig.
2.6B). Analysis of saccade direction selectivity by AUROC (Fig. 2.6C; red:
contralateral, n = 14; blue: ipsilateral, n = 4) revealed that carbachol application
resulted in a small, but significant, decrease in population selectivity (mean
control AUROC: 0.66 ± 0.02, mean carbachol AUROC: 0.62 ± 0.01, p = 0.0429;
Wilcoxon signed rank test). We also examined Fano factor as a measure of trialto-trial variability of neuronal spike count. Fano factor was not significantly
affected during application of carbachol (control: 1.5 ± 0.2, carbachol: 1.6 ± 0.2, p
= 0.286). We explored the relative contributions of changes in neuronal discharge
rate and variability in decreasing selectivity in broad-spiking saccade neurons
using a multiple linear regression model similar to that used for rule neurons. This
multiple regression model was significant (F(4,13) = 14.43, p = 0.000104) with R2 =
0.816. Carbachol-induced change in normalized preferred and nonpreferred
saccade direction discharge rates and change in preferred rule variance were
significant predictors of change in AUROC (Table 2.2). Change in preferred and
nonpreferred direction discharge rate contributed more to altered selectivity than
change in preferred direction variance, as measured by their β coefficients.
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Figure 2.6
Effect of carbachol on saccade direction selectivity of broad-spiking, putative
pyramidal neurons.
A, Rasters (above) and spike density functions (bottom) aligned on saccade
onset are shown for a neuron with preferentially higher discharge rate during
contralateral saccade trials (green) compared with ipsilateral saccade trials
(purple) during the post-saccade epoch is shown before (left) and after (right)
iontophoretic application of carbachol. The post-saccade epoch is shaded in gray
(see Materials and Methods). Qualitative schematic of main trial events is shown
above. After carbachol application, this saccade neuron increased discharge rate
in the post-saccade epoch, with a greater increase for ipsilateral trials, thereby
reducing saccade direction selectivity. B, Mean normalized spike-density
functions of preferred (blue) and nonpreferred (green) saccade trials for 18
DLPFC saccade-direction-selective neurons during control (left) and carbachol
conditions (right) are shown. C, Carbachol significantly decreased selectivity of
broad-spiking saccade neurons, as quantified by AUROC (abscissa: control
AUROC values, ordinate: drug AUROC values; n = 18, p = 0.0429, Wilcoxon
signed rank test). Ipsilateral-saccade-preferring and contralateral-saccadepreferring neurons are represented in blue and red, respectively. Dashed equality
line is shown. D, Change in normalized discharge rate during preferred saccade
direction trials of the 18 saccade neurons is compared with change in normalized
discharge rate during nonpreferred saccade direction trials. Based on k-means
cluster analysis (k = 2), two clusters of neurons are shown (pink and orange; filled
circles: neurons with decreased AUROC, open circles: neurons with increased
AUROC) with centroids shown as black crosshairs.
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Predictor of ΔAUROC
ΔFRpref
ΔFRnonpref
ΔVar pref
ΔVar nonpref

β coefficient
0.194
-0.144
-0.0599
0.0195

p
1.69E-5
0.00520
0.00140
0.414

Table 2.2
Summary of multiple linear regression analysis for broad-spiking saccadedirection-selective neurons.
𝛽 coefficients and p values from the multiple regression analysis (see Materials
and Methods) are shown to asses the impact of four predictors on change in
saccade direction AUROC: Δ𝐹𝑅!"#$ , change in mean normalized discharge rate
during preferred saccade direction trials; Δ𝐹𝑅!"!#$%& , change in mean normalized
discharge rate during nonpreferred saccade direction trials; Δ𝑉𝑎𝑟!"#$ , change in
normalized variance during preferred saccade direction trials; Δ𝑉𝑎𝑟!"!#$%& ,
change in normalized variance during nonpreferred saccade direction trials.
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We further explored the relative changes in preferred and nonpreferred

discharge rate in Figure 2.6D. Neurons are labeled with filled and unfilled circles,
indicating carbachol condition AUROC was less than or greater than control
AUROC, respectively. Because change in AUROC is largely determined by these
two variables, change in preferred and nonpreferred discharge rate, neurons
above the equality line (dark gray dashed line) often had decreased AUROCs
and neurons below the line, increased selectivity. Similar to the overall subset of
broad-spiking neurons, saccade-direction-selective broad-spiking neurons were
more often excited (n = 13, 72%; orange) by carbachol than suppressed (n = 5,
28%; purple). Carbachol reduced selectivity of almost all excited neurons (n = 13,
p = 0.0479). There was no relationship between whether a neuron was excited or
suppressed by carbachol and whether it preferred ipsilateral or contralateral
saccade (p = 1, Fisher's exact test).
Thus, carbachol-induced effects on saccade selectivity were found in
broad-spiking, putative pyramidal neurons, but not in narrow-spiking, putative
nonpyramidal neurons. Carbachol mostly excited discharge rate of broad-spiking
saccade neurons, resulting in decreased selectivity, which can be attributed to
relatively greater increase in nonpreferred saccade direction discharge rate.

2.4

Discussion
In this study we examined the effects of localized cholinergic stimulation

on primate DLPFC neurons engaged in a clinically relevant oculomotor task,
which involved using a rule maintained in working memory to produce the
appropriate saccadic responses to visual stimuli. Local carbachol application both
	
  

	
  

124

excited and suppressed DLPFC neurons. Surprisingly, we also found carbachol
disrupted neuronal rule representation in working memory, due to either
suppression of preferred rule activity or excitation of nonpreferred rule activity.
Moreover, broad-spiking putative pyramidal neurons were excited after
cholinergic agonist application, and postsaccadic directional selectivity in these
neurons was attenuated largely due to preferentially increased activity for the
nonpreferred saccade direction.

2.4.1 Effect of carbachol on neuronal discharge rate in DLPFC
We found that local cholinergic stimulation excited a greater proportion of
DLPFC neurons than those that were inhibited. However, our observation of both
facilitation and inhibition with carbachol is consistent with previous iontophoretic
applications of ACh in macaque DLPFC (Inoue et al., 1983; Sawaguchi and
Matsumura, 1985), orbitofrontal (Aou et al., 1983), premotor (Nelson et al., 1973),
motor (Matsumura et al., 1990), and primary visual cortex (V1; Soma et al.,
2012). Mixed effects of ACh on neuronal activity have also been observed in
marmoset V1 (Roberts et al., 2005; Zinke et al., 2006), cat V1 (Sato et al., 1987),
rat medial PFC (Pirch et al., 1992; Nagy et al., 2014), and in guinea pig cortical
slices (McCormick and Prince, 1985). Intriguingly, Sawaguchi and Matsumura
(1985) found that ACh-excited and ACh-inhibited DLPFC neurons were found in
separate layers.
We also found that carbachol increased activity in putative pyramidal
neurons, while having equivocal effects in putative interneurons. Heterogeneity in
responses to carbachol on interneurons has also been reported previously in
	
  

	
  

125

rodent medial PFC (Pafundo et al., 2013), hippocampal slices (Zheng et al.,
2011), and insular cortical slices (Yamamoto et al., 2010).

2.4.2 Effects of carbachol on task selectivity of DLPFC neurons
Systemic blockade of muscarinic receptors has detrimental effects on
cognitive performance in a variety of tasks (Klinkenberg and Blokland, 2010),
including spatial working memory. In macaque DLPFC, systemic injections of
muscarinic antagonist scopolamine disrupted spatial working memory (Zhou et
al., 2011), whereas local iontophoretic application strongly attenuated selectivity
for all task attributes, including rule selectivity (Major et al., 2015). We therefore
hypothesized that stimulation of DLPFC neuronal cholinergic receptors would
augment the selectivity of rule representation in working memory. Contrary to our
prediction, we found that carbachol reduced selectivity of rule neurons and broadspiking neurons with saccade direction selectivity. Selectivity of rule neurons was
reduced by two different mechanisms: in carbachol-inhibited neurons, preferred
rule activity was suppressed more than nonpreferred rule activity, whereas in
carbachol-excited neurons, activity for the nonpreferred rule increased more than
preferred. Additionally, carbachol decreased postsaccadic selectivity in putative
pyramidal saccade-direction-selective neurons, due to greater increase in
nonpreferred saccade direction activity.
Our results suggest that cholinergic stimulation can weaken DLPFC task
representations. Herrero et al. (2008) examined cholinergic modulation and
attentional enhancement in macaque V1. They found that lower dose ACh
application increased neuronal activity and enhanced attentional modulation,
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whereas at higher doses, attentional modulation was unaffected or even
disrupted due to nonspecific increase in neuronal activity. Although we did not
find systematic enhancement in rule selectivity at lower doses (Fig. 2.4D),
disruption of rule at higher doses in carbachol-excited neurons agree with
Herrero et al. (2008), wherein ceiling effects in increased excitability impaired
task representation. Similarly, Zinke et al. (2006) found that ACh iontophoresis
broadened orientation tuning of most ACh-excited neurons in marmoset V1,
possibly due to ceiling effects in optimal stimulus-induced responses and
increased activity to stimuli with nonpreferred orientations. Regardless of stimulus
orientation, Sato et al. (1987) found that ACh increased stimulus-evoked
responses in cat V1, resulting in no systematic effects on orientation selectivity.
These findings from several groups suggest that cholinergic stimulation of cortical
regions resulted in “inverted-U” dose-dependency of physiological effects on
cortical neurons, whereby too little or too much ACh is detrimental to task
performance and neuronal selectivity. This phenomenon has also been
demonstrated in the dopaminergic system (Vijayraghavan et al., 2007). Our
carbachol results may reflect the rightmost portion of a cholinergic inverted-U,
whereby excessive cholinergic stimulation is disruptive to cognitive processing.
Unlike the aforementioned investigations, we did not observe population
enhancement of task-related selectivity during low-dose cholinergic stimulation.
However, we cannot discount that the relative potency of carbachol compared
with ACh may have precluded the potential observation of improvements in
neuronal task-selectivity. Future experiments contrasting ACh and carbachol in
the same paradigm may clarify this possibility.
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We found trial-to-trial variance was not significantly affected after

carbachol. Moreover, regression analysis suggested that effects on trial
discharge rate variability had less impact on rule selectivity relative to changes in
activity. Similarly, Herrero et al. (2008) found that ACh-induced changes in Fano
factor did not contribute to attentional modulation of macaque V1 neurons.
Recently, Liu et al. (2017) examined the effects of electrical stimulation of
the macaque nucleus basalis during performance of a delayed match-to-sample
task. Intriguingly, they found that continuous stimulation was detrimental to task
performance, but intermittent stimulation resulted in significant improvement. Our
results showing reduced task selectivity during continuous iontophoretic
carbachol application in DLPFC suggest overstimulation of the cholinergic system
can be detrimental to cognitive performance.
Because carbachol is a general cholinergic agonist, both nicotinic and
muscarinic receptors could potentially mediate these effects on physiology and
task selectivity. Previously it was reported that muscarinic receptor antagonism
blocked the effects of ACh iontophoresis on orbitofrontal cortex (Aou et al., 1983)
and DLPFC (Inoue et al., 1983). We found that carbachol inhibited a significant
population of DLPFC neurons and disrupted rule selectivity in some neurons with
activity suppression. Because nicotinic actions in macaque DLPFC reported
heretofore were excitatory (Yang et al., 2013; Sun et al., 2017), the inhibitory
actions of carbachol may be muscarinic. Indeed, muscarinic receptors can
directly suppress prefrontal neurons via activation of G-protein coupled inwardrectifying potassium or SK channels (Gulledge and Stuart, 2005). Although
activation of nearby interneurons is another potential mechanism to inhibit
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neuronal activity (Disney and Aoki, 2008; Disney et al., 2014), we believe this is
less likely as we did not observe significant excitation in narrow-spiking neurons,
similar to previous reports (Gulledge et al., 2007; Pafundo et al., 2013). Further
supporting a role of muscarinic receptors, and akin to previous studies applying
ACh to DLPFC (Nelson et al., 1973; Sawaguchi and Matsumura, 1985), we
generally found that carbachol effects had longer latencies of onset and partial
recovery (seconds to minutes; Fig. 2.1C). This is inconsistent with fast ionotropic
actions mediated by nicotinic receptors, since recoveries from nicotinic agonist
stimulation are rapid (Disney et al., 2007).
However, we cannot discount nicotinic involvement in carbachol's actions
reported here. Although nicotinic receptor stimulation can augment working
memory activity in PFC (Yang et al., 2013; Sun et al., 2017) and can improve
cognitive performance (Terry et al., 2015), other studies have shown that low
doses of nicotinic antagonist enhanced attentional performance in rodents (Hahn
et al., 2011) and improved delayed match-to-sample performance in monkeys
(Terry et al., 1999). In the physiological context, Yang et al. (2013) showed that
low-dose iontophoretic stimulation of α7 nicotinic receptors during oculomotor
delayed responses increased macaque DLPFC neuronal excitability and
improved memory period spatial tuning, whereas α7 receptor antagonist reduced
delay period activity and spatial tuning. Moreover, high-dose α7 receptor
stimulation eroded tuning due to general activity increase for nonpreferred spatial
directions, similar to the effects on DLPFC task selectivity reported here. Sun et
al. (2017), in the same paradigm, found that nicotinic α4β2 receptor stimulation
strengthened delay period activity for preferred spatial locations, while,
	
  

	
  

129

interestingly, having no effect on neurons with saccade direction selectivity
(Wang et al., 2004). Because we found that carbachol disrupted saccade
direction selectivity of putative pyramidal cells, this suggests muscarinic receptors
mediate carbachol's effects on postsaccadic activity. Notably, carbachol has a
lower affinity and channel opening rate constant for nicotinic receptors than ACh
(Akk and Auerbach, 1999). Thus, both muscarinic and nicotinic mechanisms may
have contributed to carbachol's actions. Future experiments examining these
receptor families with subtype-specific compounds will be necessary to delineate
the signaling mechanisms that mediate the actions of carbachol on PFC taskrelated activity reported here.
The data reported here and previously (Major et al., 2015; Liu et al., 2017),
suggest that continuous cholinergic receptor stimulation or blockade can be
detrimental to prefrontal neuronal representations in cognitive tasks. Endogenous
ACh is transiently released with high temporal precision (Parikh et al., 2007;
Sarter et al., 2009) and continuous stimulation of cholinergic receptors may not
be beneficial to cognitive performance (Bentley et al., 2011). Subtype-selective
cholinergic agonists are being actively investigated to ameliorate cognitive
dysfunction in neuropsychiatric disorders, including Alzheimer's disease and
schizophrenia (Bodick et al., 1997; Wienrich et al., 2002; Shekhar et al., 2008).
Our findings offer a cautionary note and suggest that general cholinergic
stimulation using pharmacology may in fact be detrimental to cognitive functions.
Future work with more selective agonists may shed light on which downstream
signaling mechanisms are beneficial in treatment of cognitive dysfunction.
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CHAPTER 3 – MUSCARINIC M1 RECEPTOR OVERSTIMULATION DISRUPTS
WORKING MEMORY ACTIVITY FOR RULES IN PRIMATE PREFRONTAL
CORTEX

3.1

Introduction
Corticopetal innervation of the prefrontal cortex (PFC) by the basal

forebrain cholinergic system has a critical modulatory role in cognition and
controlled behaviour (Croxson et al., 2011, Mesulam, 2013). Acetylcholine (ACh),
through synaptic specializations and volume transmission (Mrzljak et al., 1995),
acts on pre- and postsynaptic cholinergic receptors to influence cortical function
in a variety of contexts, including working memory (WM; Croxson et al., 2011,
Zhou et al., 2011) and attentional gating of visual stimuli (Herrero et al., 2008,
Parikh et al., 2007). ACh exerts its influence through ionotropic nicotinic (Picciotto
et al., 2012) and metabotropic muscarinic receptors (Thiele, 2013). The
dorsolateral PFC (DLPFC) is a crucial node in a network of areas involved in
higher-order cognitive functions, including WM (Fuster and Alexander, 1971),
attentional processing (Miller and Cohen, 2001), maintenance of abstract rules to
guide responses (Everling and DeSouza, 2005, Wallis et al., 2001), and inhibition
of inappropriate responses (Condy et al., 2007). Dysfunction of the PFC
accompanies many disorders of cognition (Arnsten et al., 2012), and cholinergic
system pathology is widely implicated in the etiology of psychiatric disorders with
cognitive pathology, including Alzheimer’s disease (Mesulam, 2013) and
schizophrenia (Carruthers et al., 2015).
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While behavioural studies have established that muscarinic receptor

blockade is detrimental to cognition (Klinkenberg and Blokland, 2010), and to
specific PFC executive functions (Chudasama et al., 2004, Zhou et al., 2011), the
downstream mechanisms by which muscarinic actions regulate PFC function and
receptor subtype contributions thereof remain poorly understood. Both cholinergic
deafferentation of PFC (Croxson et al., 2011) and systemic injections of the
general muscarinic antagonist scopolamine (Zhou et al., 2011) cause spatial WM
performance deficits in monkeys. We have previously reported that iontophoretic
application of scopolamine on monkey DLPFC neurons suppresses DLPFC
neuronal activity and diminishes rule representation, stimulus, and saccade
direction selectivity in neuronal responses in a task in which rules maintained in
WM specify oculomotor responses (Major et al., 2015). However, the muscarinic
receptor subtypes involved in this suppression of PFC neuronal activity and task
representation in primates remain enigmatic.
There are five muscarinic receptor subtypes, comprised of the Gq-coupled
M1, M3, and M5 receptors and Gi/o-coupled M2 and M4 receptors (Jones et al.,
2012). M1 receptors (M1Rs) are the most prominently expressed subtype in
primate PFC, found in postsynaptic specializations on dendritic spines of
pyramidal neurons (Mrzljak et al., 1993), and have an excitatory influence on
cortical physiology in brain slices (Carr and Surmeier, 2007). M2 receptors
(M2Rs) are also expressed in PFC, both as a presynaptic autoreceptor on
cholinergic axons and as a postsynaptic heteroreceptor on glutamatergic and
GABAergic synapses, and are posited to have an inhibitory influence on neuronal
activity (Medalla and Barbas, 2012). Since the ACh binding site on muscarinic
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receptor subtypes is homologous and highly conserved, orthosteric agonists
targeting this site do not possess high subtype selectivity (Bubser et al., 2012).
The recent synthesis of muscarinic compounds possessing high subtype
selectivity, by acting on allosteric sites on muscarinic receptors, enables analysis
of the contributions of individual receptor subtypes in PFC cognitive physiology
during normal behaviour and in models of cognitive disorders (Bubser et al.,
2012, Conn et al., 2009, Digby et al., 2012).
Muscarinic stimulation improves cognitive indicators in patients with
Alzheimer’s disease (Bodick et al., 1997) and schizophrenia (Shekhar et al.,
2008). M1R activators improve cognitive performance during self-ordered spatial
search in monkeys (Uslaner et al., 2013) and augment medial PFC activity in
rodents (Shirey et al., 2009). M1R stimulation facilitates hippocampal long-term
potentiation (LTP) (Buchanan et al., 2010), and is expected to engender cognitive
enhancement due to increased excitability of PFC cortical neurons by blockade of
potassium currents, including the M-current (Wang et al., 2011).
Here, we examined the effects of local M1R stimulation and blockade on
PFC neuronal physiology in rhesus monkeys while they performed a task in
which a rule, maintained in WM, directed the execution of a prosaccade toward a
peripheral stimulus, or inhibition of that reflexive response, and execution of a
saccade away from the stimulus (antisaccade; Hallett, 1978). This task,
incorporating many PFC-dependent functions, including maintenance of task set,
automatic-response inhibition, and motor reprogramming, is sensitive to PFC
integrity in humans (Guitton et al., 1985, Rivaud et al., 1994) and monkeys
(Condy et al., 2007, Koval et al., 2011). Impairment of antisaccade execution is a
	
  

	
  

139

clinical manifestation of Alzheimer’s disease (Fletcher and Sharpe, 1986) and
schizophrenia (Fukushima et al., 1988). Based on previous results with general
muscarinic blockade (Major et al., 2015, Zhou et al., 2011) and other studies
summarized above, we hypothesized that M1R blockade would suppress
excitability and disrupt task selectivity of PFC neurons, while M1R stimulation
would enhance rule representation by increasing PFC excitability.
Unexpectedly, we found that M1R stimulation predominantly and dosedependently inhibited PFC neurons, with disruption of trial rule representation at
higher doses. Moreover, M1R blockade also suppressed PFC excitability, but had
no consistent effects on trial rule representation, in contrast with the strong
suppression of rule representation in WM observed upon general muscarinic
blockade (Major et al., 2015). Our results suggest that M1R overstimulation may
be detrimental to PFC activity in behaving subjects with endogenous cholinergic
tone, and that other muscarinic receptor subtypes mediate the disruptive effects
of muscarinic blockade on cognitive representations in PFC neuronal activity.

3.2

Methods

3.2.1 Experimental Model and Subject Details
These experiments were performed with two adult male rhesus monkeys
(Macaca mulatta, age 9–11 years, weight 9–12 kg). Subjects were individually or
pair-housed in temperature and humidity controlled environments maintained in a
12-hour light cycle. All procedures were performed in accordance with the
Canadian Council on Animal Care policy and a protocol approved by the Animal
Care Committee of the University of Western Ontario. Both subjects have
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previously served as subjects in other publications (Major et al., 2015, Major
et al., 2018, Skoblenick and Everling, 2012, Vijayraghavan et al., 2016). All
experimental procedures and data analysis were similar to Vijayraghavan et al.
(2016). Surgical procedures for implantation of a head-post and plastic recording
chamber were as described previously (Skoblenick and Everling, 2012). The
recording chamber was placed over the right DLPFC, as guided by MRI, in both
subjects, under anesthesia and employing standard aseptic techniques
(Figure 3.1A). Subjects were administered post-operative antibiotics and
analgesics and monitored by the university veterinarian.
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Figure 3.1
Recording Locus, Iontophoretic Electrophysiology, and Behavioural Task
(A) Schematic of recording location in PFC (pink oval). Most recordings were in
the dorsal bank of caudal principal sulcus (PS). AS, arcuate sulcus.
(B) Schematic illustrating the iontophoretic technique. M1R agonist (red dots) and
M1R antagonist (blue dots) were ejected from a multibarreled electrode by
current application.
(C) Schematic of behavioural task with time courses of a prosaccade (left) and
antisaccade trial (right) is shown. Black rectangles indicate the display. Timing of
salient epochs is indicated on the left.
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3.2.2 Behavioural Paradigm
The behavioural task, monitoring and reward delivery were implemented
with the stimulus presentation system CORTEX (National Institutes of Mental
Health, Bethesda, MD). The subjects performed a variant of the pro- and
antisaccade task (Everling and DeSouza, 2005, Hallett, 1978), where the trial rule
had to be retained in working memory (Koval et al., 2011). The subjects fixated
on a white fixation spot (0.5°), appearing centrally on a CRT monitor
(Figure 3.1C). After 300 ms, the fixation spot briefly changed to green or red
(100 ms), indicating the rule that was to be eventually applied to generate the
motor response: pro- or antisaccades. Rule cue colours indicating prosaccade
and antisaccade trials were counterbalanced between monkeys. In some
experiments, the red and green fixation spots were made isoluminant. In a few
sessions, the rule was instead indicated by central isoluminant horizontal or
vertical bars (1° width). We pooled the data from these experiments because
several groups, including ours, have previously shown that rule-selective activity
of PFC neurons is robust, and occurs regardless of the sensory attributes of the
rule cue (Vijayraghavan et al., 2016, Wallis et al., 2001). The fixation spot
reverted to white after 100 ms and the subject had to maintain the trial rule in
working memory. Central fixation was further maintained for 800–1300 ms
(pseudorandomly generated duration for each trial). In some sessions, we
maintained a constant delay of 1200 ms. Subsequently, the fixation spot
extinguished and after 200 ms (gap period), when the screen was blank, a
peripheral stimulus (0.5° white spot) was presented at 13° eccentricity at one of
two pseudorandomly chosen locations on the horizontal meridian to the left or
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right of the fixation spot. The subject had 500 ms to execute a saccade, and then
held post-saccade fixation for 120 ms. The subjects made saccadic response
based on the previously remembered task rule, which could be a prosaccade
toward the stimulus or an antisaccade away from the stimulus toward the
opponent location on the horizontal meridian. Correct responses were reinforced
with a water reward (approximately 125 ms after the saccade). The intertrial
interval was 2 s after reward onset. The gap period was introduced to increase
task difficulty (Bell et al., 2000). The rule presented on each trial and the stimulus
location was pseudorandomly chosen, and thus the subjects could not predict
which rule or stimulus location would be presented on a given trial.

3.2.3 Neuronal recordings with microiontophoresis and pneumatic injections
The M1R allosteric agonist, VU0357017 hydrochloride, M1R-preferring
agonist McN-A-343, and the M1R antagonist, pirenzepine dihydrochloride (Tocris
Bioscience, Sigma-Aldrich) were dissolved (10 mM) in pH 3.5 deionized water
and stored at −20°C in 30 µL aliquots.
Multi-barrel tungsten-in-glass electrodes were custom-fabricated and the
design was derived from previous studies (Vijayraghavan et al., 2016). Tungsten
wire (50 µm diameter; Midwest Tungsten Service), cut to a length of
approximately 11.2 cm, was tapered to a fine point by etching the wire in a
solution of sodium nitrite and potassium hydroxide as previously described
(Vijayraghavan et al., 2016). Seven-barreled, non-filamented borosilicate glass
(Friedrich-Dimmock) was pulled with the 50 µm tapered tungsten wire in the
central barrel using a micropipette puller (PMP107el, MicroData Instrument).
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Figure 3.1B illustrates the electrode design and the iontophoresis technique. The
resultant glass-coated recording tip was approximately 15–30 µm in diameter.
Typical impedance at 1 kHz was 0.5–1.0 MΩ. The remaining barrels were topfilled with the drug solutions (VU0357017, pirenzepine, McN-A-343) and saline.
The solutions were pneumatically pushed to the tip using air pressure. Barrel
impedances (measured for direct current) of the drugs used in this study typically
ranged from 35–300 MΩ. Electrode impedances and tip integrity were also
examined upon conclusion of the recording session. Tungsten wires were then
inserted into the drug barrels and used to pass current through them employing a
iontophoretic constant current generator (NeuroPhore BH-2, Harvard Apparatus).
The electrode was mounted on a hydraulic micro-manipulator (MO-95, Narishige
Group, Tokyo, Japan) and inserted through a 23-gauge dura-penetrating
stainless steel guide tube into the brain. The location in the recording chamber
was determined using a custom recording grid (Neuronitek) modified from the
Crist grid (Crist Instrument). Grid coordinates for recordings were crossreferenced with MRI images.
Neuronal signals were buffered using a unity-gain headstage and the
Omniplex system (Plexon), amplified 1000X, band-pass filtered (300–6000 Hz,
4–pole Bessel filter) for spike activity isolation and digitized at 40 kHz. Spikes
were detected online using amplitude thresholding, followed by offline
classification with principal component analysis using Offline Sorter (Plexon).
A holding/retention current was applied to barrels (−8 nA) when drugs
were not being ejected to prevent leakage. In most experiments, current
balancing was not employed, as it has been previously shown that there are no
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effects of currents of this magnitude on neuronal physiology in monkeys with this
electrode design (Vijayraghavan et al., 2007). Further, several studies have
shown that different drugs ejected with identical currents and polarities have
dissociable functional effects on physiological activity, often selective to cell type
(Vijayraghavan et al., 2007, Vijayraghavan et al., 2016, Wang et al., 2004).
Additionally, to ensure that our results were not artifacts due to current
application, in some sessions, we successively ejected Na+ (from saline) and the
M1R agonist with identical currents and polarity and found that Na+ ejection did
not result in comparable physiological effects as ejections of pharmacological
substances (see Results; also see similar results from Vijayraghavan et al.,
2007). Further, Disney et al. (2007) have demonstrated that the pH adjustment of
the drug solutions to optimize drug ionization does not affect neuronal physiology.
In some experiments (n = 6), in order to further ensure that drug effects
were not an artifact of the iontophoretic methodology used for drug delivery, we
ejected drugs using pneumatic pressure pulses for brief periods of time (50–
125 ms) using a precision solenoid (PPM2 module, Harvard Apparatus).
Electrode fabrication and drug loading was identical to the iontophoretic
experiments, except that drugs were dissolved in normal saline for these
experiments. We sealed Tygon tubing to the top opening of each filled drug barrel
(instead of a wire for ejecting current) using cyanoacrylate and epoxy resin, which
was then connected to the output of the solenoid valve system through a fluid
circuit that allowed us to eject specific drugs loaded in the electrode. We
empirically determined the pulse schedule range at which we were able to eject
drugs without causing displacement of the neuron or neuronal death, as
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assessed by lack of effect of saline ejections or by recovery after drug ejections.
We activated the solenoid using gating pulses driven by an Arduino ATmega2560
board. Gating pulse durations varied, but typically we applied 25–60 psi pulses of
50–125 ms at 1–2 Hz. Although we have not precisely quantified the volumes
ejected with each pulse in the experiments described here, we estimate the
volume is in the order of 10–30 picoliters per pulse. Since, our objective with
these experiments was to qualitatively establish the direction of drug effects on
the physiology of PFC neurons without using current based ejection, we do not
think that the caveat posed by the lack of precise volume information detracts
from the objective of the experiments here. Further, we did not include these
neurons in any of the subsequent population analyses presented in the study.

3.2.4 Data Analysis
Our experimental design involved data collection during a control condition
followed by iontophoretic application of an M1R agonist/antagonist (or saline) by
continuous ejection. Multiple doses of the drugs were tested, sometimes
successively in the same session, and in some sessions, a recovery condition
was obtained after termination of drug application. At least 8 correct trials were
obtained per rule and per stimulus direction combination, typically more.
Recordings with less than 8 correct trials in each rule and stimulus direction
combination in each condition were excluded from further analysis. Iontophoresis
results in the ejection of very small amounts of charged drugs in the neuronal
milieu, and is thus not expected to have behavioural consequences in areas with
diffuse specialization such as the PFC (Major et al., 2015, Major et al., 2018,
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Vijayraghavan et al., 2016). Thus, in this study we have restricted ourselves to
presenting the physiological consequences of M1R neuromodulation, and not the
effects on behaviour.
After waveform sorting, all data was analyzed with custom-written scripts
in MATLAB (MathWorks, Natick, MA). Cortical neurons can be classified into
narrow-spiking (NS) and broad-spiking (BS) based on width of the spike
waveform (Mountcastle et al., 1969). NS neurons are generally thought to
comprise of neocortical basket and chandelier cells expressing parvalbumin, and
thus comprise a subset of cortical interneurons (Kawaguchi and Kubota, 1993).
However, the presence of thin-spiking regular spiking cells in cortex (Nowak
et al., 2003) and of pyramidal tract neurons in macaque motor cortex with thin
extracellular waveforms (Vigneswaran et al., 2011) may complicate this
categorical correspondence. Nevertheless, identified pyramidal neurons in
DLPFC have been shown mostly have broad spike waveforms and narrowspiking neurons in macaque PFC were found to correspond to parvalbuminexpressing basket and chandelier cells (Krimer et al., 2005). Further, Johnston
et al. (2009) found that antidromically identified corticotectal neurons were broadspiking. Since prior work that has found differences in neuromodulation of narrow
and broad spiking neurons (Jacob et al., 2013), we performed an analysis of
spike waveform based categorization.
Waveforms were first spline interpolated to 1 µs resolution (Johnston et al.,
2009). We then normalized the average interpolated waveform from each
recorded neuron, such that the normalized waveform ranged from −0.5 to 0.5.
Waveforms were then aligned on the waveform trough (negative inflection) and
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the waveform peak (positive inflection) was marked for each neuron. We then
computed the trough–peak time for each neuron, which has been correlated with
the width of the intracellular action potential at half maximum (Krimer et al.,
2005). To examine the distribution of spike widths, and ensure that our
distribution was robust to sample size, trough-peak time distribution for the
population was pooled with a larger dataset that comprised of 179 recordings for
which we have conducted spike width analysis in this and previous studies (Major
et al., 2015). We tested for unimodality of the trough-peak distribution using the
Hartigan’s dip test (Hartigan and Hartigan, 1985). We found that trough-peak
times were not distributed unimodally (n = 179; p = 0.03). Based on findings from
previous studies, which examined antidromically identified macaque PFC
projection neurons (Johnston et al., 2009), and intracellular recordings from
macaque PFC slices (Krimer et al., 2005), we classified neurons as NS if the
trough-peak duration was less than 250 µs. Our analysis yielded 20/94 NS
neurons with median peak-trough duration of 195 µs (range: 133–244 µs), and
BS neurons with median peak-trough duration of 465 µs (range: 276–626 µs).
Spike density functions were constructed by convolving spike trains with a
kernel reminiscent of the alpha function (Thompson et al., 1996, Vijayraghavan
et al., 2016):
!!

!!

𝑠 𝑡 = (1 − 𝑒 α ) ∙ 𝑒 τ

where s is the convolved spike density function, t is time and the parameters α
and τ are the time constants for the growth and decline phases of the exponential
function. We used α of 2 ms, and τ of 100 ms to account for higher variability in
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PFC responses compared with sensory areas. Unlike the more commonly
employed Gaussian convolution kernel, which results in a symmetric convolution
around the spike and could thus erroneously attribute some of the impact of the
spike prior to its occurrence, the spike impact using this kernel occurs completely
after the occurrence of the spike (Thompson et al., 1996).
We excluded neurons with negligible activity (<1 Hz throughout the control
and relevant drug conditions) from further analysis. We calculated average
activity (firing rate) across the entire trial (average trial denoted throughout the
manuscript with the term) from each neuron tested with a drug. We delineated
the effects of the drug on individual neuronal activity by performing nonparametric
Wilcoxson rank sum tests on the trial activity for each neuron between control
and drug conditions. Neurons were deemed to have excited or inhibited on the
basis of the test (p < 0.05). We counted the number of neurons that were excited,
inhibited or unaffected using this analysis and constructed pie charts of the
proportions of neurons. This analysis also extended to measuring the effects of
individual dose-ranges of the drug. The Fisher exact test was used to assess if
proportions of excited and inhibited neurons were significantly different from each
other and to test if different doses of the drugs resulted in progressive inhibition
or excitation of the population (see Results).
We also calculated the population average activity for control and drug
conditions for all doses, and low/high dose ranges. We examined whether there
was significant effect of the drugs on average population activity using the paired
Wilcoxon sign rank test (p < 0.05). We further examined physiological effects of
the drugs in different epochs of the trial. For this analysis, we divided the trial into
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three epochs: early rule (0–600 ms after rule cue onset), late-rule (last 600 ms
prior to peripheral stimulus onset) and post-stimulus epoch (0–500 ms after
stimulus onset). We computed the average activity in these epochs as described
above.
We classified task-selectivity of neurons in our population using ANOVAs
as described previously (Vijayraghavan et al., 2016). We performed the ANOVA
analysis in task-relevant epochs defined as follows:
(1) Delay epoch: 600 ms before stimulus-onset to 70 ms after stimulus-onset (to
account for the afferent delay in stimulus-related responses in DLPFC). We
performed 2-way ANOVAs (factors: rule and drug) on trial activity in this epoch to
delineate neurons with rule-selectivity. Previous studies (Major et al., 2015,
Vijayraghavan et al., 2016), have found that prominent rule-selectivity during proand antisaccades in PFC occurs at a latency of about 600ms prior to stimulus
onset. Further, we were interested in rule selectivity in the time period directly
preceding stimulus onset, when it could most directly have an impact on task
performance. Based on the ANOVAs, we identified neurons as possessing ruleselectivity if there was a significant main effect of rule or a significant rule X drug
interaction in this epoch. (2) Stimulus epoch: 70 ms after peripheral stimulus
onset to 400 ms after stimulus onset. We performed 3-way ANOVAs (factors:
rule, drug and stimulus location) on trial activity in this epoch from each neuron to
identify stimulus location-selective neurons. Neurons were classified as selective
for stimulus location if there was significant main effect of stimulus location or
significant stimulus location X drug interaction in this epoch. (3) Postsaccadic
epoch: 400 ms period after saccade onset. We performed 3-way ANOVAs
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(factors: rule, drug and saccade direction) on trial activity from each neuron in this
epoch to identify postsaccade direction-selective neurons, which were defined by
a significant main effect of saccade direction or significant saccade direction X
drug interaction in this epoch. After data collection, saccade onsets were
precisely marked using an eye-velocity threshold of 70°/s.
Neurons classified by ANOVA were included in further analysis of drug
effects on task selectivity. The proportions with which DLPFC neurons displayed
individual activity types in the overall population are shown in Table 3.1.
We then quantified rule, saccade direction and stimulus location selectivity
in these individual populations defined by the ANOVA using signal detection
theory and computing the area under the Receiver-Operating characteristic
curves (AUROC) from spike counts (Green and Swets, 1966) in the relevant
epoch, as described before (Vijayraghavan et al., 2016). The AUROC metric has
been extensively employed in analyzing categorical selectivity. The AUROC
ranged from 0 to 1 with 0.5 indicating no selectivity, and values toward 0 or 1
indicating increasing selectivity for one of the opponent discriminants (i.e.,
prosaccade or antisaccade rule; contralateral or ipsilateral saccade; contralateral
or ipsilateral stimulus location). By convention, we computed AUROC values
such that AUROC > 0.5 indicated a preference for prosaccades, contralateral
saccade direction and contralateral stimulus location, while AUROC < 0.5
indicated a preference for antisaccades, ipsilateral saccades and ipsilateral
stimulus location. Neuronal selectivity (preferred rule, saccade direction or
stimulus location versus nonpreferred) was determined based AUROC values in
both control and drug conditions, to include neurons in which selectivity arose as
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a consequence of drug application (Vijayraghavan et al., 2007, Williams and
Goldman-Rakic, 1995). AUROC values were then reported based on preferred
versus nonpreferred task rule, saccade direction or stimulus location. For
example, for a neuron deemed to be antisaccade rule preferring, where the
AUROC would be less than 0.5, we report the AUROC value for the neuron as [1AUROC] for control and drug conditions. Population analysis of drug-induced
changes in selectivity were performed by comparing pairwise neuronal AUROCs
in the control and drug conditions using the sign rank test. The AUROC metric
reflects only differences between activity for opponent task attributes. However, it
is not sensitive to the raw neuronal activity that contributes to the selectivity. It is
conceivable that increase/decrease in task selectivity in a minority of neurons
accompanied by strong changes in neuronal activity can offset more numerous
opponent changes in selectivity in a majority of the neurons with weaker
opponent changes in activity. To address this possibility, we also performed
another population analysis, wherein we randomly sampled the activity from 1
trial from each neuron in the population for a given task attribute and given
condition (control or drug), and created bootstrapped trials with average activity
from these randomly sampled trials across neurons. Thus, this averaged “trial”
activity represented activity from all neurons. We repeated this to create a
dataset of averaged activity bootstrapped trials for each task attribute (i.e.,
preferred rule trials or nonpreferred rule trials). To ensure that we maintained
comparable sample sizes with the experiments, we adjusted the repetition so that
the number of trials generated would be equal to the median trial counts in the
neuronal dataset condition. From these trial sets we computed AUROCs. We ran
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the simulation for 1000 such datasets. AUROCs from this dataset would reflect
many possible combinations of trial activity of these neurons, as if they were
recorded simultaneously. If the changes in activity in individual neurons was
much stronger than weaker changes in other neurons in the opponent direction,
this analysis would provide an estimate of population selectivity changes that
reflected such an effect.
After determining the preferred and nonpreferred trial type for each type of
task selectivity (rule, saccade direction, stimulus location), we constructed minmax normalized spike density functions from each neuron to generate population
normalized spike density functions as described previously (Vijayraghavan et al.,
2016).

3.3

Results
We pharmacologically tested 152 neurons from the DLPFC of two rhesus

macaques (monkey O, 58; monkey T, 94; Figures 3.1A and 3.1B) performing the
rule working memory antisaccade task (Figure 3.1C). We tested 56 neurons with
iontophoretic application of M1R allosteric agonist, VU0357017; 17 neurons with
saline followed by VU0357017; 24 neurons with M1R-preferring agonist, McN-A343; and 55 neurons with M1R-preferring antagonist, pirenzepine. After excluding
neurons whose average activity throughout the session was less than 1 Hz
(Methods), we analyzed the effects of VU0357017 (n = 47), McN-A-343 (n = 18),
and pirenzepine (n = 47) on general neuronal physiology and task selectivity.
Behavioural trial count statistics for the population are shown in Table 3.S1.
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3.3.1 Effects of M1R Agents on DLPFC Neuronal Physiology
Based on our previously published findings and other studies with
muscarinic antagonist scopolamine (Major et al., 2015, Zhou et al., 2011), we
hypothesized that M1R stimulation with VU0357017 would increase DLPFC
neuronal excitability, while M1R blockade with pirenzepine would suppress
activity. We found that VU0357017 application suppressed average trial activity
of DLPFC neurons (Figure 3.2A, top panel; n = 47; p = 0.005, Wilcoxon sign-rank
test, control versus drug activity). A majority of neurons (62%; p < 0.05, Wilcoxon
rank-sum test on each neuron) were significantly inhibited by M1R stimulation
(Figure 3.2A, bottom panel). We then examined the dose dependence of effects
of VU0357017 on neuronal activity to ascertain if neuronal suppression was
monotonic with drug dose. We found that M1R stimulation at lower doses (≤20
nA) had no significant effects on population activity (Figure 3.2B, left; n = 35),
while higher ejection doses (21–100 nA) induced significant neuronal activity
suppression (Figure 3.2B, right; n = 26, p = 0.001). At lower doses, 49% of
neurons tested were significantly inhibited, while 31% were excited (Figure 3.2B,
left pie chart). Higher dose application significantly inhibited most DLPFC
neurons (81%) while only 4 neurons were excited (Figure 3.2B, right pie chart).
The proportion of DLPFC neurons inhibited by drug application was significantly
different between the dose ranges (low versus high doses; p = 0.016, Fisher
exact test). In 23 neurons (Figure 3.2C), we found that mean activity showed
significant recovery after drug-induced suppression (pcontrol-drug = 0.006; pdrugrecovery

= 0.019) with two-thirds of significantly inhibited neurons exhibiting

successful recovery (Table 3.S1).
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Figure 3.2
M1R Stimulation Dose-Dependently Suppresses Population Activity of PFC
Neurons
(A) Average population activity of PFC neurons during control (black) and M1R
stimulation (gray). Pie chart (bottom) shows the proportion of PFC neurons that
were significantly excited (pink) or inhibited (blue) by the drug or where the drug
had no effect (yellow). Significance was determined on each neuron with the
rank-sum test (p < 0.05). Error bars: ± SEM.
(B) Average PFC neuronal activity for neurons tested with M1R stimulation at
low-dose range (0–20 nA; left) and high-dose range (21–100 nA; right). Control,
black bars; low-dose M1R stimulation, gray; high-dose stimulation, light gray. Pie
charts below show the proportion of neurons by effect for low (left) and high
(right) dose ranges (same format as A).
(C) Average population activity of PFC neurons is shown for control (black), M1R
stimulation (gray), and recovery (brown) after drug application. Significance
testing with sign-rank test and Holm-Bonferroni correction for multiple
comparisons.
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Microiontophoresis involves passage of very small currents (0–100 nA

range) to electrically repulse charged molecules with the same polarity into the
neuronal milieu. Previous studies have demonstrated that current application
itself does not affect neuronal physiology (Vijayraghavan et al., 2007). To further
confirm this, we tested Na+ (saline) application in 17 DLPFC neurons, which did
not result in inhibition (pcontrol-Na+ = 0.99, one-tailed sign-rank test), while
subsequent comparable application of VU0357017 at positive ejection current
polarities inhibited those neurons (pNa+–drug = 0.001). Further, in 12 neurons tested
with saline, M1R agonist, and recovery, neuronal activity recovered after M1R
agonist application (pdrug-recovery = 0.003, sign-rank test with Holm-Bonferroni
correction). Thus, activity suppression due to M1R stimulation by VU0357017
was not an artifact of iontophoretic currents. To further confirm that neuronal
suppression was not an artifact of the drug ejection protocol or technique, we
also stimulated M1R by pulsed pneumatic pressure ejection of VU0357017 onto
neurons. This allowed us to rapidly apply small amounts of drugs with a pulse
schedule and mitigated potential consequences of prolonged current-induced
ejection. Pressure ejection of VU0357017 reliably resulted in suppression of the
activity of PFC neurons (Figures 3.S1A and 3.S1B), while comparable ejection of
saline had no effect (Figure 3.S1A). Thus, neuronal inhibition by the M1R
allosteric agonist was not a consequence of the drug application methodology
and was also reproduced when the drug was intermittently applied with
pneumatic ejection. Moreover, to preclude the possibility that neuronal
suppression observed after M1R blockade was an idiosyncrasy of the
pharmacology of the M1R-selective agent used (VU0357017), we also tested
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DLPFC neurons with McN-A-343, an M1R-preferring agonist with high functional
M1R selectivity that has been widely used to delineate M1R effects (Davies et al.,
2001, Mitchelson, 2012). McN-A-343 iontophoresis resulted in suppression of
DLPFC neuronal trial activity (n = 18; p = 0.043, sign-rank test; Figure 3.S2A),
whereby 61% of neurons (n = 11) were significantly suppressed. The proportion
of suppressed neurons was similar between both M1R agonists.
Next, we examined the physiological effects of M1R blockade with the
selective antagonist, pirenzepine. M1R blockade also led to overall suppression
of the neuronal population tested (n = 47; Figure 3.3A, top panel), just reaching
significance (p = 0.047). Pirenzepine application significantly suppressed half of
the tested DLPFC neurons (Figure 3.3A, bottom; n = 47, p < 0.05, rank-sum test
on each neuron). Suppression of DLPFC activity by M1R blockade was only
significant at higher dose ranges (21–100 nA; Figure 3.3B, right panel) and not
for lower doses (0–20 nA; left panel). The proportion of significantly inhibited
neurons was not different for pirenzepine application at low and high dose ranges
(Figure 3.3B, pie charts; p = 1; Fisher exact test, low versus high dose; low dose,
55%; high dose, 54% suppressed). Neurons tested for recovery from drug effects
(n = 22) showed no significant restoration of activity after pirenzepine-induced
suppression (Figure 3.3C). However, when we examined the final 200 s of the
drug and recovery conditions, population average activity was significantly
different (control versus final 200 s pirenzepine application, p = 0.002; final 200 s
pirenzepine versus final 200 s recovery, p = 0.002; sign-rank test), suggesting
that recovery was prolonged. Thus, M1R blockade also suppressed DLPFC
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activity, and while neuronal suppression was stronger at higher doses, there was
a ceiling on the proportion of inhibited neurons due to M1R blockade.
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Figure 3.3
M1R Blockade Dose-Dependently Suppresses Population Activity of PFC
Neurons
All colours, conventions, and statistical testing identical to Figure 3.2.
(A) Effects of M1R antagonist on population average activity and proportion of
neurons by drug effect (pie chart; bottom) are shown.
(B) Effects of M1R blockade at low doses (0–20 nA; left) and high doses (21–100
nA; right) on PFC population activity. Pie charts below show proportions of
neurons by drug effect at low and high doses.
(C) Average population activity of PFC neurons tested with drug and post-drug
recovery shown for control (black), M1R antagonist (gray), and recovery (brown)
conditions. Significance testing with sign-rank test and Holm-Bonferroni
correction for multiple comparisons.
Error bars: ± SEM.
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We also classified recorded PFC neurons on the basis of waveform width

into narrow-spiking (NS) and broad-spiking (BS) waveforms (Figures 3.4A and
3.4B). M1R stimulation significantly inhibited most tested NS neurons
(Figure 3.4C; 7/8 significantly inhibited) and 22/39 BS neurons (11/36 excited).
M1R blockade significantly inhibited 8/12 NS neurons (Figure 3.4D; 3/12 excited)
and 16/35 BS neurons (9/35 excited).
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Figure 3.4
Classification of DLPFC Neurons Based on Waveform Shape
(A) Shown are the normalized waveforms of 94 DLPFC neurons that were tested
with VU0357017 and pirenzepine. Narrow-spiking (NS) neurons are shown in
black and broad-spiking (BS) neurons in red.
(B) Spike trough-peak duration histogram (25 µs bins) for the neuronal population
(n = 94).
(C) Trough-peak duration for each neuron (n = 47; blue diamonds) plotted against
changes in normalized activity due to M1R agonist application. Dashed line
shows cutoff for NS and BS neuron classification. M1R agonist suppressed most
NS neurons.
(D) Trough-peak duration for each neuron (n = 47; red circles) plotted against
changes in normalized activity due to M1R antagonist application.
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Next, we examined the effects of M1R modulation on DLPFC activity in

specific task epochs (Methods): 0.6 s after rule cue onset (early-rule epoch),
0.6 s prior to stimulus onset (late-rule), and a 0.6 s period encompassing stimulus
onset, saccade, and reward (post-stimulus epoch). A two-way ANOVA of
neuronal activity with factors drug condition and epoch for M1R stimulation
resulted in significant effect of drug (F1,276 = 9.92; p = 0.0018), but no significant
effect of the trial epoch or the interaction (drug × epoch). M1R stimulation
significantly decreased DLPFC activity in all epochs (Figure 3.S3A; sign-rank test
with Holm-Bonferroni correction). With M1R blockade at all doses, there were no
significant effects of drug, epoch, or the interaction (drug × epoch). M1R blockade
overall only significantly suppressed activity in the post-stimulus epoch
(Figure 3.S3B; sign-rank test with Holm-Bonferroni correction). However, at high
doses of the M1R antagonist, the effect of the drug was significant (two-way
ANOVA, F1,228 = 8.05; p = 0.005), while the main effects of epoch and the
interaction were not.

3.3.2 Effects of M1R Agents on Task Selectivity of DLPFC Neuronal Activity
We categorized DLPFC neurons using ANOVAs (Methods) of trial activity
for each neuron during the memory (delay) epoch to delineate neurons with ruleselective WM activity and during the stimulus and post-saccade epochs
to identify neurons with saccade direction selectivity and stimulus location
selectivity. The numbers of neurons in each defined population for both drugs
tested are shown in Table 3.1. Neuronal populations selective for task attributes
were not defined to be mutually exclusive, and many neurons displayed multiple
	
  

	
  
forms of task selectivity. We then examined drug effects on trial rule, saccade
direction, and stimulus location selectivity in these respective populations by
analyzing the area under the receiver operating characteristic curve (AUROC;
Green and Swets, 1966).
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Table 3.1
Statistics of Task-Selective Neurons Identified by ANOVA
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3.3.3 Trial Rule Selectivity
Figures 3.5A and 3.5B show two example DLPFC neurons possessing
rule selectivity in the memory epoch that were challenged with M1R stimulation.
The neuron in Figure 3.5A exhibited greater control period activity prior to
stimulus onset during prosaccades than antisaccade trials (top panel;
Activitycontrol= 5.94 Hz; AUROCcontrol = 0.74). M1R stimulation significantly
suppressed neuronal activity (bottom panel; Activitydrug= 4 Hz, p < 0.0001) and
deteriorated the difference in prestimulus activity between prosaccade and
antisaccade trials, thus reducing rule selectivity in WM (AUROCdrug = 0.69).
Another neuron (Figure 3.5B) had greater delay epoch activity for antisaccade
rule trials immediately prior to stimulus onset (top panel; Activitycontrol = 2.16 Hz;
AUROC = 0.64). This neuron was tested with successive doses of VU0357017
(20 and 40 nA, second and third panels, respectively). Increasing doses of M1R
stimulation progressively decreased neuronal activity (Activitylow-dose= 1.75 Hz,
pcontrol–low = 0.0001; Activityhigh-dose= 0.18 Hz, plow-high < 0.0001). Subsequently, the
neuron’s activity was restored during the recovery condition (Activityrecovery=
2.37 Hz; pcontrol–recovery = 0.09). Concomitant with changes in neuronal excitability,
trial rule selectivity diminished with increasing doses, especially for the high dose
(AUROCcontrol = 0.64; AUROClow = 0.62; AUROChigh = 0.52) and was restored
during recovery compared to the high dose agonist application (AUROCrecovery =
0.59). In some neurons, M1R stimulation increased activity and increased rule
selectivity. Figure 3.S4A shows a DLPFC neuron with prestimulus preference for
the antisaccade rule (top panel; Activitycontrol = 5.37 Hz; AUROCcontrol = 0.66).
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M1R stimulation increased neuronal activity (bottom; Activitydrug = 8.68 Hz) and
increased neuronal antisaccade selectivity (AUROCdrug = 0.73). The M1Rpreferring agonist McN-A-343 also suppressed DLPFC neuronal rule selectivity
(Figure 3.S2B). Pneumatic pressure ejection of the M1R agonist also reduced
activity of a DLPFC rule-selective neuron (Figure 3.S4B) and reduced trial rule
selectivity, which recovered after cessation of the drug.
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Figure 3.5
Both M1R Stimulation and Blockade Inhibit Activity and Disrupt Rule Selectivity of
Individual PFC Neurons
(A) Trial rasters (blue lines, individual spikes on prosaccade trials; red lines,
individual spikes on antisaccade trials) and average spike density functions (blue
trace, prosaccades; red trace, antisaccades; line indicates average; shaded area
indicates SEM) aligned on peripheral stimulus onset are shown for a DLPFC
neuron that had selectivity for the prosaccade rule before stimulus onset. Top
panel, control; bottom panel, M1R stimulation; dashed line, stimulus onset; green
dots, rule cue onset in each trial.
(B) Conventions identical to (A). Rasters and spike density functions for PFC
antisaccade-preferring neuron are shown: control (top panel) for successive
stimulation of M1R at a low dose (second panel), high dose (third panel), and
subsequent recovery after drug application cessation (bottom panel).
(C) Conventions identical to (A). Rasters and spike density functions are shown
for a PFC neuron with selectivity for prosaccades during control (top panel) and
application of M1R antagonist pirenzepine (bottom panel).
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Next, we examined the effects of M1R blockade on DLPFC neuronal rule

selectivity. Figure 3.5C shows a DLPFC neuron with prestimulus preference for
prosaccade trials (top panel; Activitycontrol = 10.46 Hz; AUROCcontrol = 0.82).
Pirenzepine application suppressed the activity of this neuron (bottom panel;
Activitydrug = 4.80Hz; pcontrol-drug < 0.0001) and diminished rule selectivity
(AUROCdrug = 0.70).
To ascertain the overall effects of M1R stimulation and blockade on trial
rule selectivity in our population of neurons, we analyzed all rule-selective
neurons tested with either drug. M1R stimulation marginally reduced population
rule selectivity (n = 18 rule-selective neurons), but this effect did not reach
significance (AUROCcontrol = 0.61 ± 0.01; AUROCdrug = 0.59 ± 0.02; p = 0.17, signrank test). It is possible that M1R stimulation initially augments rule selectivity, but
this degrades as drug application proceeds. However, we found that rule
AUROCs in the 200 s immediately after drug application initiation did not
significantly change (n = 18; p = 0.2; sign-rank test). We then analyzed
population effects of VU0357017 separately at low (0–20 nA) and high (21–100
nA) doses. Population-normalized spike density functions (Figure 3.6A, top
panel) for 13 neurons tested with low doses of VU0357017 show that the drug
weakly suppressed population activity and had negligible effect on rule selectivity.
This is further quantified by population AUROC values for rule activity for each
neuron. (Figure 3.6B; control, abscissa; low-dose drug application, ordinate).
Although individual neuronal AUROCs increased or decreased upon drug
application, there was no significant shift in overall population AUROCs above or
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below the equality line, indicating that low-dose drug application did not have
systematic effects on rule selectivity (AUROCcontrol = 0.59 ± 0.01; AUROCdrug =
0.59 ± 0.02; p = 0.95). Population-normalized spike density functions for 12
neurons tested with high doses of VU0357017 (Figure 3.6C) demonstrate druginduced collapse of population activity for preferred and nonpreferred rules and
accompanying reduction in rule selectivity. Population AUROCs plotted for
control and high-dose drug application (Figure 3.6D) showed a shift of neuronal
AUROCs below the equality line, indicating significant disruption of rule selectivity
(AUROCcontrol = 0.62 ± 0.01; AUROCdrug = 0.55 ± 0.02; p = 0.021). Moreover,
change in rule selectivity was not significantly correlated with activity suppression
due to the M1R agonist at all doses (n = 18, Pearson’s correlation coefficient, R =
0.4, p = 0.06) and at low doses (n = 13, R = 0.48, p = 0.09). However, for higher
dose application of the M1R agonist, changes in the AUROC were significantly
correlated with activity changes (n = 12, R = 0.58, p = 0.048), indicating that
neuronal activity suppression led to reduction in population rule selectivity.
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Figure 3.6
M1R Stimulation Dose-Dependently Disrupts the Population Rule Selectivity of
PFC Rule-Selective Neurons
(A) Average normalized spike density functions aligned on stimulus onset (gray
vertical line) for the preferred rule (blue) and nonpreferred rule (red) shown for
the population of PFC rule-selective neurons during control (top) and low-dose
(0–20 nA; bottom) stimulation of M1Rs. Thick lines indicate mean; shaded area
indicates SEM.
(B) Rule selectivity (quantified by AUROC) is plotted for each rule-selective
neuron (n = 13; blue dots, prosaccade-preferring; red dots, antisaccadepreferring) during control (abscissa) and low-dose M1R stimulation (ordinate).
Green line indicates equality.
(C) All conventions same as (A). Average normalized spike density functions for
a population of PFC neurons tested with high doses of M1R stimulation (21–100
nA).
(D) All conventions same as (B). AUROC values for each neuron tested with
high-dose M1R stimulation shown for control and drug.
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An analysis of the effects of M1R blockade with pirenzepine on population

rule selectivity in 26 rule-selective neurons revealed no significant changes due
to M1R blockade (AUROCcontrol = 0.617 ± 0.01; AUROCdrug = 0.595 ± 0.01; p = 0.12,
sign-rank test). We then analyzed population selectivity for low (0–20 nA) and
high (21–100 nA) dose ranges of pirenzepine application. Population-normalized
spike density functions for 13 neurons tested at low doses (Figure 3.7A) and for
21 neurons at high doses (Figure 3.7C) show that pirenzepine application did not
appreciably change activity differences between preferred and nonpreferred rule
trials. AUROCs demonstrated no significant overall effect of M1R blockade at
both dose ranges on population rule selectivity (low doses, Figure 3.7B, p =
0.147; high doses, Figure 3.7D, p = 0.455). Thus, M1R blockade, while
influencing trial rule-related activity of individual PFC neurons, did not have a
significant overall effect on rule selectivity of the neuronal population.
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Figure 3.7
M1R Blockade Has No Effect on the Population Rule Selectivity of PFC RuleSelective Neurons
All colours, conventions, and statistical tests in panels are identical to equivalent
panels in Figure 3.6.
(A) Average normalized spike density functions are shown for control period and
low-dose (0–20 nA) M1R blockade for preferred and nonpreferred rules. Shaded
area indicates SEM.
(B) AUROCs for each neuron tested with low-dose M1R blockade shown for
control and drug.
(C) Average normalized spike density functions are shown for control and highdose (21–100 nA) M1R blockade for preferred and nonpreferred rules.
(D) AUROCs for each neuron tested with high-dose M1R blockade shown for
control and drug.
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3.3.4 Saccade Direction Selectivity
We performed a similar analysis of M1R modulation for DLPFC neurons
displaying selectivity for the direction of the saccade executed (contralateral or
ipsilateral to the recording hemisphere). Figure 3.S6A shows activity of a DLPFC
neuron preferring contralateral saccades. During the control period, this neuron
was activated at saccade onset and had differential postsaccadic activity for
contra- and ipsilateral saccades (top panel; saccade direction AUROCcontrol =
0.79). M1R blockade suppressed neuronal activity and reduced postsaccadic
directional selectivity therein (AUROCdrug = 0.63). Figure 3.S6B shows the activity
of another DLPFC neuron with preference for the contralateral saccade that was
tested with successive doses of pirenzepine, (top panel; AUROCcontrol = 0.59).
Low-dose (15 nA) pirenzepine application did not affect overall neuronal activity
(pcontrol-low = 0.09). However, the activity decrease was more pronounced for
ipsilateral saccades (Δcontralateral = 1.23 Hz; Δipsilateral = 2.3 Hz; p < 0.0001), thereby
increasing postsaccade direction selectivity (AUROClow-dose = 0.65). Subsequent
higher dose M1R blockade suppressed overall activity (pcontrol-high < 0.0001) and
decreased postsaccade direction selectivity (AUROChigh = 0.56). Saccadedirection AUROCs were significantly reduced by M1R blockade in the saccadeselective neuronal population (n = 31; p = 0.007(AUROCcontrol = 0.65 ± 0.01
(AUROCdrug = 0.61 ± 0.01). In 20 neurons selective for contralateral saccades,
pirenzepine reduced overall population AUROCs (Figure 3.S6C; p = 0.0001, signrank test). This selectivity disruption was due to a greater decrease in activity for
contralateral than ipsilateral saccades (Figure 3.S6D; p = 0.001). In 11 ipsilateral
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saccade-selective neurons, pirenzepine had no effect on saccade selectivity (p =
0.91). In contrast, M1R stimulation with VU0357017 had no significant effect on
population saccade selectivity of contralateral saccade-selective neurons (n = 18;
p = 0.472, sign-rank test on AUROC, drug versus control). Thus, moderate levels
of M1R stimulation appear to be necessary for the maintenance of saccaderelated activity in PFC neurons, while overstimulation beyond endogenous
cholinergic stimulation does not disrupt this activity.
We also analyzed the effects of M1R stimulation and blockade on neurons
possessing selectivity for the peripheral stimulus direction. We found that neither
M1R stimulation (n = 11, p = 0.10; sign-rank test) nor blockade (n = 16, p = 0.35)
affected population stimulus direction selectivity measured by AUROCs.
In summary, the major consequence of local stimulation of M1Rs was
suppression of DLPFC neuronal activity, with disruption of trial rule selectivity at
higher doses. M1R blockade also suppressed DLPFC activity overall, albeit to a
lesser extent, and had no systematic effects on trial rule selectivity, but affected
the selectivity of postsaccadic activity.

3.4

Discussion
We found that local stimulation of M1Rs suppressed PFC neuronal activity

in macaques and overstimulation at higher doses was detrimental to trial rule
representation. Increasing doses of M1R stimulation progressively increased the
proportion of inhibited PFC neurons, while individual exemplars of increased
excitability proportionally decreased. M1R blockade also marginally suppressed
PFC activity, but the proportion of PFC neurons suppressed or excited by M1R
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antagonism did not show dose dependence. Moreover, M1R blockade spared
rule WM and stimulus direction representations in PFC, but disrupted selectivity
in neuronal postsaccadic activity for contralateral saccades. Since we have
previously shown that general muscarinic blockade diminishes all aspects of task
selectivity in PFC (Major et al., 2015), our results here showing only modest
effects of M1R blockade on task selectivity suggest that another muscarinic
receptor subtype, such as the M2R, may be responsible for disruptive effects of
general muscarinic blockade on WM activity. These findings proffer a cautionary
note to strategies for pharmacological treatment of cognitive dysfunction based
on M1R stimulation (Conn et al., 2009).

3.4.1 M1R Modulation of Neuronal Excitability in DLPFC
Several studies imputing an excitatory role for M1Rs in modulating cortical
activity informed our prior hypotheses that M1R stimulation would increase PFC
activity, and conversely, that M1R blockade would reduce PFC excitability, thus
resembling the effects of general muscarinic blockade in PFC (Major et al., 2015,
Zhou et al., 2011). Muscarinic stimulation of neurons in rodent cortical slices
induces transient inhibition followed by prolonged excitation of cortical neurons
(Gulledge et al., 2009, McCormick and Prince, 1985). Pirenzepine counteracts
the slow excitation, but not the inhibitory component (McCormick and Prince,
1985), and blocks ACh-induced excitation of rat parietal cortical neurons
(Bradshaw et al., 1987). Pirenzepine also blocks persistent discharges induced
by stimulation in the presence of cholinergic agonist carbachol in rodent
entorhinal cortical slices, indicating that M1R is the conduit of this effect (Egorov
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et al., 2002). Muscarinic stimulation induces a slow afterdepolarization in rodent
medial PFC that is mediated by nonselective cationic conductances (HajDahmane and Andrade, 1996, Haj-Dahmane and Andrade, 1998) and inhibits
KCNQ channels that carry the M-current (Brown and Adams, 1980). Moreover,
blockade of the M-current reduces spatial WM activity in macaque PFC (Wang
et al., 2011). Thus, there are many identified mechanisms by which muscarinic
stimulation would be expected to increase cortical excitability.
However, M1R mechanisms have also been implicated in the transient
inhibitory responses of cortical neurons to ACh application. Hyperpolarizing
responses to ACh application have been attributed to GABAergic mechanisms,
through direct excitation of inhibitory interneurons (McCormick and Prince, 1985,
McCormick and Prince, 1986). Other studies reveal that brief muscarinic
stimulation results in IP3 receptor-mediated Ca2+ release, which subsequently
activates SK potassium channels, resulting in neuronal inhibition (Gulledge and
Stuart, 2005). We found that, in awake, task-engaged monkeys, 81% of PFC
neurons at higher doses of M1R stimulation were inhibited (62% at all doses),
while the proportion of excited neurons dose-dependently reduced. This argues
that, in primates with engaged arousal systems and normal cholinergic tone, M1R
stimulation predominantly engages the inhibitory mechanisms summarized
above. We also found that M1R blockade suppressed overall PFC activity.
However, the proportions of pirenzepine-inhibited neurons remained
approximately half of the neurons tested regardless of the dose. Inhibition due to
both blockade and stimulation of M1R suggests that, in awake, behaving
primates, there are some M1R-mediated excitatory mechanisms, including
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activation of nonselective cation channels and inhibition of the M-current, that
may, however, be near-maximally engaged by endogenous tonic ACh levels. At
higher levels of cholinergic stimulation of M1Rs, as engendered by agonist
application, cortical excitability is reduced, either through mechanisms dependent
on GABAergic feedforward inhibition (McCormick and Prince, 1985), or by
activation of SK potassium channels through IP3/Ca2+.
Here, analysis of excitability of neurons classified by waveform shape
suggested that M1R stimulation did not lead to increased excitability of
parvalbumin-positive (PV+) interneurons, which typically possess NS waveform
properties (Kawaguchi and Kubota, 1993). On the contrary, our data suggest that
NS interneurons were more strongly inhibited by M1R stimulation than BS
neurons (88% inhibited versus 59% for BS neurons). Thus, feedforward inhibition
due to increased excitability of PV+ interneurons may not explain the inhibitory
effects of M1R stimulation here. However, we cannot rule out cholinergic
mechanisms involving other interneuron types possessing BS-like waveforms in
explaining our results (Kawaguchi and Kubota, 1993). Moreover, atypical
excitatory neurons, like the thin-spiking pyramidal tract neurons found in
macaque motor areas (Vigneswaran et al., 2011), may confound interpretation of
these results.
Yi et al. (2014) found that muscarinic agonist muscarine potentiated
current-induced activity in PV+ interneurons in both hippocampus and PFC slices
in mice. Knocking out M1Rs in PV+ interneurons eliminated this effect in
hippocampal interneurons. However, the authors did not investigate the
consequences of M1R genetic deletion on muscarinic activation of PV+
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interneurons in PFC, so it is unclear if M1Rs were also responsible for
muscarine’s actions on PFC PV+ interneurons.
We propose that our findings with M1R stimulation are instead explained
by Gq-transduced activation of the IP3 receptor pathway leading to an increase in
SK channel conductance as described above. Notably, Gq-coupled α1-adrenergic
receptor stimulation reduces the excitability of macaque DLPFC WM neurons
through actions on protein kinase C (Birnbaum et al., 2004), while focal activation
of Gq-coupled metabotropic glutamate receptor type I triggers dendrosomatic
Ca2+ waves in rat PFC neurons, which induce transient inhibition/prolonged
excitation similar to muscarinic activation (Hagenston et al., 2008). Consistently,
blockade of IP3 receptors or SK channel blockade in rat medial PFC improves
WM performance (Brennan et al., 2008).
One confound of this proposed mechanism is that inhibitory SK channel
inhibitory responses in rodent cortical slices decline over time, due to Ca2+
depletion after repeated cholinergic stimulation at resting membrane potentials.
However, this decline does not occur at membrane potentials closer to threshold,
when Ca2+ stores are rapidly replenished (Dasari et al., 2017). Since in awake,
behaving primates, the cortical neuronal membrane potential is close to the spike
threshold (Tan et al., 2014), SK channel responses may remain potent with
prolonged M1R stimulation, and continue unabated, unlike cortical slices.
Another confound of this mechanistic hypothesis is that M1R-mediated
inhibition in slices is transient and followed by prolonged increase in excitability.
Gulledge et al. (2009) found that both inhibitory and excitatory responses to
cholinergic stimulation with carbachol were diminished in PFC slices from M1R
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knockout mice. Our results suggest that tonic M1R stimulation with iontophoresis
or pulsed stimulation with pressure ejection results in inhibition of a majority of
PFC neurons in behaving monkeys. It is possible we did not observe the
excitatory phase of tonic M1R-dependent cholinergic stimulation in our
experiments because of species differences or differences between cholinergic
responses in cortical slices and intact cortical circuitry in awake, behaving
animals, where cholinergic stimulation may already be substantial due to
endogenous cholinergic tone. Alternatively, excitatory actions of M1R may
manifest only in some cortical layers and not others (Gulledge et al., 2009).
Nevertheless, the PFC neuronal inhibition by M1R agonist application we
observe with both methodologies (but not by saline) indicates that, in behaving
primates, overstimulation of M1Rs directly suppresses PFC neuronal activity
through proximal signal transduction mechanisms, and that normal cortical
cholinergic tone reflects an optimal balance between inhibitory and excitatory
muscarinic modulation of frontal cortex through M1Rs.

3.4.2 M1R Modulation of Behavioural Task Representation in PFC Activity
Trial activity of DLPFC neurons encodes selectivity for many task
attributes in the pro- and antisaccade task, including maintenance of the task set
in WM (rule representation), post-stimulus activity encoding stimulus location,
and perisaccadic representation of the saccade direction (Everling and DeSouza,
2005). Previously, we demonstrated that general muscarinic blockade with
scopolamine suppressed PFC neuronal rule, stimulus location, and saccade
direction selectivity (Major et al., 2015). Systemic scopolamine injections also
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reduce PFC WM activity during memory-guided saccades, and disrupt
behavioural performance (Zhou et al., 2011). We hypothesized that the disruptive
effects of muscarinic blockade on PFC task selectivity are mediated by M1Rs
because they are the most abundant muscarinic subtype in cortex (Flynn et al.,
1995) and they are localized at asymmetric synapses in spines and dendrites,
poised to regulate glutamatergic transmission (Mrzljak et al., 1993).
Here we found, using an identical experimental paradigm as Major et al.
(2015), that unlike general muscarinic blockade, M1R blockade had no consistent
effects on population rule selectivity, even though rule representation in WM in
individual PFC neurons was affected. Moreover, this was the case at both lower
and higher doses, notwithstanding suppression of memory period activity at
higher doses (Figure 3.3). Thus, our results suggest that the previously reported
strong suppression of rule selectivity in WM by scopolamine (Major et al., 2015)
is not mediated by M1Rs. Consistent with this, intraventricular injections of
pirenzepine in rats had subtler effects on delayed match to position performance
compared to scopolamine (Andrews et al., 1994). Intriguingly, mice lacking M1Rs
have selective deficits only in certain kinds of delayed-response performance,
which may need cortico-hippocampal connectivity (Anagnostaras et al., 2003).
We have recently reported that general cholinergic stimulation with iontophoresis
of carbachol excited a greater proportion of DLPFC neurons (49%) than our
results with M1R stimulation here, also reducing neuronal rule selectivity (Major
et al., 2018). Since ACh actions in cortex are thought to be primarily mediated by
muscarinic receptors (Cox et al., 1994), our previous results with carbachol
considered with our results with M1R here suggest that other muscarinic receptor
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subtypes may have a more defining role in activity for rules and task set. M2Rs
are also expressed in DLPFC and, in addition to presynaptic expression
suggesting a role in modulating neurotransmitter release, are expressed in
pyramidal neurons mostly in spines of apical dendrites apposed to glutamatergic
synapses (Mrzljak et al., 1993, Mrzljak et al., 1998). M2Rs are Gi/o-coupled
(Hulme et al., 1990) and their activation would be expected to decrease cAMP
signaling. ACh application in mouse visual cortical slices at low and high doses
enhanced and suppressed evoked neuronal responses, respectively, and the
excitatory effect is blocked in M2R/M4R knockout mice (Kuczewski et al., 2005).
Previous iontophoretic studies have shown that increased cAMP signaling
through dopamine D1 receptors (Gs-coupled) suppresses macaque PFC
neuronal activity (Vijayraghavan et al., 2007), while decrease in cAMP signaling,
e.g., through Gi/o-coupled α2A receptor stimulation, increases DLPFC spatial WM
activity (Wang et al., 2007). Thus, postsynaptic M2R activation in pyramidal
neurons would be expected to increase PFC persistent activity, and may be the
main effector of muscarinic modulation of rule representations in PFC. Future
experiments examining this hypothesis are of paramount interest.
M1R stimulation at lower doses also did not affect rule selectivity in WM,
but M1R overstimulation at higher doses disrupted trial rule selectivity. This
suggests that M1R may have an equivocal role in maintenance of rules in WM at
low (as mimicked by M1R blockade) to moderate levels of engagement, while
excessive M1R stimulation disrupts cognitive representations, due to substantial
general suppression of cortical activity. The reason for this discrepancy may be
the engagement of different downstream signaling mechanisms by these M1R
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agents. Future experiments manipulating the pharmacology of individual
signaling components downstream of M1R may shed light on this. This is
intriguing because systemic M1R stimulation can be beneficial in some cognitive
tasks in monkeys (Shirey et al., 2009, Uslaner et al., 2013). However, it is difficult
to compare systemic injections with the local PFC manipulations here. Our
finding that prolonged overstimulation of M1R degrades rule WM is interesting
given a recent study that found intermittent stimulation of the cholinergic nucleus
basalis was beneficial to WM performance, while continuous stimulation had
adverse effects (Liu et al., 2017).
We also found that M1R blockade, while sparing rule maintenance in WM,
attenuated saccade direction selectivity of PFC neurons in the postsaccadic
epoch, while M1R stimulation did not affect this activity. This may be another
indicator that different signaling mechanisms downstream of M1R differentially
modulate cognitive representations. Previously, dopamine D2 receptors were
shown to modulate perisaccadic activity during memory-guided saccades (Wang
et al., 2004) and in the antisaccade task (Vijayraghavan et al., 2016), but did not
have consistent effects on WM for spatial stimuli and rules, respectively. This
resembles our findings here with M1R blockade. Location-selective perisaccadic
activity in PFC has been hypothesized to carry feedback signals from the
superior colliculus updating the FEF about an executed eye movement (Sommer
and Wurtz, 2006). However, its role in periprincipal PFC is not entirely clear
(Vijayraghavan et al., 2017). Interestingly, most macaque nucleus basalis
cholinergic neurons are active during the response/reward epoch, and not the
delay epoch of a delayed response task, with most activity predicting rewarding
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or aversive stimuli (Richardson and DeLong, 1986). This suggests that phasic
ACh release coincident with the motor response may strengthen information
about rewarded actions after a trial. Our results suggest that endogenous M1R
engagement may have a role in modulating this function.
M1R stimulation has been viewed with promise in the development of new
cognitive enhancers (Melancon et al., 2013). Conventional cholinergic
enhancement using cholinesterase inhibitors has dubious efficacy in the
treatment of dementia in Alzheimer’s disease (Fisher, 2008). Since this disease is
characterized by degeneration of the cholinergic system, directly targeting
downstream receptors may be more effective. Indeed, M1R allosteric modulators
have shown some promise in enhancing cognitive performance in animal models
(Shirey et al., 2009, Uslaner et al., 2013), with fewer side effects than
cholinesterase inhibitors (Vardigan et al., 2015). However, our results with M1R
modulation of DLPFC cognitive physiology suggest that, in primates, M1R
overstimulation in the PFC may be detrimental to cognitive performance. These
results will inform treatment strategies based on M1Rs for use in neuropsychiatric
disorders. Our results also broach the hypothesis that excitatory mechanisms
modulating cognitive representations in PFC are mediated by other muscarinic
receptor subtypes that may be potential targets for the synthesis next-generation
cognitive enhancers for use in health and disease.
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Supplemental Results

Table 3.S1: Trial count statistics and individual statistics of neuronal
recovery from drug effects
(A) Table enumerates means, medians, and standard deviation of trial counts for
the control conditions, various drug conditions, and recovery conditions analyzed
in this study.
(B) Statistics for neurons tested with recovery from M1R agonist and antagonist
application are shown. Trial activity from each neuron was analyzed for
significant effects (rank sum test, p < 0.05).
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Figure 3.S1
Inhibition of PFC neurons by pneumatic pressure ejection of M1R agonist
VU0357017
(A) Sliding average activity (60 s window, running average) of a PFC neuron that
was tested with several pneumatic pressure pulse ejections of VU0357017 (10
mM in saline) and saline is shown. Blue shaded areas indicate time of pressure
ejections of the M1R agonist at 30 psi using a 75 ms ON/500 ms OFF cycle. Light
green shaded area indicates time of pressure ejection of saline at 30 psi (75 ms
ON/500 ms OFF). Dark green shaded area indicates time of saline ejection at
twice the time per cycle (30 psi; 150 ms ON/500 ms OFF). Red arrowheads point
to complete suppression of neuronal activity after VU0357017 application. The
first application of M1R agonist lasted only 15 s, and the suppression was
observed after some delay. The subsequent applications were longer (57 s, 60 s,
60 s, 60 s), and turned off soon after neuronal suppression was underway. Unlike
VU0357017 ejection, activity after saline ejection at a comparable rate and at
twice the rate did not result in any suppression of neuronal activity.
(B) Sliding average activity (60 s window, running average) of another PFC
neuron which was tested with a pneumatic pressure ejection of M1R agonist,
VU0357017 is shown (10 mM in saline; blue shaded rectangle indicates the onset
and duration of application). The M1R agonist ejected at 60 psi using a 125 ms
ON/500 ms OFF cycle. Agonist application lasted for 35 s and resulted in
immediate suppression of the neuron followed by a prolonged and gradual
recovery of neuronal activity
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Figure 3.S2
Effects of M1R-preferring agonist McN-A-343 on PFC neurons
(A) Shown in the left panel is the mean trial activity of 18 neurons during control
(black) and after M1R stimulation with McN-A-343 (grey). Drug application
significantly reduced the population activity of PFC neurons. Pie chart to the right
shows proportions of neurons that were significantly inhibited (blue; rank sum
test, p < 0.05), excited (pink), and not affected (yellow). Most neurons were
inhibited by the drug (11/18).
(B) Rasters and spike density functions aligned to stimulus onset (dashed line)
for a DLPFC neuron with selectivity for the antisaccade rule (red) compared with
the prosaccade rule (blue) are shown. McN-A-343 application at 50 nA
suppressed the activity of the neuron (Activitycontrol = 4.5 Hz;  Activitydrug = 1.35
Hz) and reduced rule selectivity (AUROCcontrol = 0.64; AUROCdrug = 0.61). Green
dots indicate rule cue onset.
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Figure 3.S3
Effects of M1R agonist VU0357017 and M1R antagonist pirenzepine application
over the course of the trial
(A) Effects of M1R agonist at all doses on average trial activity are shown for the
early rule epoch (left), late rule epoch (middle), and stimulus response epoch
(right) during control (black) and drug (grey) conditions. M1R agonist application
significantly suppressed population activity in all trial epochs. ANOVA with factors
drug and epoch show no significant effect of trial epoch or the interaction (drug X
epoch), showing that M1R agonist stimulation had uniform effects on behavioural
trial activity. Statistical testing with paired sign rank test with corrections for
multiple comparisons with the Holm-Bonferroni corrections.
(B) Effects of M1R antagonist at all doses on average trial activity are shown for
the early rule epoch (left), late rule epoch (middle), and stimulus response epoch
(right) during control (black) and drug (grey). After correction for multiple
comparisons, M1R antagonist application significantly reduced population activity
only in the post-stimulus epoch epoch (sign rank test with Holm-Bonferroni
correction for multiple comparisons). ANOVA with factors drug and epoch show
no significant effect of drug, epoch, or the interaction.
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Figure 3.S4
Examples of excitation of DLPFC rule selective neuron and enhancement of
DLPFC neuronal rule selectivity by iontophoretic M1R stimulation and reduction
in rule selectivity due to M1R agonist pressure ejection.
(A) Rasters and spike density functions aligned to stimulus onset (dashed line)
are shown for prosaccade trials (blue) and antisaccade trials (red) during control
(top panel) and during M1R stimulation (bottom panel). M1R stimulation
increased the activity of this neuron and enhanced rule selectivity. Green dots
indicate rule onset.
(B) Example of effects on activity and rule selectivity of PFC rule-selective neuron
by pressure ejection of M1R agonist. Rasters and spike density functions aligned
to stimulus onset (dashed line) are shown for prosaccade trials (blue) and
antisaccade trials (red) during control (top panel) and during M1R stimulation with
pressure ejection of VU0357017 (60 psi air pressure; 50 ms ON/ 500 ms OFF;
middle panel). M1R stimulation suppressed the neuron (Activitycontrol = 4.34
Hz;  Activitydrug = 3.12 Hz) and disrupted prosaccade rule selectivity (AUROCcontrol
= 0.64; AUROCdrug = 0.61). Subsequent recovery from drug application restored
trial activity (Activityrecovery = 5.08 Hz) and rule selectivity (AUROCrecovery = 0.68).
Green dots indicate rule onset.
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Figure 3.S5
M1R blockade disrupts population postsaccadic selectivity for the contralateral
saccade PFC saccade-selective neurons
(A) Rasters and spike density functions aligned on saccade onset are shown for
a PFC saccade-selective neuron during the control period (top) and after M1R
blockade (bottom). Purple raster lines: individual spikes on contralateral saccade
trials; green raster lines: individual spikes on ipsilateral saccade trials. Purple
spike density functions: contralateral saccades; green spike density functions:
ipsilateral saccades. Dashed vertical line: saccade onset. Black dots: peripheral
stimulus onset on each trial.
(B) Conventions and colours same as (A). Rasters and spike density functions for
another PFC neuron with perisaccadic selectivity are shown during control (top
panel) and for successive doses of M1R antagonist (low dose: 2nd panel; high
dose: 3rd panel).
(C) Saccade direction selectivity (quantified by AUROC) for each PFC
contralateral-saccade-selective neuron (purple dots) is shown during control
(abscissa) and drug application (ordinate).
(D) M1R blockade-induced reduction in normalized activity was significantly
greater for contralateral than ipsilateral saccades.
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CHAPTER 4 – CHOLINERGIC RECEPTORS IN MACAQUE PREFRONTAL
CORTEX INFLUENCE CORTICAL OSCILLATIONS IN A RULE-BASED
SACCADE TASK

4.1

Introduction
Executive functions such as working memory maintenance and the use of

rules are deficient in disorders of cognition and rely on intact prefrontal cortex
(PFC; Miller and Cohen, 2001; Perlstein et al., 2001; Bussiere et al., 2003;
Schroeter et al., 2012). Oscillations in the local field potential (LFP) are thought to
flexibly coordinate neuronal activity, allowing cortex to respond to a variety of
complex behaviours (Sejnowski and Paulsen, 2006; Womelsdorf et al., 2007;
Akam and Kullmann, 2010). Cognitive processing can be represented in the LFP
of nonhuman primate PFC, which can show tuning in a variety of cognitive tasks,
including memory-guided saccades (Pesaran et al., 2002; Womelsdorf et al.,
2007; Babapoor-Farrokhran et al., 2017) and pro- and antisaccades (Ma et al.,
2018). During macaque performance in visual working memory tasks, bursts of
gamma power are observed in PFC during cue and stimuli presentations and
increased beta power is found during delay periods that require working memory
maintenance (Wimmer et al., 2016; Lundqvist et al., 2018). LFPs can also
influence interregional communication, acting as a gating mechanism to enhance
or stifle incoming information (Busch et al., 2009; Babapoor-Farrokhran et al.,
2017; Fiebelkorn et al., 2018). For example, Liebe et al. (2012) reported theta
coupling between macaque V4 and PFC can predict performance in a mnemonic
task.
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Cholinergic innervation of the PFC is essential for optimal executive

behaviour. Disruption of the cholinergic system, via cholinergic-specific lesion
(Aigner et al., 1991; Croxson et al., 2011) or pharmacological blockade
(Klinkenberg and Blokland, 2010), can elicit strong deficits in cognitive tasks such
as working memory maintenance. In Alzheimer’s disease and schizophrenia, in
which the cholinergic system is perturbed (Whitehouse et al., 1982; Mesulam,
2013; Carruthers et al., 2015), both cognitive performance and cortical LFP
oscillations are abnormal (Jeong, 2004; Uhlhaas and Singer, 2010). Therefore,
investigating the impacts of cholinergic compounds on LFP may reveal important
insights into how altered cholinergic function may influence cognition in these
neuropsychiatric conditions.
Systemic blockade of muscarinic receptors in healthy human participants
generally results in increased theta LFP power, as recorded by EEG, and
decreased alpha power (Sloan et al., 1992; Sannita et al., 1993; Neufeld et al.,
1994; Kikuchi et al., 1999). Systemic stimulation of cholinergic receptors, albeit
less thoroughly explored, may induce opposing effects on LFP power (Saletu et
al., 1989; Knott et al., 1998). For example, Fisher et al. (2012) found nicotine gum
increased alpha power in the frontal cortex of nonsmokers.
Although studies involving systemic administration of drugs are useful,
resulting neurophysiological effects may be influenced by extraneous factors
other than local receptor perturbation, such as afferent influences from distant
connected regions. This is especially relevant in the case of studying LFP, as
frequency band synchrony is thought to affect communication between brain
regions (Fries, 2015). Further, cholinergic receptors have long been proposed to
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modulate incoming information (Gil et al., 1997; Medalla and Barbas, 2012).
Local ejection of cholinergic compounds may provide more accurate insights into
how cholinergic receptor stimulation or blockade affects LFP in the local area
surrounding drug ejection. Aptly, several investigators have explored the LFP
effects of local ejection of these compounds in rats (Rowntree and Bland, 1986;
Howe et al., 2017), cats (Biedenbach, 1966), and macaque inferior temporal
cortex (Kuravi and Vogels, 2018).
However, the effects of local ejection of cholinergic compounds on LFP in
nonhuman primate PFC remain poorly characterized. The study of nonhuman
primate neurophysiology is especially important for research related to
neuropsychiatric conditions because nonhuman primates have a granular PFC, a
cytoarchitectural feature shared with human PFC (Petrides and Pandya, 1999)
that is thought to be important for higher order cognitive functions.
In this study, the muscarinic antagonist scopolamine and cholinergic
agonist carbachol were iontophoretically ejected in rhesus dorsolateral PFC
during performance of a rule-based saccade task that required monkeys to
maintain the task rule in working memory. Changes in LFP power and rule tuning
of power were quantified. Based on previous reports involving human
electrophysiology and systemic injection of cholinergic compounds, scopolamine
was expected to increase theta power and decrease alpha power. Carbachol was
expected to increase alpha power. This investigation may provide insights into
the mechanisms behind altered LFP power spectra in conditions with disrupted
cholinergic systems, such as Alzheimer’s disease and schizophrenia (Jeong,
2004; Schnitzler and Gross, 2005; Uhlhaas and Singer, 2010).
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Materials and Methods

4.2.1 Animals
Experimental procedures were performed on two male rhesus macaques
(Macaca mulatta; age 8–11 years, weight 9–12 kg) in accordance with the
Canadian Council of Animal Care policy and a protocol approved by the Animal
Care Committee of the University of Western Ontario Council on Animal Care.
This paper analyzes the LFPs from previously published datasets (Major et al.,
2015). These monkeys were previously subjects in pharmacological studies using
iontophoretic drug ejection (Major et al., 2015; Vijayraghavan et al., 2016; Major
et al., 2018; Vijayraghavan et al., 2018) and a multielectrode array recording
during systemic administration of ketamine (Skoblenick and Everling, 2012,
Skoblenick and Everling, 2014; Ma et al., 2015; Skoblenick et al., 2016). Both
animals had a head restraint and plastic recording chambers implanted above
their right lateral PFC as described previously (Skoblenick and Everling, 2012).

4.2.2 Behavioural Task
Behavioural task was identical to those described in previous reports
(Major et al., 2015; Major et al., 2018). Briefly, animals performed a rule-based
working memory task known as the pro- and antisaccade task (Fig. 4.1A;
Everling and Fischer, 1998). After fixation on a central white dot (0.5°, 300 ms,
fixation window 4° x 4°), a central coloured cue was flashed (red or green, 100
ms), before reverting to white for another 800–1300 ms. Colours represented the
current trial, pro- or antisaccade, and were counterbalanced between monkeys.
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The fixation spot then disappeared during a brief gap period (150–300 ms). A
peripheral stimulus was pseudorandomly presented to the left or right (0.5°
dot,17° eccentricity). To receive liquid reward, subjects were required to make the
appropriate saccade towards (prosaccade) or away from (antisaccade) the
stimulus within 500 ms. Thus subjects had to maintain the task rule in working
memory. Trials were separated by a 1700–2200 ms intertrial interval. Horizontal
and vertical eye movements were recorded at 1 kHz with an EyeLink 1000
infrared eye tracker and software package (SR Research). Task and reward
delivery were controlled using CORTEX (National Institutes of Mental Health).
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A

Stimulus 500 ms
Gap 150–300 ms
Delay 800–1300 ms
Cue 100 ms
gaze

Fixation 300 ms

saccade

ITI 1700–2200 ms

Prosaccade

B

Antisaccade
Iontophoretic
current ejection
10–100 nA

AS

Record

PS

Figure 4.1
Experimental paradigm and recording with concurrent iontophoresis.
A, After central fixation (300 ms), a green or red cue was flashed (100 ms),
indicating a pro- or antisaccade trial. This task rule was maintained over an 800–
1300 ms delay and a short gap (150–300 ms). Subjects then performed a
saccade towards (prosaccade) or away from (antisaccade) the peripheral
stimulus to receive liquid reward. Dashed circles represent gaze of the animal
and white arrows represent saccade direction. ITI, intertrial interval. B,
Extracellular recordings were performed in the right dorsolateral prefrontal
cortices of two rhesus macaques. Custom-made glass iontophoretic electrodes
were used to eject general muscarinic antagonist scopolamine and general
cholinergic agonist carbachol onto neurons and the local extracellular space.
Beige area represents recording locus. AC, arcuate sulcus; PS, principal sulcus.
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4.2.3 Recording and drug administration
Electrophysiological recordings were performed using custom sevenbarreled glass iontophoretic electrodes as reported previously (Major et al., 2015;
modified from the design of Millar and Williams, 1989). Briefly, seven-barreled
glass pipettes (Friedrich and Dimmock) were pulled over 50 µm diameter
tungsten wire (Midwest Tungsten Service) using a PMP107L-e Multipipette Puller
(MicroData Instrument). Typical impedances of the tungsten recording electrode
ranged from 0.5 to 1 MΩ (measured at 1 kHz). General muscarinic antagonist
scopolamine (scopolamine hydrobromide; 100 mM) and general cholinergic
agonist carbachol (carbamoylcholine chloride; 100 mM) were dissolved in pH 3
deionized water and pushed to the tip of peripheral barrels in the glass electrode
(Tocris Bioscience). Drugs were ejected using a Neuro Phore BH-2 iontophoretic
ejection system (Harvard Apparatus; ejection currents of 5–100 nA with no
current balancing, -8 nA retention current). There is no effect of pH of drug
solution on neuronal discharge rate (Disney et al., 2007; Vijayraghavan et al.,
2007). The electrode was mounted on a hydraulic micromanipulator (MO-95,
Narishige Group) and lowered into dorsolateral PFC (Fig. 4.1B) through a 23gauge dura-penetrating stainless steel guide tube.

4.2.4 Data Analysis
At least one recorded neuron was present in all analyzed channels.
Neuronal signals were amplified, digitized, and filtered (0.5–200 Hz, four-pole
Bessel) with an OmniPlex Neural Data Acquisition System (Plexon). LFP data
was analyzed offline (MATLAB, MathWorks) using the FieldTrip toolbox (Donders
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Institute for Brain, Cognition and Behaviour; Oostenveld et al., 2011).
Artifacts in the continuously recorded LFP were removed using z-score
thresholding. Due to variability in noise levels across different recording sessions,
z-score threshold was set manually for each recording. All sessions were visually
inspected for artifacts based on variance, absolute values, and physiological
shape of power spectrum. Additionally, only channels with at least 10 prosaccade
trials and 10 antisaccade trials during both control and drug conditions were
included in the analysis.
Data was low-pass filtered at 150 Hz (six-pole Butterworth) and line noise
was removed at 60 and 120 Hz with discrete Fourier transform. To determine
time-frequency representations of trial-aligned LFP power, fast Fourier
transformation was performed using a Hanning window (7 cycles for each
frequency) every 50 ms across the entire frequency range (1–60 Hz).
Changes in LFP power were examined in two task trial periods: baseline
epoch (intertrial interval; last 600 ms before start of trial) and delay epoch
(prosaccade and antisaccade trials; 200 ms to 800 ms after rule cue, first 200 ms
of delay were omitted to avoid visual representation of cue and focus on
mnemonic period). In order to reliably compare power between different
recording sessions, different animals, and to avoid any possible noise related to
iontophoretic drug ejection, decibel normalization was used. To observe effects of
drugs on individual epochs, drug condition was normalized to control condition
(Fig. 4.2B and 4.2D):
Pnorm   =  10  x  log10 (Pdrug /Pcontrol )
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To observe delay-related effects in the delay epoch, delay epoch was

normalized to baseline epoch (Fig. 4.3):
Pnorm   =  10  x  log10 (Pdelay /Pbaseline )
To quantify rule preference of LFP power, d’ was calculated to contrast
power between pro- and antisaccade rules in the delay epoch:
d’  =  

x̄ anti   -‐  x̄ pro
! !
!(s!"#$

+

  

! )
s!"#

where x̄ is mean (of antisaccade and prosaccade trials) and s is standard
deviation of a channel’s trial-wise power. Preference for pro- and antisaccades
varied significantly depending on the recording (e.g., some recordings have
greater beta power during antisaccades, some have greater beta power during
prosaccades). Therefore, we analyzed power preference using absolute d’, to
show overall ability of frequency bands to represent power regardless of binary
trial preference.
To determine significant changes in normalized power and changes in d’,
we first performed Wilcoxon signed rank tests on the classically defined
frequency bands: theta (3–7 Hz), alpha (8–13 Hz), beta (14–35 Hz), and low
gamma (36–60 Hz). However, drug-induced effects don’t necessarily operate
within these precise predefined frequency bands. Therefore, we also used a
nonparametric cluster-based method to identify significantly changed frequency
bands without a priori band definitions (Maris and Oostenveld, 2007). Specifically,
Wilcoxon signed rank tests were performed on power data, resulting in z statistics
at each frequency. Frequencies with z statistic values within the 10th and 90th
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quantiles were removed, and the remaining values were sorted into clusters
based on frequency adjacency. Each cluster’s z statistics were summed.
Significance of clusters was determined by comparing cluster z statistic sums to a
distribution of maximum z statistic sums from 1000 iterations of randomly
permuted data. Clusters with z statistic sums greater than 99.5% of shuffled z
statistic maximum sums were considered significantly different between
conditions.

4.3

Results
Two rhesus macaques were trained on the “memory gap” variant of the

antisaccade task (Fig. 4.1A), which requires both rule association with a coloured
cue and maintenance of that cue in working memory. This type of task is known
to recruit dorsolateral PFC (Fig. 4.1B; Funahashi et al., 1993b) and likely recruits
cholinergic input due to its attentional requirement (Kozak et al., 2006). We
sought to characterize the local role of cholinergic receptors in macaque
dorsolateral PFC during performance of this rule-based working memory task.
Concurrent with extracellular recordings, general muscarinic antagonist
scopolamine and general cholinergic agonist carbachol were applied via
iontophoresis. These drugs’ effects on neuronal spiking activity in macaque PFC
have been previously characterized (Major et al., 2015, Major et al., 2018). This
report now explores the effect of local cholinergic receptor perturbation on LFP
power during working memory performance. A total of 30 recording sessions
were included in the analysis of scopolamine application (Monkey T: n = 13,
Monkey O: n =17) and 30 sessions in the analysis of carbachol application
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(Monkey T: n = 16, Monkey O: n = 14). Each trial’s delay period was analyzed
from 200 ms to 800 ms after cue onset, as the subjects fixated and maintained
rule information in working memory (Fig. 4.1A). The 600 ms intertrial interval
before fixation was used as baseline. Drug application was always preceded by a
control condition, each typically lasting a minimum of 10 min. Absence of drug
effects on behavioural metrics has been described previously (Major et al., 2015,
Major et al., 2018).

4.3.1 Effect of cholinergic receptor perturbation on LFP power
Mean LFP power during baseline and delay epochs, before and after drug
applications, are shown in Figure 4.2A. Figure 4.2B illustrates the change in
power after scopolamine on individual epochs as drug condition power decibel
normalized to control condition power for each frequency (±SEM). Using
classically defined frequency bands (theta: 3–7 Hz, alpha: 8–13 Hz, beta: 14–35
Hz, and low gamma: 36–60 Hz), no significant changes in power were observed
in the baseline or delay epochs (p > 0.05, Wilcoxon signed rank test of
normalized power vs. zero). However, drug-induced changes to cortical
oscillations would not necessarily follow these predetermined frequency ranges.
We therefore performed a nonparametric cluster-based method across all
frequencies from 1 to 60 Hz (Oostenveld et al., 2011; clustering of Wilcoxon
signed rank test z statistics, see Materials and Methods). During the baseline
epoch, the cluster-based method identified that low beta power (17–21 Hz) during
scopolamine condition was significantly decreased compared to the control
condition (p < 0.005, normalized power vs. zero; shown as a horizontal bar below
	
  

	
  

207

curve in Fig. 4.2B, left panel). During the delay epoch, alpha/low beta normalized
power was increased during prosaccades (12–14 Hz, p < 0.005; Fig. 4.2B, middle
panel), and high beta normalized power was increased during both prosaccades
(26–31 Hz; p < 0.005) and antisaccades (30–35 Hz; p < 0.005; Fig. 4.2B, right
panel). Overall, scopolamine decreased low beta power during the baseline
epoch and increased high beta power during the delay epoch.
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Figure 4.2
Effect of local muscarinic blockade and cholinergic stimulation on raw local field
potential (LFP) power.
A, Mean LFP power during the baseline (black) and delay (green) epochs during
control (solid line) and scopolamine (dashed lines) conditions are shown on a
logarithmic scale for 30 sessions. B, Mean normalized power (±SEM;
scopolamine condition power normalized to control condition power) is shown for
the baseline epoch (left panel), delay epoch during prosaccade trials (middle
panel), and delay epoch during antisaccade trials (right panel). These values
signify the change in power at different frequencies between control and
scopolamine conditions for each epoch. Thick solid lines denote frequencies that
were significantly different between control and drug conditions (see Results). C,
Mean LFP power before and after carbachol application for 30 sessions.
Conventions are the same as in A. D, Mean normalized power (±SEM; carbachol
condition power normalized to control condition power). These values signify the
change in power at different frequencies between control and carbachol
conditions for each epoch. Conventions are the same as in B.
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Mean LFP power before and after cholinergic agonist carbachol

application are shown in Figure 4.2C. Relative to scopolamine, carbachol
generally had a more enhancing effect on LFP power. Using a nonparametric
cluster-based method, change in normalized high beta power (26–31 Hz) was
significantly greater than zero in the baseline epoch. During the delay period of
both pro- and antisaccade trials, change in normalized theta power (3–6 Hz) was
significantly greater than zero. In contrast to scopolamine, which had effects
limited to the beta band, carbachol significantly increased both beta and theta
power in the baseline and delay epochs, respectively.

4.3.2 Cholinergics receptors modulate delay-related beta power
Next, we searched for delay-epoch-specific effects of cholinergic drug
ejection to gain further insights into working memory maintenance in this rulebased task. To reliably compare delay-related power between different recording
sessions, delay epoch power was decibel normalized to baseline epoch.
Normalized power data in the delay epoch before and after drug applications are
shown in Figures 4.3A and 4.3D. These figures illustrate that compared to the
baseline epoch, delay power was generally decreased at most frequency bands
(shown as blue in Fig. 4.3A and 4.3D) except in the alpha and beta frequency
bands, which were enhanced (shown as red).
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Figure 4.3
Delay-related effects of scopolamine and carbachol on delay period LFP power.
A, Delay period LFP power, decibel normalized to baseline epoch, during control
(left panels) and scopolamine conditions (right panels), split into prosaccade (top
panels) and antisaccade trials (bottom panels). Data are aligned to 200 ms after
cue onset at start of delay epoch. B, Mean change in normalized power (±SEM;
delay epoch normalized to baseline epoch; scopolamine condition normalized
power minus control condition normalized power) for prosaccade trials (top panel)
and antisaccade trials (bottom panel). Thick solid lines denote frequencies that
were significantly different between control and drug conditions (see Results). C,
Scopolamine-induced change in normalized power, split into separate subjects:
Monkey T (left panels) and Monkey O (right panels). D, Delay period normalized
LFP power before and after carbachol application. Conventions are the same as
in A. E, Mean change in normalized power between control and carbachol
conditions, for both prosaccade trials (top panel) and antisaccade trials (bottom
panel). Conventions are the same as in B. F, Carbachol-induced change in
normalized power, split by separate monkeys. G,
Difference between scopolamine-induced change and carbachol-induced
change. Change in normalized power due to carbachol is subtracted from change
in normalized power due to scopolamine (±SEM) for prosaccade trials (left panel)
and antisaccade trials (right panel). Positive values signify delay-related power at
that frequency was augmented more by scopolamine than by carbachol. For
example, during the delay epoch of prosaccade trials, normalized beta power
was increased more by scopolamine application (see B, top panel) than by
carbachol application (see E, top panel), resulting in negative t statistics and thus
denoted in blue in G (right panel). Thick solid lines denote frequencies that were
significantly different between control and drug conditions.
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Mean scopolamine-induced change in normalized power (±SEM) is shown

for each frequency in Figure 4.3B. To examine drug-induced changes in delayrelated LFP power, we first examined the classically defined frequency bands
using Wilcoxon signed rank test. In these bands, neither scopolamine nor
carbachol revealed any significant effects (p > 0.05, Wilcoxon signed rank test).
Nonparametric permutation test was performed to evaluate changes in delayrelated power during prosaccade and antisaccade trials of the delay epoch (e.g.,
top panel of Fig. 4.3B is the result of a direct comparison between the upper
panels in Fig. 4.3A). Permutation test revealed that scopolamine application
significantly increased delay-related power in a select frequency range of the high
beta band during both prosaccades (27–32 Hz; p < 0.005, normalized control
power vs. normalized drug power; Fig. 4.3B, top panel) and antisaccades (31–35
Hz; p < 0.005; Fig. 4.3B, bottom panel). It is important to note that this change in
delay-related power is the result of high beta power increasing more in the delay
epoch (Fig. 4.2B, middle and right panels) than in the baseline epoch (Fig. 4.2B,
left panel). Similar patterns were observed when data were separated by subject
(Fig. 4.3C), however we did not explore single subject significance due to low
number of individual monkey sessions (Monkey T, n = 13; Monkey O, n = 17).
Delay-related power before and after iontophoretic carbachol application
are shown in Figure 4.3D. In the delay epoch of prosaccades, normalized power
after carbachol application was significantly decreased in the low beta range (14–
17 Hz; p < 0.005; Fig. 4.3E, top panel; this is a direct comparison between the
upper panels in Fig. 4.3D). This change in 14–17 Hz low beta is due to low beta
increasing more in the baseline epoch (Fig. 4.2D, left panel) than in the delay
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epoch of prosaccade trials (Fig. 4.2D, middle panel). In contrast to the delayrelated effect of scopolamine, this carbachol-induced decrease in low beta may
not be specifically related to mnemonic processing. Individual subject change in
normalized power is shown in Figure 4.3F (Monkey T, n = 16; Monkey O, n = 14).
During antisaccade trials, no changes in delay-related power were observed.
Next, we directly compared the effects of scopolamine and carbachol on
the delay-related power in prosaccade trials (Fig. 4.3B, upper panel vs. Fig. 4.3E,
upper panel), which is visualized in Figure 4.3G (left panel). We also compared
the effects during antisaccade trials (Fig. 4.3B, lower panel vs. Fig. 4.3E, lower
panel), shown in Figure 4.3G (right panel). Using classical frequency bands, no
significant differences were observed between scopolamine-induced changes
and carbachol-induced changes in normalized power (p > 0.05, Wilcoxon rank
sum test). Next we performed cluster-based permutation test and found that
scopolamine enhanced high beta activity more than carbachol, during both
prosaccades (26–30 Hz; p < 0.005, clustering of Wilcoxon rank sum test z
statistics) and antisaccades (31–35 Hz; p < 0.005). These effects are likely driven
by the scopolamine-induced increase in high beta compared to the lack of effect
of carbachol on high beta (i.e., compare Fig. 4.3B and 4.3E).
In summary, scopolamine increased delay-related high beta power in the
delay period of both trial types, while carbachol decreased delay-related low beta
power during prosaccade trials only. When compared directly, scopolamine
increased high beta power more than carbachol.

4.3.3 Effect of cholinergic receptor perturbation on rule preference of LFP power
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Prosaccade or antisaccade preference of normalized LFP power was

determined using d’, an index accounting for both differences in mean and
variance in power within each rule (see Materials and Methods; e.g., greater d’
values signify greater normalized power differences between prosaccade and
antisaccade trials). We were interested in overall ability for LFP power to
represent rule preference, rather than prosaccade- or antisaccade-specific
preference (which varied between recording locations as one would expect from
a region that represents both rules). Therefore, to explore drug-induced
enhancement or suppression in rule preference of power, we compared absolute
d’ before and after drug application at all frequencies. Figure 4.4A (left panel)
displays mean absolute d’ rule preferences (±SEM) for each frequency during
control condition (blue) and scopolamine condition (red). Permutation test
revealed absolute d’ was significantly reduced in a narrow frequency range of
gamma (57–60 Hz). As an exploratory measure, we further investigated changes
in the binned classical frequency bands using Wilcoxon signed rank test.
Scopolamine decreased absolute rule d’ in beta (14–35 Hz, p = 0.0034; Fig. 4.4B,
top panel) and low gamma (36–60 Hz, p = 0.0023; Fig. 4.4B, bottom panel)
frequency bands. Rule preference was not significantly affected in the theta (3–7
Hz; p = 0.1779) or alpha frequency bands (8–13 Hz; p = 0.2802).
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Figure 4.4
Rule preference of normalized LFP power before and after drug application.
A, Mean rule preference, as measured by absolute d’, of control (blue) and
scopolamine (red) conditions for all frequencies. Shaded error bars denote SEM.
Thick solid lines denote frequency bands with significantly different absolute d’
between control and scopolamine conditions. B, Scatter plots are shown for beta
and low gamma frequency band as an exploratory analysis, with individual
sessions’ absolute d’ during control (abscissa) and scopolamine (ordinate)
conditions. For example, sessions with greater rule preference during the control
condition compared to the drug condition are shown below the equality line. p
value from Wilcoxon signed rank test is shown for each frequency band. C, Rule
preference before and after carbachol application. Conventions are the same as
in A.
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The effect of local carbachol application on rule preference of power was

not as strong as scopolamine. Permutation test only revealed a carbacholinduced decrease in a small frequency range of high beta power (27–29 Hz).
There were no significant effects in the binned frequency bands (theta: p =
0.1846, alpha: p = 0.9754, beta: p = 1779, low gamma: p = 0.2289; Fig. 4.4B,
right panels). Overall, muscarinic blockade attenuated rule preference in beta and
low gamma frequency bands, whereas cholinergic receptor stimulation by
carbachol only affected rule preference of LFP power in a narrow beta frequency
range.

4.4

Discussion
The cholinergic system innervates PFC and is crucial for effective

cognitive processing (Ballinger et al., 2016). LFPs show task-related tuning
during cognitive tasks and mediate communication between brain areas (Fries,
2015). Neuronal activity in a given region tends to oscillate, with excited phases
followed by suppressed phases. If two connected regions are coherent (i.e.,
excited phases occurring simultaneously or with minimal lag), action potentials
delivered from one area to the other are more likely to result in a post-synaptic
action potential, compared to an action potential arriving at a suppressed phase
(Fries, 2015). LFPs can be affected by cholinergic influence and the current study
aims to characterize the effect of cholinergic receptors on LFP during rule-based
working memory. Our findings show that local application of cholinergic
compounds affect PFC oscillations and alter delay-related mnemonic LFPs. The
muscarinic antagonist scopolamine primarily affected beta activity: it decreased
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low beta power during baseline and delay epochs in prosaccade trials; and
increased high beta power in the delay epoch under both rules. This heightened
high beta during the mnemonic period led to increased delay-related high beta
power for both rules. However, these effects were not beneficial to rule
preference of LFP power, which was decreased in both beta and low gamma
frequency bands. The cholinergic agonist carbachol enhanced beta power during
the baseline epoch and increased theta power in the delay epoch. Carbachol only
affected delay-related power in the low beta band, which was decreased during
prosaccade trials. Carbachol decreased rule preference of power in a small
frequency band of beta. Below, we will discuss the effects of the cholinergic
compounds on LFP power, on delay-related oscillations, and the effect of
scopolamine on LFP power rule preference.

4.4.1 Beta power was enhanced by both scopolamine and carbachol
Similar to theta, beta oscillations may couple information between distant
cortical regions (Kay and Beshel, 2010; Parnaudeau et al., 2013; BabapoorFarrokhran et al., 2017). Beta oscillations have been thoroughly explored in
motor networks, wherein rhythmicity increases after cue presentation that directs
a movement, and diminishes upon movement onset (Sanes and Donoghue,
1993; Baker et al., 1997). Beta activity may play a similar role during cognitive
tasks, to maintain a cognitive set over delay periods (Siegel et al., 2009; Engel
and Fries, 2010; Salazar et al., 2012) via top-down coordination from higherorder cortices such as lateral PFC (Buschman and Miller, 2007; Bastos et al.,
2015; Mejias et al., 2016). In the present study, we observed an enhancement of
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beta oscillations after cue presentation, during the mnemonic delay period, in
both control and drug conditions (Fig. 4.3A and 4.3D). This appears to be
consistent with reports that beta is involved in maintenance of cognitive set, or
“status quo”, prior to an informed response (Spitzer and Haegens, 2017).
After cholinergic drug application, we found beta oscillations were the most
frequently affected frequency band. However, the low and high beta frequency
ranges experienced different effects. Both scopolamine and carbachol could
enhance LFP power, especially in the higher beta frequency range (Fig. 4.2).
Muscarinic blockade suppressed low beta power in the baseline epoch and delay
epoch during prosaccades, yet increased high beta power during the delay period
of both rules (Fig. 4.2B and 4.3B). Previous reports suggest that cholinergic
stimulation can increase beta activity, while muscarinic blockade has been
speculated to decrease beta activity (Lee et al., 2013). Therefore, our
scopolamine-induced increase in beta power was unexpected. Yet increased
beta power may follow the antimuscarinic pattern of disrupting working memory
functions: beta oscillations are proposed to be inhibitory to feedforward working
memory signals in superficial layers of PFC (Miller et al., 2018). Thus, increasing
local beta activity could decrease working memory capacity of the local
microcircuit. Without further experiments, we can only speculate on potential
mechanisms of how scopolamine increased beta activity.
There are multiple proposed generators of beta rhythms, including either
local or distal pacemakers (Whittington et al., 2000). For example, loops between
basal ganglia and cortex have been shown to propagate beta, and are overactive
in Parkinson’s disease (Holgado et al., 2010; Leventhal et al., 2012). Medial
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dorsal nucleus of the thalamus (MD) has been proposed to drive cortical beta
activity (Ketz et al., 2015) and MD-PFC beta synchrony may correlate with spatial
working memory performance (Parnaudeau et al., 2013). The connection
between MD and PFC is well established in macaques (Giguere and GoldmanRakic, 1988). Our drug application may have influenced these thalamocortical
connections. Thalamocortical terminals express muscarinic and nicotinic
receptors in rodents (Gioanni et al., 1999; Lambe et al., 2003; Broicher et al.,
2008; Bista et al., 2012), but have not been established in primates.
Using Granger causality, Babapoor-Farrokhran et al. (2017) found beta
activity in ACC may drive frontal eye field beta activity. Muscarinic receptors have
been proposed to gate such corticocortical afferents (Gil et al., 1997).
Connections between frontal areas (ACC and area 46 to area 9) express
muscarinic M2 receptors (Medalla and Barbas, 2012), which are typically
considered inhibitory. Therefore, it’s possible scopolamine disinhibited incoming
corticocortical afferents via muscarinic M2 receptor blockade, enhancing
propagation of beta activity.
Alternatively, previous models and in vitro experiments have shown that
reciprocally connected pyramidal and inhibitory neuron networks can produce
beta rhythms locally, without input from distant regions. Of particular relevance,
this proposed intrinsic beta rhythm relies on the M current in pyramidal neurons,
the very current blocked by muscarinic receptor activation (Jensen et al., 2005;
Roopun et al., 2006; Kramer et al., 2008). Models have suggested it is cholinergic
stimulation, not muscarinic blockade, that would enhance beta activity (Sherman
et al., 2016). Cholinergic stimulation has indeed been shown to induce beta
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oscillations in both hippocampal and cortical slices (Arai and Natsume, 2006; van
Aerde et al., 2009; Lee et al., 2013; Hashimoto et al., 2017). Here, carbachol
increased beta oscillations in the baseline epoch (Fig. 4.2D, left panel). It is
curious that both muscarinic blockade with scopolamine and cholinergic
stimulation with carbachol elicited increased beta activity, and suggests these
effects occurred via different mechanisms. As previously mentioned, nicotinic
receptors have been proposed to presynaptically gate cortical afferents from
thalamus (Gil et al., 1997; Gioanni et al., 1999; Lambe et al., 2003), a potential
generator of beta rhythms (Ketz et al., 2015). Further experiments are required to
disambiguate the mechanisms by which these compounds enhanced high beta
activity.
In the low beta range, carbachol increased baseline power more than
prosaccade delay power, resulting in decreased delay-related low beta power
during prosaccades (Fig. 4.3E, top panel). Although this was a delay-related
change, this nonspecific increase is reminiscent to overstimulation of cholinergic
receptors (opposed to an effect on working-memory-related circuitry), as seen
during spiking activity (Sato et al., 1987; Zinke et al., 2006; Herrero et al., 2008;
Major et al., 2018).

4.4.2 Cholinergic stimulation enhanced theta power
Theta activity is associated with entrainment of distant cortical areas, such
as during mnemonic processing (Fell and Axmacher, 2011; Colgin, 2013). Theta
phase can predict attentional performance in both macaques (Fiebelkorn et al.,
2018) and humans (Fiebelkorn et al., 2013) and is enhanced during increased
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task difficulty or working memory load (Sauseng et al., 2005; Payne and Kounios,
2009).
Acetylcholine release is coincident with visual cue presentations
(Richardson and DeLong, 1986; Parikh et al., 2007) and elicits cortical
desynchronization (Metherate et al., 1992; Harris and Thiele, 2011), which is
thought to enhance processing of sensory information (Goard and Dan, 2009).
Cholinergic drive may influence theta propagation. Cape and Jones (2000) found
NMDA microinjection to rat basal forebrain (a source of cortical acetylcholine)
increased neocortical theta activity. Some neurons of the nucleus basalis may
discharge rhythmically in the theta range (Buzsaki et al., 1988; Khateb et al.,
1992; Lee et al., 2005), but cholinergic neurons of medial septum, another
possible source of theta oscillations (Vertes and Kocsis, 1997; Colgin, 2013), do
not fire rhythmically with theta (Simon et al., 2006).
Here, cholinergic stimulation enhanced theta power in the delay epoch
(Fig. 4.2D, middle and right panels). Although we may have expected carbachol
application to mimic the aforementioned endogenous cholinergic
desynchronization (i.e., a decrease in low frequency power), previous in vitro
research has reported carbachol can induce theta oscillations in hippocampal
slices (Bland and Colom, 1993; Levesque and Avoli, 2018), anesthetized rats
(Rowntree and Bland, 1986), and human temporal cortex slices (Florez et al.,
2015). Notably, Yener et al. (2007) found untreated Alzheimer’s disease patients
(with a deficient cholinergic system) had disrupted frontal theta oscillations, but
theta activity of healthy participants and acetylcholinesterase-treated patients
was normal.
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In contrast to our predictions, our findings were not consistent with some

reports of systemic drug administration to humans and concurrent EEG
recordings. For example, cholinergic receptor stimulation was expected to
increase alpha power (Saletu et al., 1989; Knott et al., 1998; Fisher et al., 2012),
but we found alpha oscillations were not affected in any metric and may be more
resilient to local drug ejection. This discrepancy may be related to differences
between systemic and local drug application, or state differences between EEG
recordings during rest and LFP recordings during task performance. Local drug
ejection is an important tool to examine how different neurotransmitters influence
LFP, and may bridge our knowledge between systemic injections and slice
physiology.
Curiously, our findings appear more consistent with in vitro results, which
have shown carbachol can induce theta, beta, and low gamma oscillations in rat
hippocampal and medial PFC slices (Fellous and Sejnowski, 2000; Arai and
Natsume, 2006; van Aerde et al., 2009; Hashimoto et al., 2017). Florez et al.
(2015) investigated LFP activity in human temporal neocortical slices from
epileptics. They found these slices were able to produce theta and gamma
oscillatory activity when both glutamatergic and cholinergic receptors were
stimulated (via kainate and carbachol). Further, they found it was specifically the
muscarinic variety of cholinergic receptors that were required for this activity.
Florez et al. (2015) also reported phase coherence between IPSCs in pyramidal
cells and theta oscillations, suggesting this neocortical theta likely requires both
pyramidal and inhibitory neurons. In opposition of the view that cortical theta
rhythms originate from distant generators such as hippocampus (Buzsaki, 2002),
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Florez et al (2015) and others (Raghavachari et al., 2006) have shown that with
the help of glutamatergic and muscarinic receptors, theta rhythms can be
generated locally in small volumes of neocortex. It is possible that the carbacholinduced enhancement of theta power observed here (Fig. 4.2D), similar to
proposed intrinsic mechanisms of beta generation (Roopun et al., 2006), was
triggered by local muscarinic-receptor-mediated mechanisms.
Certain cell types differentially influence generation of cortical LFP
oscillations (Takada et al., 2014; Voloh and Womelsdorf, 2018). Our observed
effects may be mediated by cholinergic receptors expressed on GABAergic
interneurons (Mrzljak et al., 1993; Kawaguchi, 1997; Mrzljak et al., 1998; Porter
et al., 1999; Disney et al., 2007; Gulledge et al., 2007; Disney and Aoki, 2008;
Medalla and Barbas, 2012). Future work is required to explore the effects of
different cholinergic receptor subtypes on different interneuron populations.
Cholinergic receptors are well positioned to influence communication between
brain regions and have been shown experimentally to modulate LFP oscillations.

4.4.3 Muscarinic antagonism disrupted task rule preference of cortical
oscillations
Several investigators have shown that prefrontal field oscillations can be
tuned to represent different task aspects, such as cue location during memoryguided saccades (Pesaran et al., 2002; Womelsdorf et al., 2007; BabapoorFarrokhran et al., 2017) and pro- vs. antisaccades (Ma et al., 2018). Using multielectrode recording, Buschman and Miller (2007) found that task rules during a
saccadic task were represented in the LFP of macaque dorsolateral PFC in the
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alpha and beta frequencies. From this, we expected disruption of normal
cholinergic signaling to disturb attention-related beta signaling.
We used absolute d’ to measure magnitude of rule representation in delayrelated LFP power. Scopolamine attenuated rule preference in beta and low
gamma frequency bands, but not rule preference in theta or alpha bands (Fig.
4.4A). These effects of scopolamine are reminiscent of previous spiking data,
which showed strong attenuation of task selectivity for several task aspects
(Major et al., 2015).
The effects of carbachol on LFP rule preference were not as strong as
scopolamine. The relatively weak effect of carbachol on power rule preference is
surprising considering it disrupted selectivity of neuronal spiking (Major et al.,
2018) and suggests that LFP representation of task-relevant information may be
more resilient to change than single unit activity.
The present results illuminate potential mechanisms by which endogenous
acetylcholine affects cortical oscillations. Acetylcholine is released during
heightened attention, and influences cortical oscillations through muscarinic and
nicotinic receptors. We observed the most robust effects in the beta frequency
band, which is associated with motor preparation and maintenance of task set.
As investigators unravel laminar differences in cortical oscillations (Bastos et al.,
2018, Johnston et al., 2019), future work should examine differential cholinergic
influence on these layers. The use of receptor-subtype-selective compounds will
yield important implications for disorders of cognition, as cholinergic receptor
expression is affected in both Alzheimer’s disease (Flynn et al., 1995; RodriguezPuertas et al., 1997) and schizophrenia (Dean et al., 2002; Leonard et al., 2002).
	
  

	
  
4.5

225
References	
  

Aigner TG, Mitchell SJ, Aggleton JP, DeLong MR, Struble RG, Price DL, Wenk
GL, Pettigrew KD, Mishkin M (1991) Transient impairment of recognition
memory following ibotenic-acid lesions of the basal forebrain in macaques.
Experimental brain research 86:18-26.
Akam T, Kullmann DM (2010) Oscillations and filtering networks support flexible
routing of information. Neuron 67:308-320.
Arai J, Natsume K (2006) The properties of carbachol-induced beta oscillation in
rat hippocampal slices. Neuroscience research 54:95-103.
Babapoor-Farrokhran S, Vinck M, Womelsdorf T, Everling S (2017) Theta and
beta synchrony coordinate frontal eye fields and anterior cingulate cortex
during sensorimotor mapping. Nature communications 8:13967.
Baker SN, Olivier E, Lemon RN (1997) Coherent oscillations in monkey motor
cortex and hand muscle EMG show task-dependent modulation. The
Journal of physiology 501 ( Pt 1):225-241.
Ballinger EC, Ananth M, Talmage DA, Role LW (2016) Basal Forebrain
Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.
Neuron 91:1199-1218.
Bastos AM, Loonis R, Kornblith S, Lundqvist M, Miller EK (2018) Laminar
recordings in frontal cortex suggest distinct layers for maintenance and
control of working memory. Proceedings of the National Academy of
Sciences of the United States of America 115:1117-1122.
Bastos AM, Vezoli J, Bosman CA, Schoffelen JM, Oostenveld R, Dowdall JR, De
Weerd P, Kennedy H, Fries P (2015) Visual areas exert feedforward and
feedback influences through distinct frequency channels. Neuron 85:390401.
Biedenbach MA (1966) Effects of anesthetics and cholinergic drugs on
prepyriform electrical activity in cats. Experimental neurology 16:464-479.
Bista P, Meuth SG, Kanyshkova T, Cerina M, Pawlowski M, Ehling P, Landgraf P,
Borsotto M, Heurteaux C, Pape HC, Baukrowitz T, Budde T (2012)
Identification of the muscarinic pathway underlying cessation of sleeprelated burst activity in rat thalamocortical relay neurons. Pflugers Archiv :
European journal of physiology 463:89-102.
Bland BH, Colom LV (1993) Extrinsic and intrinsic properties underlying
oscillation and synchrony in limbic cortex. Progress in neurobiology
41:157-208.
Broicher T, Wettschureck N, Munsch T, Coulon P, Meuth SG, Kanyshkova T,
Seidenbecher T, Offermanns S, Pape HC, Budde T (2008) Muscarinic
ACh receptor-mediated control of thalamic activity via G(q)/G (11)-family
G-proteins. Pflugers Archiv : European journal of physiology 456:10491060.
Busch NA, Dubois J, VanRullen R (2009) The phase of ongoing EEG oscillations
predicts visual perception. The Journal of neuroscience : the official journal
of the Society for Neuroscience 29:7869-7876.
Buschman TJ, Miller EK (2007) Top-down versus bottom-up control of attention
in the prefrontal and posterior parietal cortices. Science 315:1860-1862.
	
  

	
  

226

Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH, Hof PR (2003)
Progressive degeneration of nonphosphorylated neurofilament proteinenriched pyramidal neurons predicts cognitive impairment in Alzheimer's
disease: stereologic analysis of prefrontal cortex area 9. The Journal of
comparative neurology 463:281-302.
Buzsaki G (2002) Theta oscillations in the hippocampus. Neuron 33:325-340.
Buzsaki G, Bickford RG, Ponomareff G, Thal LJ, Mandel R, Gage FH (1988)
Nucleus basalis and thalamic control of neocortical activity in the freely
moving rat. The Journal of neuroscience : the official journal of the Society
for Neuroscience 8:4007-4026.
Cape EG, Jones BE (2000) Effects of glutamate agonist versus procaine
microinjections into the basal forebrain cholinergic cell area upon gamma
and theta EEG activity and sleep-wake state. The European journal of
neuroscience 12:2166-2184.
Carruthers SP, Gurvich CT, Rossell SL (2015) The muscarinic system, cognition
and schizophrenia. Neuroscience and biobehavioral reviews 55:393-402.
Colgin LL (2013) Mechanisms and functions of theta rhythms. Annual review of
neuroscience 36:295-312.
Croxson PL, Kyriazis DA, Baxter MG (2011) Cholinergic modulation of a specific
memory function of prefrontal cortex. Nature neuroscience 14:1510-1512.
Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased
muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with
schizophrenia. Molecular psychiatry 7:1083-1091.
Disney AA, Aoki C (2008) Muscarinic acetylcholine receptors in macaque V1 are
most frequently expressed by parvalbumin-immunoreactive neurons. The
Journal of comparative neurology 507:1748-1762.
Disney AA, Aoki C, Hawken MJ (2007) Gain modulation by nicotine in macaque
v1. Neuron 56:701-713.
Engel AK, Fries P (2010) Beta-band oscillations--signalling the status quo?
Current opinion in neurobiology 20:156-165.
Everling S, Fischer B (1998) The antisaccade: a review of basic research and
clinical studies. Neuropsychologia 36:885-899.
Fell J, Axmacher N (2011) The role of phase synchronization in memory
processes. Nature reviews Neuroscience 12:105-118.
Fellous JM, Sejnowski TJ (2000) Cholinergic induction of oscillations in the
hippocampal slice in the slow (0.5-2 Hz), theta (5-12 Hz), and gamma (3570 Hz) bands. Hippocampus 10:187-197.
Fiebelkorn IC, Pinsk MA, Kastner S (2018) A Dynamic Interplay within the
Frontoparietal Network Underlies Rhythmic Spatial Attention. Neuron
99:842-853 e848.
Fiebelkorn IC, Saalmann YB, Kastner S (2013) Rhythmic sampling within and
between objects despite sustained attention at a cued location. Current
biology : CB 23:2553-2558.
Fisher DJ, Daniels R, Jaworska N, Knobelsdorf A, Knott VJ (2012) Effects of
acute nicotine administration on resting EEG in nonsmokers. Experimental
and clinical psychopharmacology 20:71-75.

	
  

	
  

227

Florez CM, McGinn RJ, Lukankin V, Marwa I, Sugumar S, Dian J, Hazrati LN,
Carlen PL, Zhang L, Valiante TA (2015) In vitro recordings of human
neocortical oscillations. Cerebral cortex 25:578-597.
Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI (1995) Differential regulation of
molecular subtypes of muscarinic receptors in Alzheimer's disease.
Journal of neurochemistry 64:1888-1891.
Fries P (2015) Rhythms for Cognition: Communication through Coherence.
Neuron 88:220-235.
Funahashi S, Chafee MV, Goldman-Rakic PS (1993) Prefrontal neuronal activity
in rhesus monkeys performing a delayed anti-saccade task. Nature
365:753-756.
Giguere M, Goldman-Rakic PS (1988) Mediodorsal nucleus: areal, laminar, and
tangential distribution of afferents and efferents in the frontal lobe of
rhesus monkeys. The Journal of comparative neurology 277:195-213.
Gil Z, Connors BW, Amitai Y (1997) Differential regulation of neocortical
synapses by neuromodulators and activity. Neuron 19:679-686.
Gioanni Y, Rougeot C, Clarke PB, Lepouse C, Thierry AM, Vidal C (1999)
Nicotinic receptors in the rat prefrontal cortex: increase in glutamate
release and facilitation of mediodorsal thalamo-cortical transmission. The
European journal of neuroscience 11:18-30.
Goard M, Dan Y (2009) Basal forebrain activation enhances cortical coding of
natural scenes. Nature neuroscience 12:1444-1449.
Gulledge AT, Park SB, Kawaguchi Y, Stuart GJ (2007) Heterogeneity of phasic
cholinergic signaling in neocortical neurons. Journal of neurophysiology
97:2215-2229.
Harris KD, Thiele A (2011) Cortical state and attention. Nature reviews
Neuroscience 12:509-523.
Hashimoto A, Sawada T, Natsume K (2017) The change of picrotoxin-induced
epileptiform discharges to the beta oscillation by carbachol in rat
hippocampal slices. Biophysics and physicobiology 14:137-146.
Herrero JL, Roberts MJ, Delicato LS, Gieselmann MA, Dayan P, Thiele A (2008)
Acetylcholine contributes through muscarinic receptors to attentional
modulation in V1. Nature 454:1110-1114.
Holgado AJ, Terry JR, Bogacz R (2010) Conditions for the generation of beta
oscillations in the subthalamic nucleus-globus pallidus network. The
Journal of neuroscience : the official journal of the Society for
Neuroscience 30:12340-12352.
Howe WM, Gritton HJ, Lusk NA, Roberts EA, Hetrick VL, Berke JD, Sarter M
(2017) Acetylcholine Release in Prefrontal Cortex Promotes Gamma
Oscillations and Theta-Gamma Coupling during Cue Detection. The
Journal of neuroscience : the official journal of the Society for
Neuroscience 37:3215-3230.
Jensen O, Goel P, Kopell N, Pohja M, Hari R, Ermentrout B (2005) On the human
sensorimotor-cortex beta rhythm: sources and modeling. NeuroImage
26:347-355.

	
  

	
  

228

Jeong J (2004) EEG dynamics in patients with Alzheimer's disease. Clinical
neurophysiology : official journal of the International Federation of Clinical
Neurophysiology 115:1490-1505.
Johnston K, Ma L, Schaeffer L, Everling S (2019) Alpha Oscillations Modulate
Preparatory Activity in Marmoset Area 8Ad. The Journal of neuroscience :
the official journal of the Society for Neuroscience 39:1855-1866.
Kawaguchi Y (1997) Selective cholinergic modulation of cortical GABAergic cell
subtypes. Journal of neurophysiology 78:1743-1747.
Kay LM, Beshel J (2010) A beta oscillation network in the rat olfactory system
during a 2-alternative choice odor discrimination task. Journal of
neurophysiology 104:829-839.
Ketz NA, Jensen O, O'Reilly RC (2015) Thalamic pathways underlying prefrontal
cortex-medial temporal lobe oscillatory interactions. Trends in
neurosciences 38:3-12.
Khateb A, Muhlethaler M, Alonso A, Serafin M, Mainville L, Jones BE (1992)
Cholinergic nucleus basalis neurons display the capacity for rhythmic
bursting activity mediated by low-threshold calcium spikes. Neuroscience
51:489-494.
Kikuchi M, Wada Y, Nanbu Y, Nakajima A, Tachibana H, Takeda T, Hashimoto T
(1999) EEG changes following scopolamine administration in healthy
subjects. Quantitative analysis during rest and photic stimulation.
Neuropsychobiology 39:219-226.
Klinkenberg I, Blokland A (2010) The validity of scopolamine as a
pharmacological model for cognitive impairment: a review of animal
behavioral studies. Neuroscience and biobehavioral reviews 34:13071350.
Knott VJ, Harr A, Ilivitsky V, Mahoney C (1998) The cholinergic basis of the
smoking-induced EEG activation profile. Neuropsychobiology 38:97-107.
Kozak R, Bruno JP, Sarter M (2006) Augmented prefrontal acetylcholine release
during challenged attentional performance. Cerebral cortex 16:9-17.
Kramer MA, Roopun AK, Carracedo LM, Traub RD, Whittington MA, Kopell NJ
(2008) Rhythm generation through period concatenation in rat
somatosensory cortex. PLoS computational biology 4:e1000169.
Kuravi P, Vogels R (2018) GABAergic and cholinergic modulation of repetition
suppression in inferior temporal cortex. Scientific reports 8:13160.
Lambe EK, Picciotto MR, Aghajanian GK (2003) Nicotine induces glutamate
release from thalamocortical terminals in prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology 28:216-225.
Lee JH, Whittington MA, Kopell NJ (2013) Top-down beta rhythms support
selective attention via interlaminar interaction: a model. PLoS
computational biology 9:e1003164.
Lee MG, Hassani OK, Alonso A, Jones BE (2005) Cholinergic basal forebrain
neurons burst with theta during waking and paradoxical sleep. The Journal
of neuroscience : the official journal of the Society for Neuroscience
25:4365-4369.

	
  

	
  

229

Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger
R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R
(2002) Association of promoter variants in the alpha7 nicotinic
acetylcholine receptor subunit gene with an inhibitory deficit found in
schizophrenia. Archives of general psychiatry 59:1085-1096.
Leventhal DK, Gage GJ, Schmidt R, Pettibone JR, Case AC, Berke JD (2012)
Basal ganglia beta oscillations accompany cue utilization. Neuron 73:523536.
Levesque M, Avoli M (2018) Carbachol-Induced theta-like oscillations in the
rodent brain limbic system: Underlying mechanisms and significance.
Neuroscience and biobehavioral reviews 95:406-420.
Liebe S, Hoerzer GM, Logothetis NK, Rainer G (2012) Theta coupling between
V4 and prefrontal cortex predicts visual short-term memory performance.
Nature neuroscience 15:456-462, S451-452.
Lundqvist M, Herman P, Warden MR, Brincat SL, Miller EK (2018) Gamma and
beta bursts during working memory readout suggest roles in its volitional
control. Nature communications 9:394.
Ma L, Skoblenick K, Johnston K, Everling S (2018) Ketamine alters lateral
prefrontal oscillations in a rule-based working memory task. The Journal of
neuroscience : the official journal of the Society for Neuroscience.
Ma L, Skoblenick K, Seamans JK, Everling S (2015) Ketamine-Induced Changes
in the Signal and Noise of Rule Representation in Working Memory by
Lateral Prefrontal Neurons. The Journal of neuroscience : the official
journal of the Society for Neuroscience 35:11612-11622.
Major AJ, Vijayraghavan S, Everling S (2015) Muscarinic Attenuation of
Mnemonic Rule Representation in Macaque Dorsolateral Prefrontal Cortex
during a Pro- and Anti-Saccade Task. The Journal of neuroscience : the
official journal of the Society for Neuroscience 35:16064-16076.
Major AJ, Vijayraghavan S, Everling S (2018) Cholinergic Overstimulation
Attenuates Rule Selectivity in Macaque Prefrontal Cortex. The Journal of
neuroscience : the official journal of the Society for Neuroscience 38:11371150.
Maris E, Oostenveld R (2007) Nonparametric statistical testing of EEG- and
MEG-data. Journal of neuroscience methods 164:177-190.
Medalla M, Barbas H (2012) The anterior cingulate cortex may enhance inhibition
of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic
sites. The Journal of neuroscience : the official journal of the Society for
Neuroscience 32:15611-15625.
Mejias JF, Murray JD, Kennedy H, Wang XJ (2016) Feedforward and feedback
frequency-dependent interactions in a large-scale laminar network of the
primate cortex. Science advances 2:e1601335.
Mesulam MM (2013) Cholinergic circuitry of the human nucleus basalis and its
fate in Alzheimer's disease. The Journal of comparative neurology
521:4124-4144.
Metherate R, Cox CL, Ashe JH (1992) Cellular bases of neocortical activation:
modulation of neural oscillations by the nucleus basalis and endogenous

	
  

	
  

230

acetylcholine. The Journal of neuroscience : the official journal of the
Society for Neuroscience 12:4701-4711.
Millar J, Williams GV (1989) Effects of iontophoresis of noradrenaline and
stimulation of the periaqueductal gray on single-unit activity in the rat
superficial dorsal horn. The Journal of comparative neurology 287:119133.
Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function.
Annual review of neuroscience 24:167-202.
Miller EK, Lundqvist M, Bastos AM (2018) Working Memory 2.0. Neuron 100:463475.
Mrzljak L, Levey AI, Belcher S, Goldman-Rakic PS (1998) Localization of the m2
muscarinic acetylcholine receptor protein and mRNA in cortical neurons of
the normal and cholinergically deafferented rhesus monkey. The Journal
of comparative neurology 390:112-132.
Mrzljak L, Levey AI, Goldman-Rakic PS (1993) Association of m1 and m2
muscarinic receptor proteins with asymmetric synapses in the primate
cerebral cortex: morphological evidence for cholinergic modulation of
excitatory neurotransmission. Proceedings of the National Academy of
Sciences of the United States of America 90:5194-5198.
Neufeld MY, Rabey MJ, Parmet Y, Sifris P, Treves TA, Korczyn AD (1994)
Effects of a single intravenous dose of scopolamine on the quantitative
EEG in Alzheimer's disease patients and age-matched controls.
Electroencephalography and clinical neurophysiology 91:407-412.
Oostenveld R, Fries P, Maris E, Schoffelen JM (2011) FieldTrip: Open source
software for advanced analysis of MEG, EEG, and invasive
electrophysiological data. Computational intelligence and neuroscience
2011:156869.
Parikh V, Kozak R, Martinez V, Sarter M (2007) Prefrontal acetylcholine release
controls cue detection on multiple timescales. Neuron 56:141-154.
Parnaudeau S, O'Neill PK, Bolkan SS, Ward RD, Abbas AI, Roth BL, Balsam PD,
Gordon JA, Kellendonk C (2013) Inhibition of mediodorsal thalamus
disrupts thalamofrontal connectivity and cognition. Neuron 77:1151-1162.
Payne L, Kounios J (2009) Coherent oscillatory networks supporting short-term
memory retention. Brain research 1247:126-132.
Perlstein WM, Carter CS, Noll DC, Cohen JD (2001) Relation of prefrontal cortex
dysfunction to working memory and symptoms in schizophrenia. The
American journal of psychiatry 158:1105-1113.
Pesaran B, Pezaris JS, Sahani M, Mitra PP, Andersen RA (2002) Temporal
structure in neuronal activity during working memory in macaque parietal
cortex. Nature neuroscience 5:805-811.
Petrides M, Pandya DN (1999) Dorsolateral prefrontal cortex: comparative
cytoarchitectonic analysis in the human and the macaque brain and
corticocortical connection patterns. The European journal of neuroscience
11:1011-1036.
Porter JT, Cauli B, Tsuzuki K, Lambolez B, Rossier J, Audinat E (1999) Selective
excitation of subtypes of neocortical interneurons by nicotinic receptors.

	
  

	
  

231

The Journal of neuroscience : the official journal of the Society for
Neuroscience 19:5228-5235.
Raghavachari S, Lisman JE, Tully M, Madsen JR, Bromfield EB, Kahana MJ
(2006) Theta oscillations in human cortex during a working-memory task:
evidence for local generators. Journal of neurophysiology 95:1630-1638.
Richardson RT, DeLong MR (1986) Nucleus basalis of Meynert neuronal activity
during a delayed response task in monkey. Brain research 399:364-368.
Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A (1997) Autoradiographic
distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in
Alzheimer's disease. Synapse 26:341-350.
Roopun AK, Middleton SJ, Cunningham MO, LeBeau FE, Bibbig A, Whittington
MA, Traub RD (2006) A beta2-frequency (20-30 Hz) oscillation in
nonsynaptic networks of somatosensory cortex. Proceedings of the
National Academy of Sciences of the United States of America 103:1564615650.
Rowntree CI, Bland BH (1986) An analysis of cholinoceptive neurons in the
hippocampal formation by direct microinfusion. Brain research 362:98-113.
Salazar RF, Dotson NM, Bressler SL, Gray CM (2012) Content-specific frontoparietal synchronization during visual working memory. Science 338:10971100.
Saletu B, Darragh A, Salmon P, Coen R (1989) EEG brain mapping in evaluating
the time-course of the central action of DUP 996--a new acetylcholine
releasing drug. British journal of clinical pharmacology 28:1-16.
Sanes JN, Donoghue JP (1993) Oscillations in local field potentials of the primate
motor cortex during voluntary movement. Proceedings of the National
Academy of Sciences of the United States of America 90:4470-4474.
Sannita WG, Balestra V, DiBon G, Marotta V, Rosadini G (1993) Human flashVEP and quantitative EEG are independently affected by acute
scopolamine. Electroencephalography and clinical neurophysiology
86:275-282.
Sato H, Hata Y, Masui H, Tsumoto T (1987) A functional role of cholinergic
innervation to neurons in the cat visual cortex. Journal of neurophysiology
58:765-780.
Sauseng P, Klimesch W, Schabus M, Doppelmayr M (2005) Fronto-parietal EEG
coherence in theta and upper alpha reflect central executive functions of
working memory. International journal of psychophysiology : official journal
of the International Organization of Psychophysiology 57:97-103.
Schnitzler A, Gross J (2005) Normal and pathological oscillatory communication
in the brain. Nature reviews Neuroscience 6:285-296.
Schroeter ML, Vogt B, Frisch S, Becker G, Barthel H, Mueller K, Villringer A,
Sabri O (2012) Executive deficits are related to the inferior frontal junction
in early dementia. Brain : a journal of neurology 135:201-215.
Sejnowski TJ, Paulsen O (2006) Network oscillations: emerging computational
principles. The Journal of neuroscience : the official journal of the Society
for Neuroscience 26:1673-1676.
Sherman MA, Lee S, Law R, Haegens S, Thorn CA, Hamalainen MS, Moore CI,
Jones SR (2016) Neural mechanisms of transient neocortical beta
	
  

	
  

232

rhythms: Converging evidence from humans, computational modeling,
monkeys, and mice. Proceedings of the National Academy of Sciences of
the United States of America 113:E4885-4894.
Siegel M, Warden MR, Miller EK (2009) Phase-dependent neuronal coding of
objects in short-term memory. Proceedings of the National Academy of
Sciences of the United States of America 106:21341-21346.
Simon AP, Poindessous-Jazat F, Dutar P, Epelbaum J, Bassant MH (2006) Firing
properties of anatomically identified neurons in the medial septum of
anesthetized and unanesthetized restrained rats. The Journal of
neuroscience : the official journal of the Society for Neuroscience 26:90389046.
Skoblenick K, Everling S (2012) NMDA antagonist ketamine reduces task
selectivity in macaque dorsolateral prefrontal neurons and impairs
performance of randomly interleaved prosaccades and antisaccades. The
Journal of neuroscience : the official journal of the Society for
Neuroscience 32:12018-12027.
Skoblenick K, Everling S (2014) N-methyl-d-aspartate receptor antagonist
ketamine impairs action-monitoring activity in the prefrontal cortex. Journal
of cognitive neuroscience 26:577-592.
Skoblenick KJ, Womelsdorf T, Everling S (2016) Ketamine Alters OutcomeRelated Local Field Potentials in Monkey Prefrontal Cortex. Cerebral
cortex 26:2743-2752.
Sloan EP, Fenton GW, Standage KP (1992) Anticholinergic drug effects on
quantitative electroencephalogram, visual evoked potential, and verbal
memory. Biological psychiatry 31:600-606.
Spitzer B, Haegens S (2017) Beyond the Status Quo: A Role for Beta Oscillations
in Endogenous Content (Re)Activation. eNeuro 4.
Takada N, Pi HJ, Sousa VH, Waters J, Fishell G, Kepecs A, Osten P (2014) A
developmental cell-type switch in cortical interneurons leads to a selective
defect in cortical oscillations. Nature communications 5:5333.
Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in
schizophrenia. Nature reviews Neuroscience 11:100-113.
van Aerde KI, Mann EO, Canto CB, Heistek TS, Linkenkaer-Hansen K, Mulder
AB, van der Roest M, Paulsen O, Brussaard AB, Mansvelder HD (2009)
Flexible spike timing of layer 5 neurons during dynamic beta oscillation
shifts in rat prefrontal cortex. The Journal of physiology 587:5177-5196.
Vertes RP, Kocsis B (1997) Brainstem-diencephalo-septohippocampal systems
controlling the theta rhythm of the hippocampus. Neuroscience 81:893926.
Vijayraghavan S, Major AJ, Everling S (2016) Dopamine D1 and D2 Receptors
Make Dissociable Contributions to Dorsolateral Prefrontal Cortical
Regulation of Rule-Guided Oculomotor Behavior. Cell reports 16:805-816.
Vijayraghavan S, Major AJ, Everling S (2018) Muscarinic M1 Receptor
Overstimulation Disrupts Working Memory Activity for Rules in Primate
Prefrontal Cortex. Neuron 98:1256-1268 e1254.

	
  

	
  

233

Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007)
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged
in working memory. Nature neuroscience 10:376-384.
Voloh B, Womelsdorf T (2018) Cell-Type Specific Burst Firing Interacts with
Theta and Beta Activity in Prefrontal Cortex During Attention States.
Cerebral cortex 28:4348-4364.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982)
Alzheimer's disease and senile dementia: loss of neurons in the basal
forebrain. Science 215:1237-1239.
Whittington MA, Traub RD, Kopell N, Ermentrout B, Buhl EH (2000) Inhibitionbased rhythms: experimental and mathematical observations on network
dynamics. International journal of psychophysiology : official journal of the
International Organization of Psychophysiology 38:315-336.
Wimmer K, Ramon M, Pasternak T, Compte A (2016) Transitions between
Multiband Oscillatory Patterns Characterize Memory-Guided Perceptual
Decisions in Prefrontal Circuits. The Journal of neuroscience : the official
journal of the Society for Neuroscience 36:489-505.
Womelsdorf T, Schoffelen JM, Oostenveld R, Singer W, Desimone R, Engel AK,
Fries P (2007) Modulation of neuronal interactions through neuronal
synchronization. Science 316:1609-1612.
Yener GG, Guntekin B, Oniz A, Basar E (2007) Increased frontal phase-locking
of event-related theta oscillations in Alzheimer patients treated with
cholinesterase inhibitors. International journal of psychophysiology : official
journal of the International Organization of Psychophysiology 64:46-52.
Zinke W, Roberts MJ, Guo K, McDonald JS, Robertson R, Thiele A (2006)
Cholinergic modulation of response properties and orientation tuning of
neurons in primary visual cortex of anaesthetized Marmoset monkeys. The
European journal of neuroscience 24:314-328.
	
  
	
  
	
  

	
  

	
  

234

CHAPTER 5 – GENERAL DISCUSSION

5.1

Summary of Main Findings
Disorders of cognition such as AD and SZ are burdened with impaired

cognitive functions that is associated with abnormal prefrontal and cholinergic
functioning. The objective of this research project was to examine the ability of
different cholinergic receptors to influence prefrontal neuronal activity, such that
we may gain insights into altered cognitive function in conditions of impaired
cognition. In general, we found that application of cholinergic compounds
influenced discharge rates and was often maladaptive to task-related activity,
such as delay period rule preference. Local cortical oscillatory power was also
affected, especially in the beta frequency band. Receptor subtype-specific
compounds now allow characterization of specific muscarinic receptors through
allosteric binding sites and future work is required to continue exploration of
different muscarinic receptors subtypes’ functions.

5.1.1 Local cholinergic stimulation had mixed effects on prefrontal activity and
decreased task-related rule preference
Previously, we have reported local antagonism of muscarinic receptors
suppressed prefrontal neuronal discharge rate and task-related selectivity during
macaque performance of the memory antisaccade task (Major et al., 2015).
These findings coincide with the abundant literature that shows muscarinic
blockade is disruptive to performance in multiple cognitive domains (Klinkenberg
and Blokland, 2010). Next, we sought to emulate the effects of acetylcholine
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using the general cholinergic agonist carbachol. Carbachol yielded mixed effects
on discharge rate: some neurons were excited and others were suppressed.
However, putative pyramidal neurons more often increased discharge rate.
The mechanisms behind this pyramidal-neuron-specific effect remain
speculative. Mixed effects of local cholinergic receptor stimulation have been
found in other cortical recordings (Inoue et al., 1983; Aou et al., 1983; Nelson et
al., 1973; Matsumura et al., 1990; Soma et al., 2012), including data on
interneurons (Pafundo et al., 2013). Sawaguchi and Matsumura (1985)
suggested different cortical layers respond differently to exogenous transmitter
application, e.g., with ACh having the most excitatory effect in supra- and
infragranular layers. The rise of linear electrode arrays with combined
pharmacology will allow for more precise exploration of cholinergic receptors in
different cortical layers.
Upon examination of rule neurons (i.e., neurons that preferentially fire for
one task rule over the other), we found carbachol attenuated the ability of
prefrontal neurons to discriminate between rules. Two different clusters of
neurons were identified within this group of decreased rule tuning. Some neurons
were excited, with activity increasing more for nonpreferred rules than preferred
rules. Other neurons were inhibited, with activity decreasing more for preferred
rules than nonpreferred. We can only speculate, but this finding aligns with
previous suggestions that for effective cognitive circuitry, there is an optimal
range of cholinergic stimulation, in which too little or too much stimulation is
disruptive (i.e., inverted-U curve). For example, Herrero et al. (2008) found that
ACh can enhance attentional modulation of macaque V1 neurons, but higher
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doses of ACh offered no advantage or decreased attentional modulation.
Carbachol also attenuated putative pyramidal neurons’ ability to preferentially
discharge for one saccadic direction over the other (e.g., left- or rightward
saccades).
Our results suggest that similar to muscarinic blockade, overstimulation of
cholinergic receptors can be maladaptive to normal prefrontal circuitry during
rule-based WM behaviour. The mechanisms behind the observed decrease in
task-related activity can be explored with the use of cholinergic receptor subtypespecific compounds.

5.1.2 Stimulation of muscarinic M1 receptors was inhibitory to prefrontal
discharge rate and attenuated rule preference
The exploration of muscarinic receptor subtype was historically impeded
by a lack of subtype-selective ligands. More recently, molecules have been
designed to allosterically bind muscarinic receptor subtypes, such as VU0357017
that selectively binds M1Rs. M1Rs are the most prevalent muscarinic receptor in
cortex, are prominently found postsynaptically on dendritic spines of pyramidal
neurons, and are typically considered excitatory (i.e., depolarizing to neuronal
membrane potential). M1R agonists are an interesting pharmacological target
because they have shown cognitive-enhancing abilities in macaques (Uslaner et
al., 2013), people with AD (Bodick et al., 1997), and people with SZ (Shekhar et
al., 2008). After characterizing the effects of muscarinic blockade and general
cholinergic stimulation, we sought to detail the effects of receptor subtypes.
Based on past in vitro electrophysiology, we predicted M1R stimulation would
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excite prefrontal neurons. Using similar methodology, we iontophoretically
applied M1R-selective agonist VU0357017 and M1R-preferring antagonist
pirenzepine to prefrontal neurons during rhesus performance of antisaccades.
Unexpectedly, both stimulation and blockade of M1Rs suppressed
discharge rates of prefrontal neurons. Although unexpected, inhibition after M1R
stimulation is not unique. McCormick and Prince (1985) were among the first to
show ACh application elicit two effects: brief inhibition followed by prolonged
stimulation. Muscarinic receptors signal many complex second messenger
pathways, which likely vary by cell type and receptor localization on neurons. For
example, M1Rs can activate SK channels, which hyperpolarize neurons by
allowing K+ entry (Gulledge and Stuart, 2005). M1R stimulation with VU0357017
also decreased rule selectivity of prefrontal neurons at high doses. This effect is
reminiscent of the carbachol-induced decrease in rule preference detailed in
Chapter 2. However, most cases of decreased rule tuning were due to a greater
magnitude of decreased preferred rule activity compared to nonpreferred rule
activity. This finding highlights to importance of carefully selecting doses during
pharmacological intervention of cognitive disorders.
When we found strong suppression of prefrontal activity after muscarinic
blockade, we suggested this was prominently due to inhibition of excitatory drive
from M1Rs. We tested this suspicion using local application of pirenzepine, an
M1R-preferring antagonist. Although pirenzepine was indeed suppressive to
neuronal activity, only around half of neurons were significantly inhibited, and this
effect was only significant at the population level at high doses. We must be
careful with our interpretations since pirenzepine also has binding affinity for
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other muscarinic receptors, but these findings suggest other muscarinic receptors
were also responsible for the strong inhibition observed after scopolamine
administration.

5.1.3 Cholinergic receptor perturbation primarily affects oscillatory power in the
beta frequency band
Cortical oscillations are emerging as important aspect of cognitive circuitry
during working memory behaviour (Fiebelkorn et al., 2013; Fries, 2015; Miller et
al., 2018). For example, beta oscillations are thought to represent maintenance of
task sets during delay periods of working memory tasks (Engel and Fries, 2010;
Siegel et al., 2009; Salazar et al., 2012). This beta activity is thought to be a topdown feedback signal from higher order cortices such as lateral PFC (Bastos et
al., 2015; Mejias et al., 2016; Buschman and Miller, 2007). EEG activity (a
noninvasive proxy for cortical voltage fluctuations) is disrupted in conditions of
altered cognition such as AD and SZ (Jeong, 2004; Uhlhaas and Singer, 2010)
and may represent the underlying aberrant circuitry. EEG abnormalities in AD
correlate with cognitive impairment (reviewed in Jeong, 2004). Studies of both
systemic and in vitro administration of drugs show that cholinergic receptors can
influence cortical oscillations (Sloan et al., 1992; Arai and Natsume, 2006). There
is discussion about the presence of both local and distant generators of
oscillatory rhythms such as beta activity (Raghavachari et al., 2006), and we
explored the effect of local cholinergic receptor manipulation on prefrontal LFP
power during macaque performance of antisaccades.
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Local muscarinic blockade predominantly enhanced power in the high beta

frequency band, especially during the delay period of pro- and antisaccades. The
mechanisms of this task-related increase in beta activity remain unknown. Beta
activity is associated with maintenance of task set during WM delays (Miller et al.,
2018), it is therefore unexpected that a drug with suppressive and anti-cognitive
effects boosts delay-related beta activity. Other rhesus cortical regions densely
express muscarinic receptors on PV interneurons (Disney and Aoki, 2008; Disney
et al., 2014), which are known to facilitate widespread lateral inhibition (Wang et
al., 2004). One may speculate that our observed enhancement of beta activity
could be related to the removal of PV interneuron inhibition. However, more
detailed investigations of interneurons are required.
Carbachol was found to enhance LFP power in the theta and beta
frequency ranges. Carbachol’s effect on task-related changes during the delay
epoch were not as pronounced as scopolamine. Similar to scopolamine
application, the effects of carbachol did not match expectations based on past
EEG recordings and systemic administration of cholinergic compounds (Sloan et
al., 1992; Arai and Natsume, 2006). In fact, the multiband enhancement of
oscillations seen with carbachol more closely resembled cholinergic stimulation in
vitro (Florez et al., 2015). Since our results are similar to slice
electrophysiological results, this suggests our carbachol-induced power
enhancement may be via locally-generated theta and beta generators
(Raghavachari et al., 2006). However, it is possible cholinergic stimulation is
augmenting incoming theta and beta oscillations from distant regions (Buzsaki,
2002; Roopun et al., 2006; Ketz et al., 2015). For example, cholinergic receptors
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are proposed to gate corticocortical and thalamocortical afferents (Gil et al., 1997;
Gioanni et al., 1999; Lambe et al., 2003).
The effect of cholinergic compounds on local oscillations provides insight
on conditions with altered cholinergic functioning. For example, cholinergic
receptor expression is altered in AD and SZ (Flynn et al., 1995; RodriguezPuertas et al., 1997; Dean et al., 2002; Leonard et al., 2002). Future
examinations of the role of specific receptor subtypes on different neuronal
classes will help unravel the role of the cholinergic system and oscillations in WM
circuitry.

5.2

Caveats and Limitations
Although we can argue the NHP model in neuroscience has many

advantages over rodents — especially in the study of prefrontal cognitive circuitry
— there are many differences between NHPs and humans. Firstly, humans can
simply be instructed of the task rules and can be expected to learn new
paradigms such as the antisaccade task almost immediately. In contrast,
macaques must progressively learn oculomotor tasks over the course of many
weeks through operant conditioning techniques. Training is thus long term and
possibly involves different forms of memory compared to when a human is
quickly taught the antisaccade task. Whereas a naïve human participant is relying
solely on new instructions in WM, over-trained monkeys may be invoking
procedural or conditioned responses in addition to WM. In addition, humans are
known to often rely on verbal strategies during WM behaviour. Finally, as
discussed at length in Chapter 1 (also see Coppola and Disney, 2018), there are
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several between-species differences in the cholinergic system. Patterns of
cholinergic innervation and distribution of cholinergic receptors vary between
brain regions, cortical layers, and cell types. Despite these above disparities,
NHPs remain one of the best models for studying prefrontal cognitive circuitry
and have neuromodulatory systems that are much more similar to humans than
rodent models.
Another potential caveat regarding the interpretation of these experiments
is related to the time course of drug application. Our typical drug regimen is
relatively long related to endogenous ACh dynamics. We would typically collect
approx. 15–20 min of baseline activity as control, then a drug condition of similar
length, and sometimes followed by a recovery condition. During the drug
condition, the iontophoretic drug ejection from the electrode’s drug barrel into the
extracellular space is continuous. This is our routine for a practical reason: we
need to acquire enough behavioural trials to achieve statistically informative
results. Some in vitro electrophysiology and combined pharmacology
experiments examine cholinergic receptor function in a much more transient
timeline. For example, applying drugs for seconds or a few minutes then
observing resulting changes in discharge rate or conductance (Valentino and
Raymond, 1981; Wang et al., 2003; Moore et al., 2011; Engle et al., 2012).
As discussed in Chapter 1, endogenous ACh is released and metabolized
on the order of seconds. Thus, continuous ejection of a cholinergic compound
such as carbachol is quite different from natural cholinergic receptor stimulation.
It is possible, and perhaps likely, that our drug ejection stimulated cholinergic
receptors much more than what is normal. As discussed in Chapter 2, we
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suspect this overstimulation may be why task-related selectivity of neurons was
decreased by carbachol. Although we did not observe this, it’s possible that very
lower doses of carbachol could increased task-related activity, as others have
found with low doses of ACh (i.e., in rhesus V1 during an attention-demanding
task; Herrero et al., 2008). Further, carbachol is not broken down by
cholinesterases as quickly as ACh, and therefore may have prompted a stronger
effect.
Another issue is the availability of receptors after several minutes of
receptor stimulation. Tonic exposure of exogenous cholinergic compounds over
the course of an experiment likely leads to desensitization, internalization, and
downregulation of receptors (Siman and Klein, 1979). Continuous application of
general cholinergic agonist carbachol has been shown to reduce surface
expression of muscarinic receptors within 30 minutes, especially for muscarinic
M2 receptors and muscarinic M4 receptors (Thangaraju and Sawyer, 2012).
Continuous application of muscarinic receptor antagonists such as scopolamine
can actually lead to increased surface expression of muscarinic receptors (Wall
et al., 1992; Witt-Enderby et al., 1995). Further, stimulation of muscarinic
autoreceptors are known to decrease endogenous acetylcholine release from
cholinergic terminals (Yonehara et al., 1980; Smiley et al., 1999; Zhang et al.,
1998). Originally, this was thought to be the primary function of M2Rs in cortex.
Unfortunately, we do not know the state of cholinergic receptor expression over
the time course of our experiments and must keep this in mind when drawing
interpretations.
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Future Directions
Future experiments should take a comprehensive approach to the design

of local drug application timeline. For the reasons discussed above, it is important
to supplement tonic drug ejection with transient drug ejection. For example, in a
separate recording session, applying carbachol for 10 s and observing the shortterm effects on neuronal discharge rate and LFP power. This would be useful to
complement the results on discharge rate from continuous drug ejection,
although analysis of task-related neuronal activity would not be practical for this
design. Also, future experimenters must remember the importance of using
multiple drugs for each pharmacological target of interest. For example, the use
of both VU0357017 and McN-A-343 to probe the role of M1R provided added
certainty to the results. As discussed in Chapter 1, this is also important because
different drugs can often display functional selectivity of second messenger
pathways (Urban et al., 2007; Thomas et al., 2008; Digby et al., 2012). Using
multiple drugs can be especially important for newly developed compounds for
which functional details are not complete, e.g., if binding affinities for different
receptors have not been fully explored. VU0357017 was originally thought to only
stimulate M1Rs via allosteric mechanisms, but a more recent study reports this
molecule can also bind M1Rs orthosterically, making it a bitopic ligand (Digby et
al., 2012).
The study of neuromodulatory receptors should also take advantage of the
emergence of linear multielectrode arrays, which allow recording of neuronal
activity and LFP across all layers of cortex. Further, some linear probes are now
available that can pressure eject fluid into specific cortical layers. Several labs
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have reported the effects of local drug ejection using such probes and resultant
effects on different cortical layers in NHPs (Self et al., 2012; van Kerkoerle et al.,
2014; Liu and Pack, 2017; Liu et al., 2018). An exciting prospective experiment
would be to dissociate the actions of NMDA receptor (or cholinergic receptor)
stimulation in superficial layer III and infragranular layer V. One potential
drawback of this technique would be if ejected fluid leaked vertically along the
shaft of the probe. An experimenter would have to observe the laminar spread of
drug over time (e.g., by observing changes in discharge rates or gamma power of
adjacent recording channels) and only use timepoints when drug effected the
layer of interest. Despite several technical difficulties, such experiments could
accurately reveal the role of different neurotransmitters in different cortical layers,
which are known to vary in neurotransmitter innervation and receptor expression.
In addition to local drug ejections, future researchers exploring the role of
cholinergic receptors should also focus on what is occurring naturally:
endogenous release of ACh. New techniques now allow for quantification of
different neurochemicals on a second-to-second timescale. This is important data
that can be compared with neuronal and network activity, LFP and
communication between brain regions, and of course behaviour of animals. For
example, Quanteon LLC develops probes that can detect various endogenous
neurotransmitters such as acetylcholine, glutamate, and dopamine at the
resolution of seconds.
Finally, an enormous niche that remains to be filled is microanatomy of
cholinergic receptors in cortex. Despite many histochemical examinations, a clear
picture of muscarinic receptor expression in different prefrontal areas, layers, and
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cell types remains intangible. Researchers are often left speculating on how
cholinergic perturbation affects WM circuitry and downstream effectors, and more
detailed anatomy would be extremely beneficial. For example, knowing the
expression of cholinergic receptors (and other neuromodulatory receptors) on the
different classes of interneurons would provide helpful direction to
pharmacological targets to influence WM circuitry.

5.4

Concluding Remarks
Many conditions are afflicted with disrupted cholinergic functioning and

impaired executive function. Investigations of the cholinergic system using rodent
models have provided a wealth of information, but inferences to human clinical
outcomes are difficult due to between-species differences. The NHP model of
cognitive behaviour offers a bridge between rodent literature on cholinergic
functioning and human neuropsychiatric conditions that rely on pharmacological
intervention. The granular PFC and cholinergic system of rhesus macaques are
more similar to that of humans, and in vivo electrophysiology allows online
observation of prefrontal neurons that are involved in cognitive circuitry.
Concurrent local pharmacological manipulation with iontophoresis allowed us to
characterize the impacts of direct cholinergic receptor stimulation.
Over the course of this project, the effects of stimulation and blockade of
different receptors were described in putative pyramidal and nonpyramidal
neurons of macaque prefrontal cortex, during performance of an oculomotor rulebased WM task. The effects of M1R-specific compounds came as a surprise and
are a reminder of the differences between pharmacology in slice
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electrophysiology and in an awake, behaving NHPs. Local ejections were also
found to manipulate cortical oscillatory power, particularly the beta frequency
band. Future studies will continue to illuminate the role of muscarinic receptors in
prefrontal LFP and cognitive circuitry. My hope is this work will inform the ongoing
progression of neuroscience research, such that the sciences can alleviate the
symptoms and development of neuropsychiatric conditions that affect millions
worldwide.
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